The infective pulmonary exacerbation in cystic fibrosis : an ecological perspective by Jones, Andrew
 
 
THE INFECTIVE PULMONARY 
EXACERBATION IN CYSTIC FIBROSIS:  
AN ECOLOGICAL PERSPECTIVE 
 
 
Dr Andrew Jones 
 
Imperial College London 
 
Department of Cystic Fibrosis, Population Genetics 
and Gene Therapy, National Heart and Lung 
Institute 
 
MD (Research) 
 
 
 
 
 
 
2 
 
Declaration of Originality 
I declare that the work in this manuscript has been carried out by myself unless where stated. 
The Pseudomonas aeruginosa hypermutator assays were performed by the Research 
Microbiology team, Papworth Hospital, 
The Liverpool Epidemic Strain PA PCR was performed by the HPA Laboratory, Cambridge 
The 16S rRNA gene sequencing was performed commercially by the Sanger Institute, 
Cambridge University. Preparation of raw sequencing data was performed by Dr Michael 
Cox, Department of Molecular Genetics and Genomics, NHLI, Imperial College. 
The quorum-sensing assays were performed by Mr Nigel Halliday, School of Molecular 
Medicine, University of Nottingham.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The copyright of this thesis rests with the author and is made available under a Creative 
Commons Attribution Non-Commercial No Derivatives licence. Researchers are free to copy, 
distribute or transmit the thesis on the condition that they attribute it, they do not use it for 
commercial purposes and that they do not alter, transform or build upon it. For any reuse or 
redistribution, researchers must make clear to others the licence terms of this work. 
3 
 
 
  
ACKNOWLEDGEMENTS 
 
Dr Diana Bilton and Dr Jane Davies, my supervisors, for their advice and support. 
 
Prof Margaret Hodson, for her advice during the development of this study and thesis writing. 
 
Dr Sandra Scott and Myril Mariveles, the CF research nurses for all their help with subject 
recruitment and study visits 
 
Dr Michael Cox, for his teaching of gene sequencing and for his patience with my endless 
questions. 
 
Dr Juliet Foweraker, for her assistance and insight with the microbiology and hypermutator 
assays. 
 
Prof Miguel Camara and Nigel Halliday at the University of Nottingham for providing the 
quorum sensing assay. 
 
To all the staff at the NHLI and Royal Brompton Hospital that have helped me in completing 
this work 
 
To the patients who agreed to take part in this study, without whose generosity this study 
would not have been possible. 
 
 
 
 
 
4 
 
ABSTRACT 
 
Introduction 
In CF, infective pulmonary exacerbations are common. Despite this, significant aspects of 
pathogenesis and patient responses to treatment remain poorly understood. This study 
examined a cohort of subjects receiving antibiotic therapy for exacerbations, correlated 
clinical findings with microbiological data and examined the factors leading to non-response 
to treatment. 
Methods 
Subjects were recruited when they commenced IV antibiotics. Measures of lung function, 
inflammatory markers and quality of life scores were collected with sputum samples during 
treatment. Samples were analysed for (i) routine microbiology, (ii) Pseudomonas aeruginosa 
(PA) hypermutator frequency (ii) 16S rRNA gene sequences to identify bacteria present, (iv) 
PA quorum-sensing (QS) molecule concentrations using LC-MS/MS. 
Results 
Patients who failed to return lung function to baseline at the end of treatment were shown to 
have a larger decline in FEV1 at exacerbation and a longer time since stable measures. In 
treatment success, no significant improvement in lung function was seen after 7 days 
treatment. No association was seen between severity of exacerbation or treatment response 
and PA mucoidy or presence of Staphylococcus aureus. Hypermutator PA was seen more in 
older patients and associated with milder exacerbations. Bacterial diversity was shown not to 
change significantly during antibiotic treatment but there was a significant relationship 
between the change in diversity and change in PA bacterial density. Meropenem was shown 
to have greater effect on diversity than ceftazidime. A significant association between QS 
molecule concentration and lung function decline at exacerbation was shown. QS 
concentrations were seen to decrease significantly during antibiotic treatment which was not 
associated with a decline in bacterial numbers. 
Discussion 
Current durations of antibiotic treatment may not be appropriate as most improvement is seen 
within 7 days. The effect of repeated course of meropenem on bacterial diversity requires 
investigation. QS inhibition may provide alternative therapeutic options to exacerbation 
treatments. 
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ABBREVIATIONS USED IN THIS THESIS 
 
3-oxo-C12-AHL N-(3-oxo-dodecanoyl)-L-homoserine lactone 
ASL     Airway Surface Layer 
ATP   Adenosine Tri-phosphate 
BCFQ   Brompton Cystic Fibrosis Questionnaire 
BMI   Body Mass Index 
C4-AHL  N-butanoyl-homoserine lactone 
CF   Cystic Fibrosis 
CFTR   Cystic Fibrosis Transmembrane Conductance Regulator 
CFQ-R  Cystic Fibrosis Questionnaire - Revised 
CRP   C-reactive Protein 
ENaC   Epithelial sodium (Na) Channel 
FEF25-75  Forced Expiratory Flow (mean flow between 25 and 75% of remaining FVC) 
FEV1   Forced Expiratory Volume in 1 second 
FEV1 %OBL  FEV1 as a percentage of the stable baseline value 
FVC   Forced Vital Capacity 
HAQ   4-hydroxy-2-alkylquinolones 
HHQ   4-hydroxy-2-heptylquinolone 
HQNO  2-heptyl-4-hydroxyquinolone N-oxide 
IECF   Infective Exacerbation of CF 
IQR   Inter-quartile range 
IV   Intravenous 
LC-MS/MS  Liquid chromatography-tandem mass spectrometry 
LES   Liverpool Epidemic Strain 
MARPA  Multiple Antibiotic Resistant Pseudomonas aeruginosa 
MHA   Mueller-Hinton Agar 
OTU   Operational Taxon Unit 
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PA   Pseudomonas aeruginosa 
PC1   Principal Co-ordinate 1 
PCL   Peri-ciliary Layer  
PCoA   Principle Co-ordinate Analysis 
PCR   Polymerase Chain Reaction 
PQS   2-heptyl-3,4-dihydroxyquinolone 
qPCR   Quantitative Polymerase Chain Reaction 
QOL   Quality of Life 
QS   Quorum Sensing 
RBH   Royal Brompton Hospital 
rRNA   Ribosomal Ribonucleic Acid 
SA   Staphylococcus aureus 
TRFLP  Terminal Restriction Fragment Length Polymorphism 
TTNE   Time to Next Exacerbation 
WCC   White Cell Count  
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CHAPTER 1 
INTRODUCTION 
 
1.1 What Is Cystic Fibrosis? 
Cystic Fibrosis (CF) is an inherited multi-system disorder and is the commonest autosomal 
recessive condition in Caucasian populations with 1 in 25 people carrying a disease-causing 
mutation. It is characterised by bronchiectasis and disorders of the bowel and pancreas 
including pancreatic insufficiency, CF-related diabetes and liver disease. 
Where once it was a disease that led to death in early childhood from bowel or respiratory 
complications, intensive treatments, driven by dedicated scientific research, have led to great 
improvements in survival rates and patient morbidity.   In the UK, median life expectancy has 
improved rapidly over the past few decades and is currently 41.5 years (2011 registry data).  
The story of the discovery of CF as a condition and the subsequent experimental data that led 
to diagnostic tests and then the underlying genetic cause is well documented. 
The   term   “Cystic   Fibrosis”   was   first   used   in   the   1930’s   by   an   American   pathologist,   Dr  
Dorothy Andersen1. She reported on a case series of children with bowel disease and 
bronchiectasis and collected clinical histories and data from detailed autopsy studies on 49 
patients. While others had previously noted an association between pancreatic disease and 
bronchiectasis, she was the first to compile a complete description of CF as a distinct disease. 
“Cystic   Fibrosis”   is   actually   the   term   used   to   describe   characteristic   pathological   changes  
seen in the pancreas of the cohort group.   
Dr Andersen was also the first to note the autosomal recessive nature of CF as an inheritable 
disease2. 
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In the 1950s, during a heat wave on the Eastern Seaboard in the United States, the majority of 
children admitted with heatstroke to New York hospitals had CF3. Another New York 
paediatrician, Paul di  Sant’Agnese  investigated  the  cause  of  this  and discovered that the sweat 
of these patients contained high levels of sodium chloride4, an observation that led to the first 
diagnostic tests for CF, the sweat sodium and sweat chloride tests. In the ensuing decades, 
survival rates for CF patients improved due to the introduction of antibiotics and a greater 
understanding of the increased nutritional needs of CF patients. In 1983, Quinton reported on 
a series of experiments showing that the underlying cause for the abnormal sweat test was 
chloride impermeability, thus giving the first description of the underlying cellular defect as 
specifically related to chloride channels5. Later in the 1980s, with the rise in genetic research, 
an intensive search was made to discover the gene whose mutation was responsible for CF. 
Tsui et al were the first to locate it at the chromosomal level, to the long arm of chromosome 
76. Within a few years of this discovery, the gene responsible for CF was accurately located, 
characterised and termed the cystic fibrosis transmembrane conductance regulator (CFTR) 
gene 7-9. The CFTR gene is located in region q31.2 on the long arm of chromosome 7. It 
contains approximately 250,000 base pairs with 27 exons and codes for a protein of 1480 
amino acids, known as the CFTR protein. This protein is part of a family known as ATP-
binding cassette (ABC) transporters. It is a trans-membrane protein that transports chloride 
ions across the cell membrane under the regulation of cAMP signalling and is located 
predominantly in the apical membrane of epithelial cells.10  
Since the discovery of the CFTR gene nearly two thousand mutations have been noted to 
cause a defect in CFTR protein synthesis, although not all of these have been confirmed as 
causing CF. 
 The commonest mutation is a deletion of 3 base pairs at codon 508 (Phe508del). It accounts 
for approximately two thirds of all CF mutations. Worldwide, only 4 other mutations have 
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frequencies greater than 1% among CF chromosomes (G542X, N1303K, G551D, and 
W1282X)11. 
Mutations of the CFTR gene have been classified according to their effect on CFTR 
function.12  
Class I mutations prevent production of full-length CFTR protein because of nonsense or 
frameshift mutations, or because of aberrant splicing of mRNA due to stop codon-inducing 
mutations. A common example of this is G542X. 
Class II mutations affect protein maturation. Such mutations cause misfolding of the CFTR 
protein leading to an inability of the protein to transfer to the cell membrane; Phe508del is an 
example of this. 
Class III mutations affect chloride channel regulation. In these mutations CFTR is transferred 
to the cell surface but then does not respond appropriately to cAMP stimulation, remaining 
closed for most of the time. G551D is an example of such a mutation. 
Class IV mutations affect chloride ion conductance. The CFTR protein is in the correct place 
in the cell membrane, responds appropriately to cAMP stimulation but chloride current is 
reduced. An example would be the R117H mutation 
Class V mutations affect protein stability. Truncated CFTR proteins produced by this 
mutation act normally but have a much reduced half-life in the cell membrane. An example of 
this is the Q1412X mutation.  
It   is   clear   from   clinical   practice   that   the   knowledge   of   a   patient’s   gene  mutations   does   not  
allow us to predict with certainty their clinical outcome. While some mutations are associated 
with generally mild phenotypes, even those associated with potentially more deleterious 
effects such as Phe508del have a wide range of phenotypes from severe disease to being 
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relatively asymptomatic. A study of long term survivors (those reaching the age of 40 years) 
showed that 30% of patients were homozygous for Phe508del.13 
It is unlikely that the CFTR mutation alone can fully explain the CF disease process, and it 
may be that other genes, so called modifier genes, may also contribute to the expression of 
the CF phenotype which is an area of ongoing study. 
 
1.2 Functions of CFTR Protein and Cellular Basis for Airway Disease 
The CFTR protein acts as a chloride ion transporter, mainly at the apical surface of epithelial 
cells. However CFTR is found in a wide number of different cells and may be involved in 
many other intracellular processes not directly related to ion transport. 
The CFTR Protein as an Ion Transporter 
The CFTR protein is one of many ion channels that regulate ion and water transportation 
across the airway epithelium. A number of studies have examined the cellular mechanisms 
that occur in healthy lung and the effect that CF has on these processes is summarised in a 
review by Boucher14. Using these data, a hypothesis known as the low volume airways 
surface liquid theory is the most widely accepted model for the cause of airway disease in 
CF15. 
The apical surface of the airway epithelial cells is ciliated. A layer of fluid, known as the 
airway surface layer (ASL), bathes these cilia. The ASL is composed of two layers. The peri-
ciliary layer (PCL) abuts the epithelial cell surface and contains fluid that bathes the cilia. 
Lying above this is the mucus layer which is continuously moved by the cilia to transport 
debris and bacteria out of the lungs. This mucus layer can also act as a reservoir of fluid for 
the peri-ciliary layer. In healthy lungs the epithelial cells have an ability to both deplete and 
add fluid to the PCL layer. 
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 Both the apical surface and basolateral surface of the epithelial cells have ion transporters to 
regulate fluid volume within the ASL. In healthy tissue an electrochemical gradient is 
generated across the epithelium by a basolateral Na+/K+/ATPase pump. This attracts Na+ ions 
from the airway surface liquid to the interstitium. In the resting state the major ion transport 
process is active Na+ absorption which is regulated by an apical membrane epithelial Na 
channel (ENaC).  In this resting state chloride is transported via a paracellular pathway to 
maintain electrochemical neutrality with Na+ ions and water follows Na+ and Cl- via cell 
membrane channels (aquaporins). 
CFTR is active when the ASL is dehydrated. The major activity of CFTR in healthy tissue is 
inhibition of ENaC, preventing Na+ entering the intracellular space. It appears that this is 
occurring at all times to a greater or lesser extent, so called tonic inhibition. CFTR also acts to 
secrete Cl- ions into the ASL which leads to a net movement of water into the ASL thus 
rehydrating the PCL and mucus layers. 
When the CFTR protein is absent or dysfunctional, as in CF, this regulation of ASL fluid is 
lost. The lack of ENaC inhibition leads to hyperabsorption of Na+ ions with a net movement 
of water out of the ASL. Equally Cl- secretion into the ASL is markedly decreased (some 
occurs via an alternative chloride channel, the calcium-activated chloride channel). The 
overall effect is to dehydrate the PCL and mucus layers leading to viscous, sticky mucus 
coating the epithelial cilia. This leads to a loss of effective mucus clearance and subsequent 
risk of bacterial infection.  
While this low volume hypothesis is currently the favoured hypothesis it is unlikely that this 
defect alone causes the clinical picture we see.  For example, investigators have shown that 
the introduction of a shear stress through use of a phasic motion to CF cell cultures can 
release sufficient ATP to decrease Na+ absorption and activate alternative Cl- channels so as to 
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return  the  PCL  to  a  physiological  depth.  The  same  authors  identified  that  a  “second-hit”  to  the  
CF epithelia of a viral infection such as respiratory syncytial virus (RSV) may activate 
hydrolysis of ATP and as such ameliorate the effect of the shear stress and lead to depletion 
of the PCL volume16. 
Non-Ion Transport Functions of the CFTR Protein 
While the original discovery of the underlying pathology of CF and indeed the identification 
of the CFTR protein as a transmembrane channel, would suggest the primary function of the 
CFTR protein is that of an ion transporter channel it is clear from a large number of studies 
that CFTR has other roles within human cells including glycosylation and sialylation of 
glycoproteins 17, and effects on bicarbonate secretion18.  
It is also likely that CFTR dysfunction has an effect separate to ion transportation that leads to 
upregulation of the inflammatory pathway which may be exaggerated by the presence of 
bacteria19. A discussion of these mechanisms is beyond the scope of this report but include 
upregulation of NF-kB and resultant over-expression of pro-inflammatory cytokines, an effect 
of the unfolded CFTR protein on the endoplasmic reticulum leading to disorders of 
intracellular calcium homeostasis, and the action of CFTR as a transporter of the anti-oxidant, 
glutathione. 
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1.3 Microbiology of CF Airway Disease 
The loss of effective mucociliary clearance in the CF airway leads to infection with inhaled 
pathogens such as bacteria, viruses and certain fungi.  Pulmonary infection is the leading 
cause of morbidity and mortality in CF and as such, a clear understanding of the processes 
involved in the acquisition and treatment of infections is paramount in treating the CF patient. 
 Bacterial Flora 
 A wide variety of organisms can infect the CF airway, often initially common pathogens 
such as Staphylococcus aureus (SA) and Haemophilus influenza (HI) and then, at a later 
stage, opportunistic bacteria such as Pseudomonas aeruginosa (PA) and Burkholderia sp.  A 
number of investigators have examined the changing nature of respiratory pathogens in CF, 
looking both at how changes in individual patients have occurred and also the population in 
general with the emergence of new pathogens. 
Prior to the introduction of antibiotics to medical practice, the commonest pathogen isolated 
from CF patients was SA. This is likely to represent the young age at which CF patients died 
in that era as the most recent US registry data suggests that in children and adolescents SA 
remains the  commonest respiratory pathogen isolated 20. This organism is a commensal of 
human skin and is commonly isolated from the anterior nares of asymptomatic healthy 
people. It therefore has a large community reservoir from which the CF patient can acquire 
the organism. A recent study has highlighted that the family members of CF children with SA 
infection are far more likely to carry an identical strain in their noses, thus providing a source 
or common exposure to the infecting organism. 21 
Effective antibiotic therapy for SA and prolonged life spans has led to the emergence of other 
respiratory pathogens. Mearns et al. examined changing patterns of CF airway microbiology 
from the 1950s through to 197122. She noted a decrease in SA infection from 86% in 1950-
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57, to 30% in 1969-71 in children of less than 1 year of age. Overall for her clinic, she noted a 
decrease in SA isolation from 45% to 12% and an increase in PA from 3 to 28%. It was also 
noted that the largest decrease in SA infection and the greatest increase in PA infection was 
seen in those with the most severe lung disease.  Mearns postulated that infection with PA 
was a marker of disease severity rather than the cause of the damage seen. 
 A more recent adult cohort was examined in a single centre for the years 1985-2005. Millar 
et al23 noted the commonest organism isolated from the patient group was PA, the incidence 
of which remained stable over the study period (77-82%). The incidence of SA infection also 
remained relatively stable (54- 47%).The incidence of Haemophilus influenzae, Aspergillus 
and Burkholderia cepacia complex all decreased while Stenotrophomonas maltophilia 
increased. It was noted that the incidence of methicillin-resistant S. aureus (MRSA) also 
increased (1% to 4%) over the study period. 
While these studies are only related to single centres, the introduction of national CF 
databases has allowed us to examine respiratory pathogens on a much larger scale. Both the 
UK and US CF databases confirm that PA is the commonest respiratory pathogen in adults. In 
the UK data, from the 2009 report, 67% of CF patients aged 28-31 are infected with the 
organism, (Figure 1.1). The US data registry generally concurs with this data although 
records much higher rates of MRSA infection (23.7% of all CF patients, adult and paediatric). 
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Figure1.1. UK CF Registry data demonstrating the changing bacterial infections with age in the UK 
CF population. UK CF Registry Data 2009.  
More recently investigators have examined the role of anaerobic bacteria in CF infections. 
These bacteria are often overlooked as they are not routinely cultured. A number of studies 
have confirmed that anaerobic bacteria are present in significant numbers in CF sputum 
samples. Worlitzsch et al24 identified 35 different species of anaerobic bacteria in 114 CF 
sputum samples, with a maximum number of 4 species in one sample. The authors also noted 
that of the samples taken at the time of an exacerbation, 58% of anaerobic bacteria were 
resistant in vivo to the prescribed antibiotics. Some would argue that the anaerobes present 
represent oro-pharyngeal contamination but significant numbers of anaerobic bacteria in 
broncho-alveloar lavage fluid, would suggest against this25.  As anaerobic bacteria are 
commensal organism in the oro-pharynx, is there evidence they are pathogenic in the lungs? 
An editorial by AM Jones26 succinctly summarises the arguments regarding this discussion 
and concludes that the evidence for pathogenicity is not sufficient to warrant a change in 
current antibiotic practices. 
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 Non-Culture Techniques for Bacterial Identification 
In clinical practice, current laboratory methods for identifying bacteria in sputum involve the 
culturing of sputum samples on selective media to determine bacterial growth. This process is 
relatively slow and, perhaps more importantly, by using selective media a full picture of 
bacterial biodiversity within the CF lung may not be appreciated. 
Bacterial identification by genetic sequencing is not a particularly new science, but recent 
technological advances have allowed large amounts of genetic material to be sequenced in 
relatively short time frames and much more economically.  Such techniques involve the 
analysis of the 16S ribosomal RNA (rRNA) gene. The 16S rRNA gene codes for the small 
subunit of the bacterial ribosome (16S rRNA is only seen in prokaryotic organisms, 
eukaryotes have an 18S rRNA gene). The 16S rRNA gene is ideal for identification as it is 
constant between bacterial species and is relatively short (1.5K base pairs) allowing full 
sequencing. Such techniques do not require the sputum sample to be incubated and cultured 
on selective media allowing a far more accurate analysis of the diversity of the bacteria that 
are present in the CF lung. In the CF literature, 2 main forms of bacterial identification have 
been used; (i) terminal restriction fragment length polymorphism (T-RFLP) analysis, (ii) 
sequencing of the 16S rRNA gene. 
Both methods involve the extraction of bacterial DNA from clinical samples followed by 
amplification of the 16S rRNA gene using a polymerase chain reaction (PCR) and primers 
directed at the appropriate gene. In T-RFLP analysis, the amplified gene products (amplicons) 
are then digested with a restriction endonuclease enzyme. This fragments the amplicons into 
variable sizes dependent on the position of the restriction site which differs between bacterial 
species. These fragments can then be separated by gel electrophoresis and the presence of 
bacterial species can be determined by fragment size. T-RFLP is limited by the resolution of 
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the data; many bacterial species have similar T-RFLP fragment lengths and it can be difficult 
to distinguish separate species in some cases. Gene sequencing allows a much higher 
resolution of the data and gives a more accurate picture of the level of microbiological 
diversity seen in clinical samples. 
The commonest form of gene sequencing used in microbiology is pyrosequencing. 
Essentially this process involves the sequencing of a single strand of DNA (amplicon) by 
sequentially adding nucleotides in the presence of the enzymes, DNA polymerase, ATP 
sulfurylase and a luciferase (light-emitting enzyme). When a complementary base is added 
pyrophosphate is released from the DNA polymerase. This is then converted to ATP by ATP 
sulfurylase, activating the luciferase which leads to a detectable light emission. Any 
remaining nucleotide is removed with apyrase before the next nucleotide is added. By 
comparing the pattern of light emissions with the nucleotide added it is possible to determine 
the DNA sequence.  
Early work examining the CF lung microbiome utilised T-RFLP. One of the first studies, 
performed by Rogers et al, analysed 71 CF sputum samples. They revealed the presence of 19 
species of bacteria including 15 never before documented in CF infection and a significant 
number of strict anaerobes27. They determined mean species richness (the number of bacteria 
per sample) of 13.3 distinct T-RF bands, clearly establishing the CF lung as a complex 
microbiological environment with a far more diverse population of bacteria than previously 
thought. 
Armed with more in-depth knowledge of the true diversity of bacteria in the CF lung it is 
interesting to postulate what clinical effect this could have.  For example, a condition such as 
Clostridium difficile diarrhoea is due to an overgrowth of the bacteria in an environment 
which usually has a diverse range of bacteria. It is therefore possible that alterations to the 
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bacterial diversity within the CF lung, with selective growth of one virulent bacterial species 
could have similar pathological effects. 
Certainly it appears that bacterial diversity does change with age. A small study of a cross 
section of CF patients of all ages noted an increase in bacterial diversity during the first 
decade of life followed by a gradual decrease in diversity as patients were older28. The study 
is limited by its small number of patients and its cross sectional nature and further work is 
required to determine any link between bacterial diversity and disease progression and 
severity. 
Two studies have examined the changes in diversity of bacteria in CF sputum during 
treatment of an exacerbation29;30. In a paper by Tunney et al the authors found that bacterial 
diversity between patients was large but that antibiotic therapy did not significantly affect 
diversity29. However the study was limited by the small number of patients, the wide range of 
antibiotics used and the use of T-RFLP, which may have underestimated the diversity of 
organisms present. A more recent paper by Daniels et al30, also examined the CF 
exacerbation. They found that relative PA abundance increased during antibiotic therapy with 
a decrease in the number of non-pseudomonal species detected. This study also used T-RFLP 
and included patients receiving both oral and intravenous antibiotic courses. A further 
longitudinal study by Zhao et al31, followed 6 CF patients for up to 9 years with regular 
sputum collection. These samples were then analysed with 16s rRNA pyrosequencing. While 
this study was not designed to look at exacerbations per se, they did record the clinical status 
of the patient at the time of sputum collection and some samples were taken at the time of 
exacerbation. They found that bacterial diversity decreased over time in patients who had a 
progressive decline in lung function but remained stable in those with no significant 
progression of their lung disease. They also found that exacerbations did not significantly 
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change the community structure but antibiotic treatment was associated with a decrease in 
bacterial diversity, with recovery of diversity following the cessation of antibiotics.   
There does appear to be some contradiction in these exacerbation studies that requires further 
examination using prospectively gathered data with clearly defined exacerbations and 
treatment protocols. Clearly patients are improving in terms of symptoms, increases in lung 
function, and reductions in inflammatory markers. It remains unclear therefore whether 
bacterial diversity is important or whether we need to examine more closely the role of intra-
species diversity such as the relative abundance of quorum-sensing proficient PA organisms, 
which will be discussed further. 
1.4 Acute Respiratory Infections in CF 
Respiratory infections are responsible for the bulk of morbidity and mortality in CF. They 
cause a chronic decline in lung function which eventually leads to death from respiratory 
failure.  Initial infection with SA or PA may be relatively asymptomatic and as such, regular 
sputum cultures are required as a surveillance tactic to pick up new infections and to attempt 
eradication of the organism before chronic infection can be established.  However, the bulk of 
treatment for infections in CF patients is for acute exacerbations of chronic infection. Clearly, 
understanding the trigger for these exacerbations and the response of the organisms to 
treatment should allow optimisation of therapy.  
Data from the UK CF registry showed that 50% of CF patients received a course of IV 
antibiotics over a one year period with the mean total duration of antibiotic treatment over a 
year of 28 days20. These figures vary with age, being highest in the age group 24-27 years 
where 65% of patients received IV antibiotics for a mean of 31 days.  
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This figure is really only the tip of iceberg when it comes to the treatment burden of CF 
infection. Many acute exacerbations are treated successfully with oral antibiotics. Equally 
chronic infections with some organisms require long-term inhaled and/or oral antibiotics in an 
attempt to suppress bacteria and prevent acute infective exacerbations. 
Defining an Infective Exacerbation 
While it may seem a simple task, defining what constitutes an acute infective exacerbation 
has generated a large amount of discussion in the CF medical community. Many studies have 
adopted a Cartesian philosophy, suggesting that an exacerbation exists when an attending 
clinician says it does. This is problematic as it has clearly been demonstrated that a lack of 
consensus exists between clinicians as to what constitutes an infective exacerbation 32 
 As yet there are no fixed criteria for what defines an infective exacerbation.  Perhaps the 
closest we have are the criteria produced following the 1994 Cystic Fibrosis Foundation 
Microbiology and Infectious Disease Consensus Conference33. 
This requires the presence of at least three of the following eleven new findings or changes in 
clinical status when compared to the most recent baseline visit: 
1. Increased cough 
2. Increased sputum production, change in appearance of sputum, or both 
3. Fever on more than one occasion in the previous week 
4. Weight loss greater than or equal to 1kg or 5% of body weight associated with 
anorexia and decreased dietary intake 
5. School or work absenteeism in the previous week 
6. Increased respiratory rate, increased work of breathing or both 
7. New findings on chest examination 
8. Decreased exercise tolerance 
9. Decrease in FEV1 of greater than or equal to 10 % from previous baseline study 
(defined as best outpatient FEV1 in past 12 months) 
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10. Decrease in oxygen saturation from baseline value within three months of >10% 
11. New finding on chest radiograph 
A number of other criteria have been used in CF studies. These include the Fuchs criteria34 
and criteria determined by Ramsey et al. for the inhaled TOBI trial35, and are broadly similar 
to the 1994 consensus criteria described above.  
Rosenfeld et al describe a multivariate model to create an algorithm identifying patients with 
a pulmonary exacerbation. They determined that clinical signs and symptoms had a greater 
predictive value than any laboratory measured values. Most predictive were increased cough, 
change in sputum volume or consistency, decreased appetite/weight, change in respiratory 
examination and respiratory rate36. The authors produced a scoring system known as the PEx 
score. However this has not been significantly used or validated in other clinical trials. 
Treatment of Infective Pulmonary Exacerbations 
The majority of CF infective pulmonary exacerbations are treated with antibiotics directed at 
the organism that chronically infects the airways. For many bacteria the choice of antibiotics 
is a simple one. However, given the virulence factors of PA and its ability to rapidly develop 
antibiotic resistance, choosing appropriate antibiotics to treat this organism has been 
extensively studied. 
Only one class of oral antibiotics, the quinolones, are recognised to have activity against PA. 
Unfortunately resistance to ciprofloxacin (the most commonly used oral quinolone) has been 
reported as high as 30% in the UK37. Because of the relative lack of good oral treatments 
patients often require intravenous antibiotics as a first line treatment for PA-induced infective 
exacerbations. 
A significant number of intravenous antibiotics have activity against PA. These included 
aminoglycosides such as gentamicin and tobramycin, polymixins such as colistin sulphate, 
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and   β-lactam   based   antibiotics   (those   containing   a   β-lactam ring) such as penicillins 
(temocillin, piperacillin), carbepenems (imipenem, meropenem) and some cephalosporins 
(ceftazidime). 
Current guidelines recommend combination antibiotic therapy38. Most patients will therefore 
receive   a   β-lactam-based antibiotic in combination with an aminoglycoside. The reasoning 
behind this decision is that of preventing the development of antibiotic resistance. While this 
is a theoretical concern, no study has shown this to occur. A number of small studies 
comparing antibiotic monotherapy with combination therapy have shown no significant 
increase in the development of resistance and similar clinical outcomes for both treatment 
groups 39-46. It could be argued that the serious side effects of aminoglycosides such as renal 
and oto-toxicity, present a greater risk than the benefit of perceived decrease in antibiotic 
resistance. The most recent American CF Foundation guidelines suggest further work needs 
to be undertaken in this area to determine the true benefit of combination therapy47. 
Many CF centres (>90% of European centres) select antibiotics based on the susceptibility 
profile from the most recent sputum samples 48. Aaron et al have demonstrated that for the 
majority of adult patients suffering an infective exacerbation of cystic fibrosis, the infecting 
organism is that chronically infecting rather than a newly acquired organism49. Of note, this 
has been shown to note be the case for children with CF50. As such, in adult patients, one 
would expect a similar antibiotic susceptibility profile between samples if no new antibiotic 
treatment had been given in the intervening period. However a recent study has highlighted 
significant inconsistencies in antibiotic susceptibility profiles taken from a single sputum 
sample51. Foweraker et al describe how PA susceptibility profiles from a single sputum 
sample tested in duplicate in 8 separate laboratories had a very poor correlation. They 
demonstrated that even when colonies on the culture plate had the same morphotypes (i.e. 
looked the same) they actually had different susceptibility profiles. The authors suggested that 
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any process of choosing a single sample of a morphotype for susceptibility testing would not 
be predictive for the whole sputum sample and not indicative of the microbial response to 
treatment in vivo, casting doubt over the true benefit of conventional antibiotic susceptibility 
testing and its use in selecting appropriate intravenous therapy. 
1.5 What Causes an Acute Pulmonary Exacerbation in CF? 
Despite acute pulmonary exacerbations in CF being common, the mechanisms which trigger 
them are unknown. In chronic PA infection, it could be hypothesized that when a patient is 
clinically stable, there is a balance between both the number and activity of bacteria in the 
lung   and   the   patient’s   immune   response   to   the   organisms.   An   acute   exacerbation   could 
therefore be triggered by either an increase in the number of bacteria, a change in activity of 
the bacteria (expression of new virulence factors), or an upregulation of the immune system; 
the latter could be caused by another pathogen such as a virus. The following discussions will 
focus on PA infections which are the most extensively studied in experimental models.  
 Bacterial Levels During Acute Exacerbations 
A simple explanation for the cause of an acute exacerbation would be an overgrowth of 
bacteria in the lung which triggers an immune response and the clinical symptoms of an 
exacerbation. Previous studies provide conflicting data. Ordoñez et al have previously shown 
significant decreases in PA levels from induced sputum samples during treatment of 
exacerbations52. A recent study examined the sputum density of PA (and total bacterial 
density) in the weeks leading up to an exacerbation using a quantitative PCR method 53.  
Using this technique it was shown that there were no changes in either total bacterial density 
or PA density prior to the onset of symptoms of an acute exacerbation. Equally a study has 
shown non-significant changes in bacterial density during treatment of an exacerbation54, and 
others have reported no relationship between lung function improvement and changes in PA 
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density 39;55. It would seem therefore that this simple explanation of changes in bacterial 
numbers causing acute exacerbations may not completely fit with the experimental data. 
Effect of Viral Infections on Acute Exacerbations 
Viral infections have been shown to be relatively common during acute pulmonary 
exacerbations of CF. For example, in one paediatric study viral particles were detected in 
40% of patients experiencing an exacerbation, compared with only 9% of those who were 
clinically stable56. It has also been shown that new bacterial colonisation is more common 
during seasons when viral infections are more common, with one study showing that 85% of 
new PA infections followed within 3 weeks of a viral upper-respiratory tract infection 57. 
Viral infections have been shown to denude respiratory epithelium which may make bacterial 
adhesion easier. Equally, rhinovirus has been shown to disrupt the PA biofilm allowing 
motile bacteria to escape which may trigger an exacerbation. 58 
Change in P.aeruginosa Activity 
PA has a number of virulence factors that can be activated to facilitate chronic infection. Not 
all bacteria have all virulence factors active at any one time, many of them activated through 
genetic mutation. Activation of some of these virulence factors may lead to an acute 
exacerbation.  
The remainder of this discussion will examine PA more closely and some of the virulence 
factors that may be implicated in an acute exacerbations and how some of these factors have 
been studied. 
1.6 Pseudomonas aeruginosa 
Pseudomonas aeruginosa is a gram negative organism that is ubiquitous in the environment. 
It has been detected in a diverse range of habitats from garden soil to jet fuel, but natural 
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carriage by humans is relatively rare. It is however an opportunistic pathogen and is seen in a 
number of hospital  settings such as ventilator-associated pneumonia in intensive care units, 
urinary tract infections in patients with urinary catheters and soft tissue infections in burns 
patients. It is also, as previously mentioned, the commonest respiratory pathogen in adult CF 
patients.  
Virulence Factors 
How is PA able to survive and grow in such a diverse range of habitats? 
It can utilise an armamentarium of virulence factors in both aerobic and anaerobic conditions 
that allow it to persist and thrive in the CF airway. These include structural feature such as 
flagella, pili, the lipopolysaccharide coating of the outer membrane and a type III secretion 
system; as well as the ability to secrete compounds such as proteases, exotoxins and alginate. 
Bacteria can also form into a structure known as a biofilm - a way of aggregating large 
numbers of bacteria together and protecting them from external agents. Equally, in common 
with a number of bacteria, PA utilises an organism-to-organism signalling system, known as 
quorum sensing which allows communities of bacteria to communicate. 
Biofilms 
Microbial biofilms are populations of micro-organisms that are concentrated at an interface 
(usually solid-liquid) and are typically surrounded by an extracellular polymeric substance 
(EPS) matrix. 
The transition from a single cell planktonic phenotype of PA to a biofilm is thought to be a 
critical moment of conversion in the setting of CF lung disease. Initial infection with PA in 
CF is thought to be with environmental, planktonic PA. At some time point later, conversion 
to a biofilm mode growth occurs, a mode of growth which may make eradication of the 
bacteria from the airway more difficult and as such lead to chronic infection. 
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In vitro Models of PA Biofilm Formation 
Sauer documented the 5 stages of PA biofilm formation in an in vitro model59. 
Stage 0 – Planktonic 
This is the wild-type, motile organism 
Stage I – Reversible attachment 
The PA cell attaches transiently to the surface via the cell-pole. This has been shown to be 
mediated by PA flagella and pili; mutants not exhibiting flagella or pili have much lower rates 
of surface attachment60.  
Stage II – Irreversible attachment 
PA bacteria attach permanently to the surface by re-orientating to longitudinal cell axis. At 
this point the bacteria become non-motile, and begin to cluster. Sauer noted activation of the 
las quorum-sensing system during this period of development. Both mutants with a defect in 
the las quorum sensing system and wildtypes produce EPS. However, las mutants do not 
exhibit an EPS matrix where bacterial cells lie spaced apart with EPS between them, a 
structure thought to be important for biofilm production. 
Stage III – Maturation-1 
During this stage cells are seen to layer into clusters with layer thickness >10μm and protein 
expression by the cell is massively upregulated. Among the proteins upregulated are Arc 
proteins, which are thought responsible for the ability of the bacteria to undertake anaerobic 
processes61, suggesting that cells in the biofilm are exposed to an oxygen depleted 
environment. 
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Stage IV – Maturation-2 
At this stage the cell cluster layer reaches its maximum thickness of up to 100μm and the 
bacteria are at their most phenotypically different from planktonic bacteria, with greater than 
50% of detectable proteins undergoing changes in regulation. Equally there is a large 
difference in protein expression from the Maturation-1 stage, possibly related to the high 
numbers of cells experiencing an anaerobic or low oxygen environment. Cell clusters are seen 
to be detached from the surface during this stage. 
Stage V – Dispersion 
In this final stage of development some bacteria develop the ability to become motile and 
swim away from the interior of cell cluster through pores and channels that develop, 
presumably to obtain access to better nutrients outside of the cluster. At this point a number 
of proteins are downregulated and the bacteria more closely resemble the planktonic bacteria 
compared with Maturation-2 stage bacteria. 
In vivo PA Biofilms 
Can  Sauer’s  model  of  biofilm  formation  be  directly  extrapolated  to  the  complex  environment  
of the CF airway? Work by Worlitzsch et al in a chronic infection model suggests that rather 
than occurring at the epithelial cell surface, biofilm formation takes place in the intraluminal 
space62. They demonstrated that, using both electron microscopy and immuno-localisation 
techniques of explanted CF lungs, PA bacteria did not attach to the airway epithelial cells. 
Over 95 % of organisms were localised to the airway lumen 5-17μm distant from the cell 
surface in spherical colonies and the rest were positioned between 2-5μm   from   the   cell  
surface. They also demonstrated preferential binding of PA bacteria to mucus rather than 
airway epithelial cells. The spherical colonies of bacteria seen in the intra-luminal space were 
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shown  to  be  oxygen  depleted(which  is  in  concordance  with  Sauer’s  in  vitro  studies  showing  
upregulation of proteins involved in anaerobic respiration) and PA was demonstrated to 
respond to hypoxia by increasing alginate production, a major component of the EPS matrix 
of the biofilm. They determined that, in CF, there was a hypoxic gradient in the mucus 
adherent to the airway surface caused by consumption of oxygen by the hyperactivity of the 
ENaC channel. They postulate that this gradient encourages PA to produce alginate and 
develop a biofilm. 
If, in chronic infections, PA bacteria are not infecting the airway cells, how can we account 
for the intense inflammation and neutrophilic infiltration seen in the CF airway? The answer 
may lie in the response of the innate immune system to the biofilm or possibly quorum 
sensing molecules. 
Pseudomonas aeruginosa and the Innate Immune System 
As discussed earlier, chronic infection with PA is usually associated with mutation of the 
planktonic PA to a mucoid phenotype. This mutant produces alginate which acts as a 
protective barrier for the bacteria against the immune response. A number of studies have 
identified that PA bacteria with alginate production are associated with persistent infection in 
murine models63;64. High levels of alginate produced by PA have also been implicated in the 
ability of the bacteria to evade the complement system65. 
 The development of the PA biofilm is also an important step in protecting the bacteria from 
the immune system. Experimental biofilms have been shown to be associated with an 
accumulation of neutrophils close to the biofilm66. Within the biofilm, PA bacteria produce 
rhamnolipids (among other virulence factors). These compounds have been shown to be 
active against neutrophils, causing cell lysis67. While the full response of the immune system 
to chronic biofilm infection is still being examined, a theme of the research is the innate 
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immune response to the bacteria may well be contributing to the disease process with large 
quantities of inflammatory cells unsuccessfully attacking the biofilm and releasing toxic 
substances into the airway. The ability of the bacteria to lyse neutrophils leads to large 
quantities of inflammatory mediators being released into the airway. 
As mentioned the PA bacteria in a biofilm have a number of virulence factors capable of 
protecting the bacteria from the immune system, with many of these virulence factors being 
controlled through quorum-sensing signalling systems. 
1.7 Quorum Sensing Systems in Pseudomonas aeruginosa 
Quorum sensing (QS) systems are mechanisms by which cell-to-cell communication can 
occur in bacterial populations. Each bacterium secretes a small amount of QS molecules. As 
the number of bacteria increases, the level of QS molecules increases in the extracellular 
environment and diffuses through the cell membrane of nearby bacteria. At a threshold intra-
cellular concentration of these molecules, target QS genes are activated within the bacterium 
which may alter the expression of virulence factors. It therefore acts, as the name suggests, as 
a density-dependent regulatory system 
PA has a complex multi-compound QS system. The bulk of the QS system is controlled by 
two genes, the lasR and rhlR genes, which regulate over 10% of the entire PA genome.68 The 
two principal QS proteins that bind to and activate these genes are N-(3-oxododecanoyl) 
homoserine lactone (3-oxo-C12-AHL), which binds to the lasR gene, and N-
butanoylhomoserine lactone (C4-AHL), which binds to the rhlR gene. These proteins are 
from a group known as acylated homoserine lactones (AHLs). More recently a further group 
of molecules, known as 2-alkyl-4(1H)-quinolones (AQ), have been shown to be important in 
PA QS systems69.  
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QS-controlled genes encode a number of virulence factors required by PA to survive in the 
CF airway.  The presence of 3-oxo-C12-AHL has been shown to be required for PA biofilm 
formation70and it was through measuring of QS proteins in CF sputum that it was initially 
determined PA grew in a biofilm in CF airway disease.71  
QS-systems are also involved the development of resistance to some antibiotics. Suppressors 
of the PA QS system have been shown to increase susceptibility to tobramycin72, and 
mutations leading to deletion of QS genes have been shown to increase PA susceptibility to 
oxidative stress and make them more readily phagocytosed by polymorphonuclear 
leukocytes73. 
The QS molecules may also play an important role in the relationship between PA and the CF 
airway. As previously mentioned the PA biofilm is located within intraluminal mucus rather 
than attached to the epithelial cells in the CF lung.  3-oxo-C12-AHL in particular has been 
shown to stimulate human airway epithelial cells to produce IL-8, a potent chemo-attractant 
for neutrophils, induce cyclo-oxygenase-2 (Cox-2), a pro-inflammatory enzyme, in human 
lung fibroblasts and stimulate the production of PGE2 in fibroblasts74;75. PGE2 is known to 
induce mucus secretion, vasodilatation and oedema within the airway. 
Therefore it may be that the QS molecules are activating inflammatory pathways in the CF 
airway which may augment the upregulated inflammatory pathways previously discussed. No 
work has yet been done to examine QS molecules during infective exacerbations of CF due to 
PA, which will be a further area of study in this thesis. 
It has been noted by some investigators that QS signalling systems are lost in chronic PA 
infections through genetic mutation76. However it may be that at times of acute exacerbation, 
QS-proficient organisms proliferate and play a role in the pathogenesis of an infection. 
Certainly it would appear that QS-proficient organisms appear more able to cause acute 
38 
 
infections. A study of mechanically ventilated patients in an intensive care setting identified 
that patients infected with QS-proficient PA were more likely to develop ventilator-associated 
pneumonia than those without.77 
QS-systems may also allow interaction between different species of bacteria. In the condition 
otitis media, co-infection with H.influenza and M. cattarhalis promotes increased resistance 
to antibiotics. The QS molecule autoinducer-2, secreted by H.influenzae was identified as a 
promoter of M.cattarhalis biofilm production and increased resistance to antibiotic 
therapies78. 
A number of compounds have been shown to disrupt QS signalling. One such compound is 
the macrolide antibiotic, azithromycin. In chronic PA infections the long term use of 
azithromycin is associated with reduced frequency of pulmonary exacerbations and improved 
lung function79. While the full mechanism of this action has yet to be elucidated a number of 
studies have clearly shown a decrease in QS molecule production by PA in the presence of 
azithromycin in urinary tract infections, ventilator-associated pneumonia and a CF mouse 
model80-82. 
1.8 Hypermutator Strains of Pseudomonas aeruginosa 
The wide range of virulence factors seen in PA is not all expressed at once. For example PA 
bacteria causing an acute ventilator-associated pneumonia is phenotypically very different 
from that seen in chronic CF lung infection. Changing virulence factors are acquired through 
mutations which occur as an adaptation to their environment.   
Evolutionary genetics would suggest that, in general, the spontaneous mutation rate of 
bacteria should be low83. The majority of genetic mutations involve DNA deletion or errors of 
transcription which lead to the loss of cellular function and cell death. Beneficial mutations to 
the bacteria are theoretically relatively rare. However in reality that is not the case; PA is seen 
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to mutate regularly in CF lungs to improve the fitness of the bacteria. One study examined the 
genetic mutations of PA in a single patient over an 8 year period commencing at the time of 
initial infection. They noted 68 mutations over the time period including the loss of a number 
of genes coding for virulence factors required for initial infection such as twitch motility and 
serotype-specific antigenicity84.  
Bacteria with high mutation rates were first identified in experimental colonies of E. Coli.85 
These “hypermutators”   have   a  mutation   rate   up   to   a   thousand   times   greater   than  wild-type 
caused by a defect in their DNA repair system. While the majority of these mutations will be 
deleterious, occasionally, and at a much higher frequency than wild-type bacteria, a beneficial 
mutation will occur allowing a new virulence factor to be expressed. PA hypermutators have 
also been identified and shown to exist in high numbers in CF sputum samples86.  
While PA hypermutators have been linked to the development of antibiotic resistance and 
development of a mucoid phenotype87;88, it is likely that the ability to hypermutate is also 
associated with a biological cost. During in vitro competition tests, wild-type outcompeted 
hypermutator strains and in vivo experiments, using a murine model of chronic infection, 
demonstrated hypermutators were less able to establish infection89. These studies suggest that 
at times of changing airway environment e.g. acute infective exacerbations, hypermutation 
helps bacterial communities adapt to changes in the local environment. In a stable bacterial 
community however they may be less useful because of their associated biological cost and 
decreased virulence. As such, hypermutators levels may drop after treatment of acute 
infections. 
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1.9 Study Hypotheses 
This study examined three major hypotheses: 
Study Hypothesis 1 
“P.  aeruginosa hypermutators are representative of a bacterial population under stress rather 
than acting as a more pathogenic organism. Their presence does not relate to clinical outcome 
but  may  be  associated  with  increased  antibiotic  resistance  emerging” 
Study Hypothesis 2  
“Increased   microbiological   diversity   represents   a   balanced   community   of   bacteria.   The  
presence of a diverse population therefore predicts a better outcome for treatment than when a 
population consists of a small number of virulent organisms predominate” 
Study Hypothesis 3 
“Quorum   sensing   molecules   released   by   P.aeruginosa contribute to upregulation of 
inflammatory pathways within the CF airway. Increasing populations of QS- producing 
organisms trigger acute exacerbations and treating this population will resolve acute 
exacerbations. Persistence of QS production would therefore reflect non-resolution of acute 
infection” 
1.10 Plan of Investigation 
The thesis examined the treatment of an infective exacerbation of CF using intravenous 
antibiotic therapy as its study model. The study recruited patients prior to commencing 
antibiotic therapy and then followed them through treatment and to a stable point following 
completion of therapy. 
 
41 
 
Aims of the Thesis 
x A clinical tracking study will be performed to determine the clinical factors associated 
with treatment response to infection and predictors of successful treatment. 
x A microbiological study using culture-based microbiology will identify the effect of 
P.aeruginosa morphotypes and antibiotic resistance patterns on treatment response, 
the effect of antibiotic therapy on bacterial numbers and the effect of other bacteria on 
treatment response. 
x The presence of P.aeruginosa hypermutators using a culture based assay will be 
determined. This will be correlated with clinical outcomes such as improvement in 
lung function, changes in inflammatory markers, and the development of antibiotic 
resistance. 
x Using 16s rRNA gene pyrosequencing from collected sputum samples, bacterial 
populations will be examined at a molecular level to determine relationships between 
bacterial diversity and treatment outcomes. 
x Quorum sensing molecule concentrations will be measured during treatment to 
determine whether a relationship exists between bacterial signalling and clinical 
measures, as well as treatment response. 
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CHAPTER 2 
 
THE CF INFECTIVE EXACERBATION – A CLINICAL TRACKING STUDY 
 
2.1 Introduction 
The CF exacerbation is a well documented but perhaps poorly understood clinical occurrence. 
As part of this study into bacterial ecology in CF exacerbations it is first important to examine 
the exacerbations at a clinical level, both with objective markers such as lung spirometry and 
inflammatory markers, but also subjective markers as reported by quality of life 
questionnaires completed by the patients.  
While the main purpose of the clinical tracking study is to obtain clinical data and matched 
sputum samples for a study of the microbiology of CF exacerbations, it also provides an 
opportunity for a detailed investigation of the CF exacerbation in terms of the response of 
lung function and inflammatory markers to treatment and to determine if any factors 
measured at the start of treatment appear to predict treatment outcome. In CF clinical care the 
aim of treating exacerbations is to preserve lung function and this study therefore examined 
whether patients returned to their baseline lung function (a treatment success) or completed 
treatment without returning to baseline (a treatment failure).  
2.2 Methods 
Ethical Approval and Study Registration 
Ethical approval for the study was sought from the Central London Research Ethics 
Committee and given a favourable opinion (REC reference 11/H0713/7). The trial was also 
registered on clinicaltrials.gov (Identifier: NCT01306279). 
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 Study Design 
The study was designed as a longitudinal study, observing patients during the treatment of an 
infective exacerbation of CF (IECF) and at a stable time after their infection has been treated.  
Sputum samples collected in this tracking study were processed as discussed below and used 
in further assays along with the clinical measurements collected as described in later chapters. 
Participant selection and recruitment 
Patients were recruited from the adult cystic fibrosis patient group attending the Royal 
Brompton Hospital (RBH). Only those patients who were chronically infected with 
Pseudomonas aeruginosa were included. Chronic infection was defined as a minimum of 2 
positive sputum cultures in the preceding 6 months prior to study recruitment. This was a 
local modification of the Copenhagen criteria90, requiring persistent presence of PA over a 6 
month period (most patients have sputum samples taken every 3 months). 
Patients were invited to participate in the study when they attended RBH to commence 
intravenous antibiotic treatment for an IECF. 
Inclusion and Exclusion Criteria 
Patients were included in the study only if they met the criteria for a definition of an IECF as 
set out by the 1994 CF Foundation Microbiology and Infectious Disease Consensus 
Conference as described on page 27-28. These criteria were decided upon as they were based 
on clinical consensus rather than designed for a particular study. 
Patients were excluded from the study if any of the following applied: 
1. Age under 16 years at time of recruitment. 
2. Unable to give consent or patients with significant mental health problems. 
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3. Co-existent active allergic bronchopulmonary aspergillosis (ABPA) requiring a 
change in steroid or anti-fungal therapy. 
4. A previous participant in the study. 
5. Antibiotic therapy for an exacerbation in the previous 4 weeks 
 
Treatment of Pulmonary Exacerbations 
Study participants received a combination of two antibiotics, generally a beta-lactam 
antibiotic and an aminoglycoside, as per routine clinical practice at RBH. Antibiotic choice 
was determine by the treating clinician based on previous antibiotic sensitivity patterns and 
known drug allergies. Maintenance oral or inhaled antibiotics, oral corticosteroids, and 
inhaled dornase alpha were continued if they had been on these therapies at a stable dose for 
the preceding 2 months. 
Subjects were scheduled to receive a 14 day course of intravenous antibiotics as was routine 
clinical practice at RBH at the time of the study. 
Subjects could receive the antibiotic therapy either in the hospital or at home. Patients who 
received their antibiotic therapy at home were asked to return to RBH on the study days for 
assessment. 
Study Visits  
Subjects were assessed on days 1, 7, and the last day of treatment (day 10 or 14) of their 
antibiotic therapy. The day 1 assessments were completed prior to commencing antibiotic 
therapy. Data was also collected from the subject’s medical records of the best spirometry 
values in the preceding six months. 
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Study Questionnaires 
At each study visit, subjects were asked to complete 2 quality of life (QOL) questionnaires, 
the Brompton CF Questionnaire (BCFQ) and the Cystic Fibrosis Questionnaire-revised 
(CFQR).  
The CFQR is a well recognised and validated QOL questionnaire. In this study the 
Adolescent and Adult UK version was used. The form (see appendix) is 50 questions 
pertaining to all areas of symptoms related to CF. The resultant score is given in 13 separate 
domains. In this study only the respiratory domain score was analysed. A maximum score is 
100, the minimum being 0, and a lower score is indicative of a greater burden of symptoms. 
The BCFQ is a shorter questionnaire of 38 questions providing a single score out of 100. In 
this questionnaire a higher score is indicative of increased symptoms. 
Spirometry 
Subjects performed spirometry using forced manoeuvres to obtain FEV1, FVC and FEF25-75. 
The best of a maximum of 3 attempts made on a hand   held   spirometer   (Easyone™  
Spirometer, ndd Medizintechnik, Switzerland) was recorded, as per clinical practice at RBH. 
Percent predicted values were calculated using the European Coal and Steel Community 
(ECSC) reference values. 
Blood Testing 
A sample of blood (approximately 5ml) was obtained from patients at each study day during 
antibiotic therapy. Samples were processed in the haematology and biochemistry labs at RBH 
for measures of total white cell count, neutrophil count and C-reactive protein (CRP). 
Sputum Sample 
A sputum sample was collected from each subject and processed as described in the 
following section. Patients who were non-productive remained in the study. 
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Sputum Processing  
Sputum was collected from patients in sterile pots and processed within 30 minutes of 
expectoration with aliquotting into 4 samples under sterile conditions.  
A – Routine microbiology culture and sensitivities 
B – Pseudomonas hypermutator assay 
C – Identification of bacteria using 16SRNA identification techniques 
D – Quorum sensing molecule assay 
A minimum of 0.5ml of sputum was aliquoted into each pot. 
Sample A was transferred to the microbiology laboratory at RBH for further processing as per 
usual clinical practice. Sample B was shipped at ambient temperature overnight to a separate 
facility (Papworth Hospital) for the hypermutator assay described in Chapter 4. Samples C 
and D were immediately placed on dry ice and then stored as whole sputum at -80°C for later 
testing. 
Treatment Outcomes 
For the purpose of analysis a successful outcome of antibiotic treatment was defined as a 
return of FEV1% predicted to within 10% of their previous stable value (defined as the best 
FEV1 in the preceding 6 months) and a CRP less than 30 at the completion of antibiotic 
therapy. This spirometry definition was based on a large registry data study that defined 
failure to recover baseline lung function as being less than 90% of baseline91, with CRP value 
being based on clinical experience.  
Subject Monitoring after Completion of Antibiotic Therapy 
Patients were followed up as per routine clinical practice. One month after completion of 
antibiotic therapy patients were reviewed in outpatient clinic and measures of spirometry 
were recorded along with collection of a sputum sample which was processed as above. 
Patients were then monitored for up to 6 months after treatment while under usual clinical 
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follow-up for any further exacerbations to determine time to next exacerbation (which could 
be treated with either oral or intravenous antibiotics). 
 
Statistical Methodology 
Continuous variables were compared using Mann-Whitney testing for non-paired data, and 
Wilcoxon Matched pairs test for paired data. Categorical variables were examined user 
Fisher’s  exact  test.   
Correlations were performed using Spearman’s   rank   correlation   co-efficient. Time to next 
exacerbation data was examined using a log rank test. 
All data is expressed as median values with the interquartile range. All statistical analysis was 
performed using Graphpad Prism (GraphPad Software Inc). 
No power calculations were performed for this study as it was intended as a hypothesis 
generating pilot study to guide future larger studies. Equally no correction has been made for 
multiple comparisons to assist in generation of hypotheses, rather than confirmation of an 
effect.  
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2.3 Results 
Patient Population 
Subjects were recruited from 01/06/2010 until 30/09/2011. Over this time, 30 subjects 
consented to participate in the study. Two patients were withdrawn from the study in the first 
week (1 withdrew consent, 1 began treatment for allergic bronchopulmonary aspergillosis), 
one patient did not culture PA from sputum samples. Data from 27 subjects were analysed.  
The median age of subjects was 30 years, and there were 12 males and 15 females. Thirteen 
of the subjects (48%) were homozygous for the phe508del mutation, ten were heterozygote. 
Only one patient did not carry the phe508del mutation and genotyping was not available for a 
further 3 patients. Twenty-six patients were pancreatic insufficient. Eight patients had co-
existent CF related diabetes. Prior to the exacerbation, subjects had a stable baseline median 
FEV1 of 1.6 litres (IQR 1, 2.2), with a median FEV1 % predicted of 48% (IQR 35, 67). 
Baseline characteristics were analysed by comparing treatment outcome groups. Twenty 
patients were deemed a treatment success and 7 were a treatment failure. When comparing 
groups by outcomes, those in the treatment success group were significantly older than those 
in the treatment failure group (median age 37 (28, 46) vs. 23 (18, 30), p=0.04). There were no 
differences between the treatment outcome groups when comparing gender, phe508del 
homozygosity, pancreatic insufficiency or the presence of diabetes. 
There were no significant differences in stable lung function prior to the exacerbation 
between the treatment success and failure groups. However, there was a significantly longer 
time from stable measure to exacerbation in the treatment failure group as compared with the 
treatment success group as demonstrated in table 2.1. There were no differences between the 
groups when comparing regular medications. 
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Table 2.1  Baseline characteristics of study subjects. Last stable lung function was the best measure in the preceding 6 months. Data is presented as all 
subjects and then a comparison of groups defined by treatment outcomes. p values are determined with Mann-Whitney test for continuous 
variables and Fishers exact test for categorical variables.
 All 
(n=27) 
Treatment 
Success 
(n=20) 
Treatment 
Failure 
(n=7) 
p-value 
Age (Median (IQR)) 30 (23,43) 37 (28,46) 23 (18,30) 0.04 
M:F 12:15 10:10 2:5 0.41 
phe508del homozygous 13 8 5 0.21 
Pancreatic insufficiency 26 19 7 1.0 
CF related diabetes 8 6 2 1.0 
Last Stable Lung Function-  median (IQR)                                                           
FEV1 (litres) 1.6 (1.0,2.2) 1.6 (1.0,1.9) 2.1 (1.0,2.5) 0.52 
FEV1 %pred 48 (35,67) 46 (35,62) 51 (33,78) 0.42 
FVC (litres) 2.8 (2.0,3.7) 2.8 (2.1,3.8) 2.8 (2.0,3.1) 0.30 
FVC %pred 78 (66,92) 81 (67,93) 71 (55,91) 0.26 
Median days from stable measure to 
exacerbation 
149 (94,207) 130(82,170) 240(160,260) 0.01 
Regular CF medications 
Inhaled Colomycin 21 15 6 1.0 
Inhaled Tobramycin 7 5 2 1.0 
Inhaled DNAse 24 17 7 0.55 
Inhaled Hypertonic Saline 6 4 2 0.63 
Azithromycin 23 16 7 0.55 
Flucloxacillin 11 8 3 1.0 
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Antibiotic Therapy 
Duration of Antibiotic Therapy 
Twenty seven subjects completed courses of intravenous antibiotics. Nineteen subjects 
completed a 14 day course of antibiotics with the remaining 8 completing a 10 day course of 
antibiotics. Patients who stopped treatment at 10 days did so due to patient preference with 
clinician approval. There was no relationship between antibiotic duration and treatment 
success, day 1 lung function or lung function improvement. Day 1 FEV1 as percentage of 
baseline values were not significantly different between those who received 10 days of 
treatment (71% (59,96)) compared with those who received 14 day (87% (76,90)), p = 0.42. 
Median percentage improvement in FEV1 for 10 days therapy was 19% compared with 16% 
for 14 days therapy (p>0.05). Median FEV1 as a percentage of baseline values at the end of 
treatment for those stopping at day 10 were 92% (87,100) with a minimum value of 65%. 
Antibiotic Choice 
As per local clinical guidelines, all subjects received two intravenous antibiotics, a beta-
lactam antibiotic and an aminoglycoside or colomycin. Twelve subjects received ceftazidime, 
13 received meropenem and 2 received aztreonam. Of the aminoglycosides/colomycin, 22 
received tobramycin, 4 received colomycin and 1 subject received gentamicin. 
There were no significant differences in treatment success or improvement in FEV1 when 
comparing antibiotic groups. Median percentage improvement in FEV1 in those receiving 
ceftazidime was 19% compared with 18% for those receiving meropenem (p=0.93) as shown 
in Figure 2.1. The number of patients receiving aztreonam was too small for non-parametric 
comparison.
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Figure 2.1 The % change in FEV1 during treatment of an exacerbation with a comparison of 
subjects receiving ceftazidime with subject receiving meropenem. Data is presented 
as a box-and-whisker plot with the box representing median value with interquartile 
range and the whiskers representing minimum and maximum values. No significant 
difference is seen between groups (p=0.93) 
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Figure 2.2  The % change in FEV1 during treatment of an exacerbation with a comparison of 
subjects receiving 10 days of treatment with those receiving 14 days. Data is 
presented as a box-and-whisker plot. The boxes represent median values and 
interquartile ranges. The whiskers represent maximum and minimum values. No 
significant difference is seen between groups (p= 0.42) 
 
Antibiotic Usage and Time-to-Next-Exacerbation (TTNE) 
Time to next exacerbation was not affected by either antibiotic choice or antibiotic duration. 
When comparing beta-lactam antibiotics, the median TTNE following a course of 
meropenem was 66 (33,157) days compared with 92 (72,157) for those subjects who received 
ceftazidime (p=0.78). 
Subjects who received ten days of antibiotic therapy had a median TTNE of 96 days, 
compared with 73 days for those who received 14 day courses, (p=0.83). 
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Figure 2.3  A comparison of time to next exacerbation values in subjects receiving meropenem or 
ceftazidime. Data is presented as a Kaplan-Meier plot, with the x-axis representing 
time to next exacerbation. No significant difference is seen between groups (p=0.78) 
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Figure 2.4  A comparison of time to next exacerbation values in subjects receiving 10 or 14 days 
of antibiotic therapy. Data is presented as a Kaplan-Meier plot, with the x-axis 
representing time to next exacerbation. No significant difference is seen between 
groups (p=0.83) 
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Lung Function Changes During the Exacerbation Treatment 
FEV1 
Examining the subject group as a whole there was a significant drop in median FEV1 at the 
start of the exacerbation (1.3L (0.9,1.5) as compared with the stable, pre-exacerbation 
baseline value (1.6L (1.0,2.2)), p= <0.0001. There was a significant rise in median FEV1 
during treatment which was seen at day 7 and maintained throughout the treatment to the 
stable post-treatment result (Table 2.2 and Figure 2.5a). 
When examining subgroups based on treatment success or failure, both groups had 
experienced a significant decrease in median FEV1 from baseline to the start of the 
exacerbation as documented in table 2.2. In the treatment success group a significant rise in 
median FEV1 was seen at day 7 and maintained through treatment and to the stable post-
treatment measure. In the treatment failure group there was no significant difference between 
the day 1 and day 7 median FEV1. However, by the end of treatment a significant rise in 
FEV1 was noted but this was not continued onto the stable post-treatment value. There were 
no significant differences between the groups for median FEV1 values at any time-point of 
the study (Table 2.2 and Figures 2.6 and 2.9a). 
FEV1 %predicted 
As with FEV1, when looking at the subject group as a whole, there was a significant drop in 
median FEV1 % predicted from stable baseline to the start of the exacerbation. A significant 
improvement was seen at day 7 and this improvement was maintained through all measured 
time-points including the stable post-treatment value (Table 2.2 and Figure 2.5b). 
When examining subgroups, the significant drop in FEV1 % predicted was seen at the start of 
exacerbations in both treatment success and failure groups with no significant difference in 
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median values between the groups. In the treatment success group there is a significant 
improvement in FEV1 % predicted at day 7 which is maintained throughout all following 
time points. In the treatment failure group no significant improvement in FEV1 % predicted is 
seen at any treatment time point. (Table 2.2 and Figures 2.7 and 2.9b). 
FEV1 as a percentage of the baseline value (FEV1 %OBL) 
In the study population as a whole there was a significant drop in FEV1 %OBL from a 
baseline value of 100% to the day 1 value. After the commencement of treatment there were 
significant improvements in FEV1 %OBL for all time-points (Table 2.2 and Figure 2.5c) 
When comparing subgroups divided by treatment success or failure, there was a significant 
drop in median FEV1 %OBL at day 1 in both groups, but the value in the treatment failure 
group was significantly lower (65% vs. 89%, p= 0.001). In the treatment success group there 
were significant improvements in median FEV1 %OBL at all subsequent time groups. In the 
treatment failure group the improvement in median FEV1 %OBL was only seen at the end of 
treatment values. The median value of FEV1 %OBL was significantly greater in all treatment 
time-points for the treatment success group with the exception of the stable post-treatment 
value (Table 2.2 and Figures 2.8 and 2.9c) as would be expected given the definition of 
treatment success was based on the FEV1 %OBL value at the end of treatment being greater 
than 90% . 
FVC and FVC% predicted 
Overall there was a significant drop in median FVC from baseline values to the start of an 
exacerbation. After commencing antibiotic therapy there were significant improvements in 
median FVC for all time-points. In both treatment success and treatment failure subgroups 
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there were significant drops in median FVC in both groups with a significant improvement 
seen at the end of treatment. A similar pattern was seen with FVC % predicted. 
FEF25-75 % predicted 
When reviewing all patients the median FEF25-75 % predicted values improved marginally at 
day 7 and day 10 but this significance in improvement was lost by the end of treatment 
values. A similar pattern was seen in the treatment success group but no significant changes 
in FEF25-75 % predicted were seen in the treatment failure group. 
 
 
 
 
 
 
 
 
 
Table 2.2  Spirometry values during treatment CF exacerbation for all patients and then a 
comparison of groups defined by treatment outcome. Baseline values is the best value 
in the preceding 6 months. *   p<0.05   compared   with   baseline   value.   †   p<0.05  
compared with day 1 value. 
 
 All 
(n=27) 
Treatment 
Success 
(n=20) 
Treatment 
Failure 
(n=7) 
p-value 
FEV1 
Baseline 1.6 (1.0,2.2) 1.6 (0.9,1.9) 2.1 (1.0,2.5) 0.35 
Day 1 1.3 (0.9,1.5)* 1.3 (0.9,1.6)* 1.3 (0.7,1.4)* 0.65 
Day 7 1.7  (1.1,2.0)† 1.7  (1.4,2.0)† 1.3 (0.9,1.9) 0.56 
End of Treatment 1.6  (0.9,2.1)† 1.6  (1.0,2.1)† 1.5  (0.9,2.2)† 0.79 
Stable Post 1.4  (0.8,1.9)† 1.5  (1.2,2.2)† 0.8 (0.7,1.6) 0.60 
FEV1 % predicted 
Baseline 48 (35,67) 46 (35,62) 51 (33,78) 0.42 
Day 1 39 (29,48)* 41 (31,48)* 33 (24,48)* 0.30 
Day 7 51  (36,60)† 52  (40,65)† 37 (25,56)* 0.16 
End of Treatment 48  (27,59)† 51  (37,59)† 44 (25,67) 0.84 
Stable Post 44  (26,58)† 47  (32,67)† 24 (24,45) 0.10 
FEV1 as % of baseline 
Day 1 85 (69,93)* 89 (81,95)* 65 (57,71)* 0.001 
Day 7 101  (89,105)† 104  (96,115)† 83 (73,91) 0.002 
End of Treatment 102  (89,106)† 104  (96,111)† 86  (68,87)† 0.0001 
Stable Post 97  (89,105)† 97  (90,105)† 75 (73,99) 0.13 
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Comparing changes in lung function between treatment outcome groups 
The change in FEV1, FEV1 % predicted and FEV1 as a percentage of baseline were examined 
between baseline values and day 1 values, and between day 1 values and the end of treatment. 
When comparing the change from baseline to the start of the exacerbation there was a 
significantly greater decrease in all of the measured parameters for the treatment failure 
group as compared with the treatment success group. No significant differences were seen 
between treatment success and treatment failure groups when comparing changes in 
spirometry values between day 1 of treatment and the end of treatment (Table 2.3) 
 
 
 
 
 
 
 
 
 
 
Table 2.3  Median changes in lung function during exacerbation treatment and comparing 
groups defined by treatment outcomes. Baseline value is the best value in the 
preceding 6 months. All values are medians with interquartile ranges. 
 All 
(n=27) 
Treatment 
Success 
(n=20) 
Treatment 
Failure 
(n=7) 
p-value 
Change in FEV1 
Baseline to day 1 -0.3 
(-0.7,-0.1) 
-0.2 
(-0.4,-0.1) 
-0.8 
(-1.1, -0.3) 
0.01 
Day 1 to End of Rx 0.2 (0.1,0.6) 0.3 
(0.1,0.6) 
0.2 
(0,0.8) 
0.91 
Day 1 to Day 7 0.2  (0.1,0.5) 0.2 (0,0.5) 0.3(0.1,0.5) 0.67 
Day 7 to End of Rx 0 (0,0.2) 0.1(0,0.2) 0(-0.1, 0.1) 0.17 
Change in FEV1 % predicted 
Baseline to day 1 -9 
(-18,-3) 
-7 
(-11,-2) 
-23 
(-30,-9) 
0.009 
Day 1 to End of Rx 7 
(3,15) 
6 
(3, 15) 
8 
(0,24) 
0.88 
Day 1 to Day 7 7 (2,13) 7 (1,13) 6 (3,13) 0.95 
Day 7 to End of Rx 1(-2,3) 1 (-3,3) -1 (-2,4) 0.69 
Change in FEV1 as % of baseline 
Baseline to day 1 -16 
(-34,-8) 
-12 
(-22,-5) 
-35 
(-43,-29) 
0.003 
Day 1 to End of Rx 15 
(8,27) 
15 
(9,27) 
16 
(4,30) 
0.84 
Day 1 to Day 7 15 (4,24) 14 (2, 29) 18 (11,22) 0.65 
Day 7 to End of Rx 2 (-2,7) 3(-2,10) -2(-9,3) 0.14 
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Figure 2.5 (a) Median FEV1 for all subjects at each time point of treatment. Data is presented as a box 
and whisker plot with boxes representing median and interquartile ranges and whiskers 
representing minimum and maximum values 
 (b) Median FEV1 % predicted for all subjects at each time point of treatment. Data is 
presented as a box and whisker plot with boxes representing median and interquartile 
ranges and whiskers representing minimum and maximum values 
 (c) Median FEV1 %OBL all subjects at each time point of treatment. Data is presented as a 
box and whisker plot with boxes representing median and interquartile ranges and 
whiskers representing minimum and maximum values 
(a) 
(b) 
(c) 
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Figure 2.6 A plot of FEV1 during antibiotic treatment for all subjects at each time point with treatment 
success subjects in blue and treatment failure subjects in red. Baseline value is the best 
value in the preceding 6 months   
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Figure 2.7 A plot of FEV1 % predicted during antibiotic treatment for all subjects at each time point 
with treatment success subjects in blue and treatment failure subjects in red. Baseline value 
is the best value in the preceding 6 months  
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Figure 2.8 A plot of FEV1 as a % of baseline during antibiotic treatment for all subjects at each time 
point with treatment success subjects in blue and treatment failure subjects in red. Baseline 
value is the best value in the preceding 6 months 
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2.9 (a) 
2.9 (b) 
63 
 
 
Ba
sel
ine
Da
y 1 Da
y7
En
d o
f R
x
Sta
ble
 po
st
0
50
100
150
Treatment Failure
Treatment Success
FE
V 1
as
 %
 o
f b
as
el
in
e
 
Figure 2.9 (a) Median FEV1 values with interquartile ranges (error bars) for each time point of 
antibiotic treatment. Treatment success subjects in blue, treatment failure subjects in red. 
No significant differences are seen at any time point between groups. 
 (b) Median FEV1 % predicted values with interquartile ranges (error bars) for each time 
point of antibiotic treatment. Treatment success subjects in blue, treatment failure subjects 
in red. No significant differences are seen at any time point between groups. 
 (c) Median FEV1 as a percentage of baseline values with interquartile ranges (error bars) 
for each time point of antibiotic treatment. Treatment success subjects in blue, treatment 
failure subjects in red. Values are significantly different (p<0.05) for the day 1, day 7 and 
end of treatment values. 
 
  
2.9 (c) 
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Markers of Inflammation During the Exacerbation 
C-reactive Protein (CRP) 
Thirteen patients had CRP levels above the normal range (0-10mg/L) at the beginning of the 
exacerbation. When examining all patients there was a significant decrease in the median 
CRP value between the start of antibiotic therapy and day 7 of treatment (10 vs. 4, p<0.002) 
as demonstrated in Table 2.4 and Figure 2.10. No significant difference was seen in median 
CRP values between treatment outcome groups; treatment success 9 (5, 24), treatment failure 
33 (9, 49) 
 
 
 
 
 
 
Table 2.4  CRP median values (with IQRs) during antibiotic therapy and comparison of 
treatment groups.  †  p<0.05  compared  with  day  1  value.    
 All 
(n=27) 
Rx 
Success 
(n=20) 
Rx 
Failure 
(n=7) 
p-value 
CRP (mg/L) median and IQR 
Day 1 10 (6,33) 9 (5,24) 33 (9,49) 0.09 
Day 7 4  (1,9)† 4 (1,8) 9 (4,12) 0.23 
End Rx 4  (1,7)† 2 (1,6) 6 (3,24) 0.17 
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Figure 2.10   Individual CRP responses to antibiotic therapy. Treatment success subjects in blue, 
treatment failure patients in red. No significant differences are seen between treatment 
outcome groups 
Correlations were performed to examine the relationship between changes in CRP with 
changes in spirometry values. There were no significant correlations between the change in 
CRP and absolute change in FEV1 (r= -0.068, p= 0.74), or between change in CRP and 
percent change in FEV1 (r= 0.014 p= 0.95). 
White Cell Count 
The total white cell count reduced significantly in all groups when comparing the start of 
treatment with day 7 and the end of treatment. There were no significant differences in white 
cell count between the treatment outcome groups. Analysis of neutrophil counts revealed a 
similar pattern with significant decreases in neutrophil values in both treatment outcome 
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groups, but no significant differences between the groups as shown in Table 2.5 and Figures 
2.11 and 2.12) 
 
 
 
 
 
 
 
Table 2.5  Median total white cell counts and neutrophil counts during exacerbation treatment 
and a comparison of groups defined by  treatment  outcome.  †  p<0.05  compared  with  
day 1 value. 
 
 
 
 
 All 
(n=27) 
Rx 
Success 
(n=20) 
Rx 
Failure 
(n=7) 
p-value 
White cell count (x109/L) 
Day 1 13.1 
(9.9,14.9) 
11.9 
(8.7,14.6) 
14.3 
(12.6,15.7) 
0.11 
Day 7 8.8 
(6.9,10.8)† 
8.7 
(6.8,10.8)† 
8.9 
(7.7,10.9)† 
0.69 
End Rx 9.0 
(6.5,10.9)† 
9.6 
(6.7,10.6)† 
7.3 
(5.5,12.8)† 
0.35 
Neutrophil count (x109/L) 
Day 1 9.7 
(7.7,12) 
8.9 
(6.4,12) 
11.0 (9.8, 
14) 
0.09 
Day 7 6.2 
(4.3,7.5)† 
5.5 
(4.3,7.4)† 
7.0 
(4.7,8.9)† 
0.40 
End Rx 6.0 
(3.9,8.7)† 
6.3 
(4.2,8.3)† 
5.8 
(3.1,9.4)† 
0.74 
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Figure 2.11   Individual total white cell count responses to antibiotic therapy. Treatment success 
subjects in blue, treatment failure patients in red. No significant differences are seen 
between outcome groups 
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Figure 2.12    Individual neutrophil count responses to antibiotic therapy. Treatment success 
subjects in blue, treatment failure patients in red. No significant differences are seen 
between treatment outcome groups. 
 
Relationships between day 1 total white cell and neutrophil counts and the FEV1 as a 
percentage of baseline were examined. There were no significant correlations seen. The 
relationship between changes in lung function and changes in total white cell counts and 
neutrophil counts was also examined. While in general no significant association was found 
there was a moderate correlation between the percent change in FEV1 and change in 
neutrophil count. Finally the relationship between inflammatory markers at the end of 
treatment and the time to exacerbation was examined with no significant correlations being 
found as documented in table 2.6.  
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Table 2.6  Correlations between spirometry and white cell counts and between inflammatory 
markers and time to next exacerbation. Correlations were performed using 
Spearman’s  rank  correlation  co-efficient. 
Body Mass Index Changes During Treatment 
Body mass index (BMI) was measured at the beginning and end of antibiotic treatment 
(Table 2.7). BMI at the start of the exacerbation was not significantly different between the 
treatment outcome groups. Equally there were no significant changes in BMI during 
treatment for any patient group. No relationship was seen between change in BMI and change 
in FEV1 during treatment (r= -0.02, p= 0.93). 
 
 
 
Correlations  
 
R value P value 
Spirometry 
Day 1 FEV1%OBL  vs. day 1 WCC -0.22 0.27 
Day 1 FEV1 %OBL vs. day 1 neutrophil 
count 
-0.28 0.16 
Absolute change in FEV1 vs. change in 
WCC during treatment 
-0.19 0.34 
Absolute change in FEV1 vs. change in 
neutrophil count during treatment 
-0.22 0.27 
Percent change in FEV1 vs. change in 
WCC during treatment 
-0.32 0.12 
Percent change in FEV1 vs. change in 
neutrophil count during treatment 
-0.51 0.008 
Time to Next Exacerbation 
End of treatment CRP vs. TTNE 0.20 0.38 
End of treatment WCC vs. TTNE 0.26 0.25 
End of treatment neutrophil count vs. 
TTNE 
-0.13 0.56 
70 
 
 
 
 
 
Table 2.7  Median BMI values at the start and end of exacerbation treatment and a comparison 
of groups defined by treatment outcome. Data is presented as median values and 
interquartile range. 
Quality of Life Scores 
Correlations between Quality of Life Scores and Spirometry Values 
There were no significant correlations between CFQ-R respiratory domain score and 
spirometry values (FEV1, FEV1% predicted or FEV1 as percentage of baseline) at day 1 of 
treatment. There was a mild but significant correlation between FEV1 as a percentage of 
baseline and the respiratory domain score of the CFQ-R when all study days were collated 
(Spearman r = 0.33, p = 0.003). There were no significant correlations between the BCFQ 
score and FEV1 as a percentage of baseline or FEV1 % predicted. 
Changes in Quality Of Life Scores During Antibiotic Treatment 
When examining all subjects, there was a significant improvement in the CFQR respiratory 
domain score between the beginning and end of therapy (median 44 vs. 61, p=0.003) as 
documented in Table 2.8. When examining different treatment groups there were similar 
improvements in CFQR respiratory domain scores for both groups. 
 
 
 All 
(n=27) 
Rx Success 
(n=20) 
Rx 
Failure 
(n=7) 
p-value 
BMI (kg/m2) 
Day 1 20.4 
(18.1,22.6) 
21.1 
(17.8,22.8) 
19.6 
(18.1,23.1) 
0.80 
End Rx 21.0 
(18.0,22.7) 
21.0 
(17.8,22.8) 
21.2 
(19.9,22.6) 
0.72 
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Table 2.8  CFQ-R respiratory domain score during treatment and comparing treatment outcome 
groups. * p<0.05 compared with day 1 value. 
 
When examining BCFQ scores in all patients there was a statistical significant decrease in the 
median score at the end of treatment compared to when treatment was commenced as shown 
in Table 2.9. This was also seen in the treatment success group but not the treatment failure 
group. However, there were no significant differences of median scores between the 
treatment groups at either time point. 
 
 
 
 
Table 2.9  BCFQ score during treatment and comparing treatment outcome groups. * p<0.05 
compared with day 1 value 
There were no significant correlations between changes in QOL scores and changes in 
spirometry values during treatment of an exacerbation. As the Brompton Cystic Fibrosis 
Questionnaire is not yet in widespread use, the BCFQ scores were correlated with the CFQR 
respiratory domain scores for all measured values. There was a moderate correlation between 
scores (r= -0.49, p<0.0001) 
 All 
(n=27) 
Rx 
Success 
(n=20) 
Rx 
Failure 
(n=7) 
p-value 
CFQ-R Respiratory Domain Score 
Day 1 44 
(39,61) 
50 
(39,61) 
42 
(22,47) 
0.25 
End Rx 61 
(44,82)* 
67 
(44,83)* 
50 
(36,72)* 
0.21 
 All 
(n=27) 
Rx 
Success 
(n=20) 
Rx 
Failure 
(n=7) 
p-value 
BCFQ score 
Day 1 61 
(53,71) 
61 
(50,67) 
66 
(55,79) 
0.27 
End Rx 52 
(35,61)* 
50 
(26,58)* 
68 (41,75) 0.20 
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2.4 Discussion 
In this study a number of significant findings have been recognised. A number of patients did 
not return to baseline lung function at the end of treatment of an exacerbation. This group is 
characterised by a larger drop in lung function from stable baseline values and a longer 
interval between the stable measure and the start of antibiotic treatment. When antibiotic 
treatment is commenced, these patients have similar percentage lung function improvements 
to those who recovered their baseline lung function. A further finding was that in those 
patients deemed a treatment success, the majority of lung function improvement is seen 
within the first 7 days of antibiotic treatment with no significant increase in spirometry 
measures after this time. These will be discussed in the following sections. 
Is the Subject Cohort an Accurate Representation of the CF Population? 
Clearly a limiting factor of any exacerbation study, especially one that is only analysing those 
receiving intravenous antibiotics, could be a skew towards patients who have more severe 
disease and lower baseline lung function. To some extent this is seen in this study. The 
median FEV1 % predicted for the adult CF clinic at RBH is 62.3% (CF Registry data 2012) 
compared with 48% for this cohort. However it is also possible to use the CF registry to 
identify only those patients who have received intravenous antibiotics and have chronic PA 
for each clinic centre. At RBH the median FEV1 % predicted for such a cohort is 50.2%. 
Those patients who are phe508del homozygous are not over-represented in this cohort (48% 
in cohort compared with 50% in the CF registry). It would therefore appear that the subjects 
recruited to this study were an accurate representation of the CF clinic at the centre involved. 
Differences in Baseline Characteristics of Treatment Outcome Groups 
Treatment outcomes of success and failure were based on the recovery of FEV1 to within 
90% of baseline and a CRP of less than 30 mg/L. Only one patient failed to have a CRP of 
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less than 30 mg/L and this subject also failed to improve the FEV1 value to within 90%. 
20/27 patients recovered FEV1 back to within 90% of baseline. This is a lower ratio than has 
been seen in other studies. Sanders et al92 analysed US CF Registry Data and determined that 
75% of patients returned to within 90% of baseline. 
One of the main aims of the clinical tracking study was to determine if there were any 
predisposing factors at the time of an exacerbation that could predict treatment success. There 
were no significant differences in the baseline characteristics between the treatment outcome 
groups except for age and median time from stable measure to the start of treatment of the 
exacerbation. 
At first examination it is difficult to explain the significantly lower age of the treatment 
failure group and it may well be an effect of the small numbers in the treatment failure group 
and a cluster of older people in the treatment success group (6/20 were older than 45 years). 
The level of statistical significance when comparing the differences in time from stable 
measure suggests it is unlikely to be explained by small numbers in the treatment failure 
group. In combination with the significantly larger drop in lung function from baseline to day 
1 seen in the treatment failure group, it could be considered that those in the treatment failure 
group have been unwell for longer before commencing antibiotic therapy. This prolonged 
time without treatment leads to them having worse lung function at the time of commencing 
antibiotic therapy. These findings agree broadly with those of Sanders et al92 who found that 
failure to return to baseline was associated with, among other things, a greater drop in FEV1 
at the time of commencing treatment and a longer time from stable baseline measure of lung 
function. Unfortunately the study did not examine the immediate prodrome to the 
exacerbation. By utilising a symptom diary, for example, a much clearer indication of when 
the exacerbation started would have been possible and this would have enabled a clear 
relationship between duration of symptoms and decline in lung function to have been 
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determined. If such a relationship did exist then this would have significant implications to 
the clinical management of CF patients with regards to waiting times for admission to 
commence antibiotic therapy.  
Antibiotic Choice and Duration 
This study could be criticised for not restricting patients to a single combination of 
antibiotics. However, studies have previously shown no significant differences in clinical 
outcomes between the use of meropenem and ceftazidime93;94. This study would concur with 
these previous findings, demonstrating no effect on lung function improvement or time to 
next exacerbation following treatment, although it is important to note that antibiotic choice 
was not randomly allocated. 
The appropriate duration of antibiotic therapy for CF exacerbations is a much debated subject 
with no overall consensus. The aim of the study was to treat patients for 14 days as was 
routine clinical practice at RBH. However some subjects stopped treatment at 10 days. The 
results showed no significant difference in lung function changes and time to next 
exacerbation between those who received 10 days and those who received 14 days. Given the 
small sample size it is difficult to draw any meaningful conclusion from the data regarding 
antibiotic  duration.  Clearly  as  the  patients  are  going  home  “early”  they  are  more   likely to be 
well with recovered lung function and those with lower baseline lung function were likely to 
have been given longer courses of antibiotics. To determine the number of patients required 
in a study to give adequate power to show equivalence of durations of treatment, a power 
calculation was performed. Assuming that equivalence is a difference in median 
improvement in FEV1 of ≤10%, 136 subjects would be required in each group to determine 
equivalence (significance 5%, power 90%) (If the FEV1 difference is reduced to 5%, 542 
subjects would be required in each group). 
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Spirometry Measures During Antibiotic Therapy 
The question of antibiotic duration could also be debated when lung function responses 
during treatment are examined. When the entire cohort was analysed it was clear that, as 
would be expected, there were significant decreases in spirometry values from stable baseline 
to the start of antibiotic therapy. Perhaps more interesting is the finding that in the treatment 
success group, lung function was back to baseline values by day 7 and no significant 
improvement in lung function was seen after this date. Those patients who did not return to 
baseline did not show a significant improvement in lung function at day 7 but did show some 
improvement by the end of treatment. The spirometry measures taken at the stable time post 
treatment were affected by relatively low numbers with patients not attending for the follow-
up visit. This is not the first to show a plateau of spirometry improvement. Collaco et al.95 
have previously shown a similar occurrence with no significant improvements in FEV1 after 
8-10 days of treatment. 
A comparison of treatment outcome groups revealed no significant differences between 
groups for measures of FEV1 and FEV1 % predicted for any time points. As treatment 
outcome was determined by an FEV1 % OBL of greater than 90%, it is unsurprising that this 
measure was significantly different between the groups for each treatment time-point. It 
should also be noted that in the treatment success group, the median FEV1 %OBL was 89% 
(and some patient would fit the criteria for treatment success at the start of treatment with 
FEV1 %OBL greater than 90% and CRP <30 mg/L). 
Perhaps more informative are the analyses of changes in lung function between the treatment 
groups. The treatment failure group had a significantly greater drop in all spirometry 
measures between the baseline values and the day 1 values. There were no significant 
differences between the groups when lung function response to treatment was analysed. It 
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would therefore seem that those patients who failed to return to baseline lung values did so 
because of a larger drop in lung function prior to treatment rather than a failure to respond to 
antibiotic therapy. It is unfortunately beyond the remit of this study to determine whether a 
change in antibiotics would lead to further lung function improvement. It does however raise 
an interesting question regarding antibiotic duration. If baseline lung function is recovered 
within 7 days of treatment for those patients who are going to achieve a return to baseline, 
would it be appropriate to stop antibiotic therapy at this point? Of course, lung function 
recovery is not the only factor to be considered and it may well be that time to next 
exacerbation would be significantly affected by shorter courses of antibiotics. Such questions 
need to be answered in a larger study. 
Inflammatory markers 
The measurement of inflammatory markers is routine in clinical practice. This study 
examined CRP, total white cell count and neutrophil count during CF exacerbations. CRP is a 
sensitive marker for systemic inflammation. Only 13 of the 27 patients had a CRP above the 
normal limit at the start of therapy and the median level of all subject values was 10 mg/L, 
which is within normal limits. The median CRP in the treatment failure group was higher 
than the success group to a level that would be considered clinically significant but it failed to 
reach statistical significance. This finding would be in keeping with the treatment failure 
group being generally more unwell at the beginning of the exacerbation, rather than failing to 
respond to treatment. Total white cell count and neutrophil count were not significantly 
different between the groups and are perhaps less discriminating for systemic inflammation. 
The lack of significant correlation between changes in spirometry and changes in 
inflammatory markers that was noted is likely related to the levels being generally within the 
normal ranges. 
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BMI 
Body mass index (BMI) was shown to be relatively unaffected by treatment for an 
exacerbation with no significant changes seen in either treatment outcome groups. This is 
perhaps not surprising given the relatively short duration of antibiotic therapy. 
Patient Reported Outcome Measures 
Patient reported outcome measures such as quality of life questionnaires are being increasing 
used in clinical research. In CF the most widely used is the Cystic Fibrosis Questionnaire- 
revised (CFQR). The questionnaire has a number of symptom domains, but this study 
examined only the respiratory domain score. The Royal Brompton Hospital CF Department 
has devised a shorter questionnaire, the Brompton CF Questionnaire (BCFQ) which gives a 
total score but combines a number of symptom domains. It is important to note that neither 
questionnaire was designed to be used during an exacerbation, with many questions asking 
about chronic symptoms. Despite this however, significant changes were seen between the 
beginning and end of antibiotic therapy for both questionnaires. Scores were not significantly 
different between treatment outcome groups. This leads to the interesting observation that 
although the patients have bigger drops in lung function, they did not feel more unwell as 
determined by symptom score. This however may be an effect of the potential lack of 
sensitivity of the questionnaires to pick up severity of an exacerbation, something they were 
neither designed nor validated for in this clinical scenario. An important validation of the 
BCFQ was the significant correlation between CFQR respiratory domain and BCFQ scores. 
A higher degree of correlation was likely not seen as the BCFQ includes all symptom 
domains. 
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Treatment Outcomes 
This study utilised the definition of a treatment success as a return to within 90% of the 
baseline FEV1 and a CRP of less than 30. The CRP was less than 30 in all but one patient 
(who also had an inadequate lung function response). This definition is based on our clinical 
practice  rather  than  a  validated  measure  of  “treatment  success”.  At  present  no  such  measure 
exists with clinical studies concerning CF exacerbations often suggesting treatment success 
as decided by the clinician. It is therefore important not to place too much weight on the 
comparison of treatment outcome groups. In fact as this study shows, there was no significant 
difference in the improvement in lung function during treatment between the groups. More 
correctly  our   treatment   failure   group   is   not   a   “failure   to   respond   to   treatment”  group  but   a  
group who were more unwell at the start of treatment of an exacerbation. In light of this all 
subsequent analyses were also performed as correlations between changes in the analysed 
variable with changes in spirometry values. 
 In conclusion, it has been demonstrated that this cohort of patients is a reasonable 
representation of the adult CF population. A significant proportion of patients have 
spirometry values that do not return to baseline at the end of a course of intravenous 
antibiotic therapy. It has been shown that this is due to a larger decline in lung function prior 
to commencement of antibiotics rather than a failure to respond to treatment. Subjects who 
returned lung function back to baseline did so within 7 days of treatment. This may indicate 
that shorter antibiotic course than are widely used at present may be equally effective. 
Serum inflammatory markers and quality of life questionnaires have not been demonstrated 
to be effective at determining treatment response and do not correlate with spirometry 
measures. 
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Having demonstrated the clinical variables during treatment of an exacerbation the following 
chapters will examine microbiological aspects of the CF exacerbation, and comparing with 
the data collected in this study. This will involve an examination of the culture based 
microbiological assays to examine the relationship of PA mucoidy, bacterial density and the 
presence of other organisms with clinical measures of treatment response. The role of PA 
hypermutators in exacerbation severity and treatment response will also be examined. 
An in-depth examination of the CF microbiome using 16S rRNA gene sequencing to identify 
bacteria will then explore the effect of antibiotic therapy on the diversity of the bacteria 
present and if changes in diversity have clinical effects. Finally, an examination of quorum 
sensing molecules during antibiotic treatment will explore the role of cell-to-cell 
communication at the time of exacerbation and whether antibiotic therapy has any effect on 
these systems. 
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CHAPTER 3 
 
THE CF INFECTIVE EXACERBATION – A MICROBIOLOGICAL STUDY 
 
3.1 Introduction 
The majority of microbiology input into CF care is based on routine culture of sputum 
samples on selective media plates. As well as providing information regarding the bacteria 
present, routine culture can be used to calculate bacterial density within sputum samples and 
cultures can be tested against antibiotics to determine in vitro bacterial resistance to therapy. 
This study will examine sputum samples collected during the previous clinical tracking study 
and examine the microbiological response to exacerbation and treatment by comparing with 
the previous obtained clinical measures. 
Aims of the microbiological study 
1. To determine the effect of Pseudomonas aeruginosa (PA) mucoidy on clinical 
outcome measures of lung function and inflammatory markers. 
2. To determine whether PA bacterial density is affected by antibiotic treatment. 
3. To determine whether resistance to the treatment antibiotic affects treatment 
outcomes. 
4. To determine whether the presence of bacteria cultured in addition to PA has an effect 
on clinical outcome measures. 
5. To determine whether the emergence of Candida albicans is associated with worse 
clinical outcome in antibiotic treatment. 
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3.2 Methods 
Sputum samples were collected as described in the previous chapter. Sputum cultures were 
processed and reported by the Microbiology Department, Royal Brompton Hospital, 
following the laboratory protocol for routine clinical processing of CF sputum samples. As 
described in more detail below, sputum samples underwent homogenisation prior to 
inoculation of culture plates. After 24-48 hours of incubation, PA isolates underwent 
antibiotic sensitivity testing.  
Sputum homogenisation and dilution 
An equal volume of  Ringer’s  solution  containing  approximately  10 sterile glass beads (4mm 
diameter) was added to sputum and vortexed to emulsify giving a 1:2 dilution of sputum. 
Further   dilutions  with  Ringer’s   solution  were   performed   to   give   a   final   dilution   of   1:1000  
sputum homogenate 
Inoculation of microbiology plates 
Sputum homogenate was inoculated onto non-selective and selective growth media plates for 
incubation. 
20μl of the 1:1000 dilution sputum homogenate was spread over a chocolate agar plate (a 
non-selective growth medium) and then incubated in CO2 at 37°C. 20 μl of 1:2 dilution 
sputum homogenate was spread over 6 other selective media plates and incubated at 37°C in 
aerobic conditions: 
(i) Difco Pseudomonas agar plate (enhances pyocyanin production to allow 
identification of PA), 
(ii) MacConkey agar plate (selective media for Gram negative organisms and stains 
for lactose fermenters such as E.Coli, Klebsiella sp), 
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(iii)  B.cepacia agar plate (contains antibiotics to allow selective growth of B.cepacia 
and contains an indicator dye which turns the agar pink in the presence of 
B.cepacia),  
(iv) Sabouraud’s   agar   plate      (selective   fungal   growth, low pH inhibits bacterial 
growth),  
(v) Dermasel plate (selective dermatophyte fungal growth),  
(vi) Mannitol salt agar plate (selective growth for Gram positive organisms and 
contains indicator for coagulase reaction). 
All plates were examined and colony counting was performed after 48 hours of incubation. 
Bacterial identification was based on morphological appearances, growth on selective media 
and use of API-20E (bioMerieux Clinical Diagnostics, France) biochemical reaction kits96. 
PA mucoidy was determined by visual appearance of colonies by experienced microbiology 
technicians. PA colony forming units per millilitre of sputum (cfu/ml) were calculated from 
cultured sputum samples for each point study visit. The total cfu/ml was calculated 
combining all morphotypes of PA. 
Antibiotic sensitivity testing – BSAC Disc Diffusion Method 
Antimicrobial susceptibility testing of PA was performed using the disc diffusion method as 
recommended by the British Society for Antimicrobial Chemotherapy (BSAC)97. 
Using a sterile loop, at least 4 four morphologically similar colonies were transferred to 4ml 
of sensitivity broth (ISO-sensitest broth, Oxoid Ltd, Cambridge). The broth was then placed 
in a shaking incubator at 37°C until the visible turbidity was equal to or greater than 0.5 
McFarland standard. The inoculum was spread evenly over the surface of an ISO-sensitest 
agar plate (Oxoid, Cambridge). Within 15 minutes of inoculation antimicrobial discs were 
applied to the surface of the plate with a maximum of 6 discs per plate and then incubated for 
18-20 hours at 37°C. PA organisms were tested against the following antibiotics: amikacin, 
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azithromycin, aztreonam, ceftazidime, chloramphenicol, ciprofloxacin, colistin, gentamicin, 
meropenem, temocillin, timentin and tobramycin. 
After incubation plates were read using the OXOID AURA automated zone reader (Oxoid, 
Cambridge) to measure zone diameters and interpret sensitivity results. 
Liverpool Epidemic Strain typing 
To ensure results were not skewed by the presence of an epidemic strain of PA, which have 
been shown to have increased virulence and transmissibility98;99, PA isolates were also 
assayed for the presence of Liverpool Epidemic Strain (LES) PA. This was kindly performed 
by the HPA Laboratory, Cambridge using an in-house multiplex PCR assay to detect the 
suppression subtractive hybridisation (SSH) sequences PS21 and F9 in bacterial DNA which 
have previously been identified as being specific to LES PA100. 
Statistical methodology 
Statistical analysis was performed as described in the methods section of Chapter 2.  
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3.3 Results 
Of the 27 patients included in the analyses, 12 cultured only a mucoid phenotype of PA, 8 
cultured only non-mucoid PA, with the remaining 7 culturing both mucoid and non-mucoid 
morphotypes of PA. For the purposes of analysis those isolating both mucoid and non-
mucoid morphotypes have been grouped with those isolating the mucoid phenotype. 
Does PA morphotype affect clinical measures? 
There were no significant differences between morphotype groups for day 1 median values of 
FEV1, FEV1 % predicted or FEV1 as a % of baseline, CRP, or total white cell count (Table 
3.1). There was no significant difference in the median age of subjects isolating mucoid 
morphotypes as compared with non-mucoid (mucoid 33 yrs (25,43); non-mucoid 29 yrs (18-
46); p = 0.51) 
Using a Fishers exact test, the distribution of morphotypes between treatment outcomes 
(success or failure, as described in the previous chapter) was examined. There were no 
significant differences between the relative number of subjects isolating the mucoid 
morphotype versus the non-mucoid morphotype in either treatment outcome group at any of 
the study time points (p values; day 1, 1.0; day 7, 0.38; end of treatment, 0.11). 
There were no differences between the groups when comparing the morphotypes present at 
day 1 and the overall improvement in FEV1 (Table 3.1 and Figures 3.1 and 3.2)   
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 Non-mucoid 
(n=8) 
Mucoid 
(n=19) 
p-value 
 
Day 1 median values (IQR) 
FEV1 (litres) 1.5 (0.9, 2.1) 1.3 (0.9, 1.4) 0.52 
FEV1 % pred 38 (25, 66) 39 (30, 47) 0.81 
FEV1 as % of 
baseline 
88 (71, 97) 84 (65, 90) 0.36 
CRP (mg/L) 7 (2, 30) 16 (7,33) 0.14 
WCC (x 109/L) 8.3 (7.4,16.3) 13.2 (10.9, 15.0) 0.13 
Spirometry change during treatment, median (IQR) 
FEV1 improvement 
(Litres) 
0.1 (0, 0.5) 0.3 (0.1, 0.6) 0.26 
FEV1 improvement 
% 
14 (-1, 20) 22 (13, 37) 0.13 
 
Table 3.1   Day 1 spirometry values and inflammatory markers comparing non-mucoid and 
mucoid morphotypes of PA 
  Changes in spirometry during treatment comparing non-mucoid and mucoid 
morphotypes of PA 
 
 
No
n-m
uc
oid
Mu
co
id
0
50
100
CR
P
No
n-m
uco
id
Mu
coi
d
0
5
10
15
20
25
W
hi
te
 c
ell
 c
ou
nt
 
Figure 3.1  Day 1 inflammatory markers comparing non-mucoid and mucoid morphotypes of PA. 
Data is presented as box and whisker plots with boxes representing median and 
interquartile ranges and the whiskers representing maximum and minimum values. No 
significant differences were seen for CRP or white cell count. 
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Figure 3.2 (a)Day 1 spirometry values comparing non-mucoid and mucoid morphotypes of PA 
(b) change in spirometry (FEV1 improvement and %FEV1 improvement) comparing 
morphotypes. Data is presented as box and whisker plots with boxes representing 
median and interquartile ranges and the whiskers representing maximum and 
minimum values. No significant differences were seen for any of the spirometry 
measures. 
(a) 
(b) 
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Is PA Bacterial Density Affected by Antibiotic Treatment?  
The median PA bacterial density on day 1, prior to commencement of antibiotics, was 7.3 
x107 cfu/ml (6.8 x106, 7.3 x108). There were no significant relationships between spirometry 
values on day 1 of treatment with bacterial density as detailed in table 3.2. 
 
 
 
 
Table 3.2  Correlations between day 1 spirometry values and PA bacterial numbers (cfu/ml). No 
significant   correlations   are   seen.  Correlations   are   performed  using  Spearman’s   rank  
correlation co-efficient.  
 
There was a greater density of bacteria in the treatment failure group but this did not reach 
statistical significance (4.5 x 107 vs. 4.5 x 108, p=0.24) as represented in figure 3.3. 
In the total study population there were no significant differences between PA cfu/ml prior to 
starting therapy compared with the end of therapy or the stable post therapy measure as 
demonstrated in Table 3.3 and Figure 3.4. No difference was seen in the change in PA cfu/ml 
between the treatment success and failure groups (success: -3.3 x108, failure: -2.9 x106, p= 
0.40).  
 
 
Correlations  
 
R value P value 
Day 1 Spirometry vs. PA cfu/ml 
FEV1 -0.01 0.95 
FEV1 % predicted 0.05 0.83 
FEV1 % OBL -0.22 0.30 
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Figure 3.3 PA CFU/ml prior to commencing therapy comparing treatment outcomes. Data is 
presented as box and whisker plots with the boxes representing median values and 
interquartile ranges. The whiskers represent maximum and minimum values. No 
significant difference in PA bacterial density is seen between treatment outcome 
groups 
 
 
 
 
 
 
89 
 
 
 
 
 
 
 
Table 3.3  The change in PA bacterial numbers during treatment and comparing treatment outcome 
groups. No comparison was possible for the stable post treatment values due to insufficient 
numbers of subjects in the treatment failure group. 
 
Day 1 Day 7 End of Rx
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Figure 3.4 PA bacterial numbers during treatment and comparing treatment outcome groups. Data is 
presented a histogram representing median values with interquartile ranges represented by 
error bars. No significant differences are seen between groups for any time point. 
 
 
  All 
(n=27) 
Rx Success 
(n=20) 
Rx 
Failure 
(n=7) 
p-value 
PA cfu/ml median 
Day 1 7.3 x 107 4.5 x 107 
(5.2x106,7.1x108) 
4.5 x 108 
(1.7x107,1.8x109) 
0.24 
Day 7 2.8 x 107 
 
4.0 x 107 
(2.5x106,3.3x108) 
2.7 x 103 
(0, 2.1x108) 
0.12 
End Rx 1.5 x 107 1.5 x 107 
(1.6x106,9.4x107) 
4.7 x 108 
(2.2x106,2.3x107) 
0.96 
Stable post 2.4 x 108 
(1.4x107,9.6x108) 
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The change in PA density was correlated with spirometry changes to determine whether a 
relationship existed. While there appeared to be a moderate correlation for both absolute 
FEV1 and percentage change in FEV1, this did not meet statistical significance as shown in 
table 3.4 and figures 3.5 and 3.6. 
 
 
 
 
Table 3.4 Correlations comparing changes in spirometry measures during antibiotic treatment with 
changes in PA bacterial numbers. 
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Figure 3.5   The correlation between change in FEV1(L) and the change in PA cfu/ml during 
antibiotic treatment. Correlation  was  performed  using  Spearman’s  rank  correlation  
co-efficient.  R= -0.40, p=0.08 
Correlations  
 
R value P value 
Change in Spirometry vs. Change in PA cfu/ml 
Change in absolute FEV1 -0.40 0.08 
%change in FEV1 -0.40 0.09 
End cfu/ml vs. TTNE -0.01 0.98 
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Figure 3.6 The correlation between change in FEV1 as a percentage and change in PA cfu/ml 
during antibiotic treatment. Correlation  was  performed  using  Spearman’s  rank  
correlation co-efficient, R=-0.40, p=0.09. 
 
Five subjects who cultured PA from their sputum samples at the beginning of treatment failed 
to isolate PA in sputum culture by the end of treatment. Of these, one subject had both 
mucoid and non-mucoid phenotypes of PA on day 1 of treatment, 2 had only the mucoid 
phenotype and 2 had only the non-mucoid phenotype. There was no relationship between 
clearance of PA and baseline lung function, change in lung function during treatment of the 
exacerbation, end of treatment CRP or antibiotic choice. This may not represent eradication 
of the bacteria as the limit of detection for culture is 103cfu/ml 
Antibiotic Sensitivity and Treatment Response 
Eight patients isolated PA on day 1 that exhibited in-vitro resistant to one of the antibiotics 
being used to treat the exacerbation. One patient isolated PA that exhibited in-vitro resistance 
to both antibiotics used. During antibiotic treatment, no PA isolates developed resistance to 
those antibiotics being used. 
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The presence of antibiotic resistance from day 1 had no effect on FEV1 improvement during 
treatment (% improvement in FEV1, fully sensitive 21 (14, 37), resistant 13 (6, 45) p= 0.52) 
or CRP at the end of treatment (sensitive 3.5 (1, 5.8) vs. resistant 6 (1,15) p= 0.3) as 
documented in Table 3.5 and Figure 3.7 
When examining bacterial numbers, those subjects with an antibiotic resistant organism had 
significantly higher bacterial levels at the beginning and end of treatment but the change in 
bacterial numbers during treatment were not significantly different between groups. 
All subjects that failed to culture PA on routine microbiological testing during treatment had 
initially isolates that were fully sensitive to the antibiotic therapy. 
 
 Table 3.5  A comparison of spirometry and bacterial density changes during antibiotic treatment 
between groups defined by the presence or absence of PA bacteria resistant to at least 
one of the antibiotic used in treatment. 
 
 Fully sensitive 
bacteria 
Presence of antibiotic 
resistance 
p-value 
FEV1 % change 
during treatment 
21 (14,37) 13(6, 45) 0.52 
CRP at end of 
treatment (mg/L) 
3.5 (1,5.8) 6 (1,15) 0.3 
PA cfu/ml start of 
treatment 
2.1 x 107 
(2.1 x 106, 3.3 x 108) 
7.4 x 108 
(8.9 x 107, 1.5 x 109) 
0.01 
PA cfu/ml end of 
treatment 
730,000 
(0, 2.6 x 107) 
2.1 x 108 
(5.0 x 107, 1.1 x109) 
0.009 
Change in PA 
cfu/ml 
-1.2 x107 
(-2.7 x 108,8.9 x 106) 
-2.2 x 108 
(-6.1 x 108, 1.9 x 108) 
0.4 
93 
 
Day 1 End of Rx
1.0u1000
1.0u1001
1.0u1002
1.0u1003
1.0u1004
1.0u1005
1.0u1006
1.0u1007
1.0u1008
1.0u1009
1.0u1010
Antibiotic Sensitive
Antibiotic Resistant
p=0.01 p=0.009
Lo
g
10
PA
 cf
u/
m
l
 
Figure 3.7 Changes in PA bacterial density grouped by whether the antibiotic sensitivity profile of the 
bacterial was resistant to one or more of the antibiotic therapies given. Data is presented as 
box plots representing median values with interquartile ranges represented by error bars 
 
Liverpool Epidemic Strain Pseudomonas Aeruginosa 
PCR assays of DNA extracted from PA isolates were performed to determine the presence of 
Liverpool Epidemic Strain (LES) PA. Two subjects were found to isolate the LES PA. Both 
of these patients were in the treatment failure group and both isolated PA that was resistant 
in-vitro to one of the antibiotics used to treat the exacerbation. 
Co-existent Bacteria 
In nine subjects Staphylococcus aureus (SA) was cultured from sputum samples at the 
beginning of the exacerbation, these were all methicillin-sensitive (MSSA) strains. Two 
subjects cultured a fungal species, one patient grew Aspergillus fumigatus and the other 
Scedosporium sp. No subjects cultured Achromobacter xylosidans, Stenotrophomonas 
maltophilia or Burkholderia species. 
There was no significant difference between those subjects who cultured SA at the beginning 
of an exacerbation when comparing FEV1 (1.38 litres in those with SA, 1.19 in those without, 
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p= 0.13), FEV1 %pred (42.0 vs. 38.0, p=0.71), FEV1 as a % of baseline (74.3 vs. 88.2, 
p=0.36) or CRP (8.5 vs. 16.0, p=0.29) (Figure 3.8). The presence of SA at the beginning of 
treatment had no effect on treatment success or overall FEV1 improvement. There was a trend 
to subjects who isolated SA to have a lower median age, but this did not reach significance 
(SA present, median age 26 (21, 24), SA absent, median age 37 (28, 47), p=0.08) 
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Figure 3.8  Graphs representing median values of spirometry measures in groups defined by the 
presence or absence of SA on bacterial culture. Data is presented as box and whisker 
plots with the boxes representing median values and interquartile ranges. The 
whiskers represent maximum and minimum values. No significant differences are 
seen between groups for any measure.  
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Isolation of Candida Albicans 
Fifteen subjects (55%) isolated Candida Albicans from sputum culture while receiving 
antibiotic therapy. The isolation of Candida was not associated with differences in FEV1 
improvement or CRP. Candida isolation was associated with a greater treatment-related 
decline in PA bacterial density but this did not reach statistical significance (Table 3.6). 
Candida was not isolated more commonly in those patients who failed to isolate PA during 
treatment. There were no relationships between the isolation of Candida and the use of 
steroids, the use of meropenem, or the presence of hypermutators. There were no significant 
differences between treatment outcome groups with regard to Candida isolation. 
 
Table 3.6 The clinical effect and associations with isolation of Candida albicans in sputum 
culture. Continuous variables p value determined by Mann-Whitney test. Categorical 
variable p values determined by Fisher exact test. 
  
 Candida Albicans 
Isolated (n=15) 
No Candida Isolated 
(n=12) 
p-value 
FEV1 % change 
during treatment 
16 
(7,37) 
20 
(9,37) 
0.68 
Change in PA 
cfu/ml 
-2.4 x 108 
(-6.6 x 108, -3 x 106) 
-1.0 x 105 
(-1.1 x 108, 1.4 x 108) 
0.07 
CRP at end of Rx 4 (1,7) 2.5 (1,7) 0.77 
PA 
Hypermutators 
present 
8 4 0.68 
Meropenem use 5 8 0.13 
Treatment 
success 
12 8 1.0 
96 
 
3.4 Discussion 
This analysis of the microbiological changes seen at the time of exacerbation and subsequent 
treatment has shown that severity of exacerbation is not related to the PA bacterial numbers 
and that, in this small cohort, bacterial numbers do not change significantly during treatment. 
PA mucoidy was not shown to have a significant effect on exacerbation severity or treatment 
response. The presence of bacterial resistance to the antibiotic treatment used did not appear 
to affect treatment responses but the resistant bacteria were present in greater numbers. The 
only other bacterium present in significant numbers was Staphylococcus aureus but its 
presence did not appear to relate to exacerbation severity or treatment response. In a 
significant number of patients Candida albicans emerged in sputum cultures during 
treatment. This was not associated with any clinical outcome measure but there was a trend to 
lower PA bacterial numbers in those patients who isolated Candida. 
Mucoidy 
In this study the presence of mucoid morphotypes of PA had no significant effect on any 
clinical markers of severity of the exacerbations. Is this a surprising finding? Alginate 
production in PA is complex and involves the interplay of a number of genes. The conversion 
to a mucoid phenotype has been shown to be related to genetic mutation, most commonly in 
the mucA gene63 and is thought to be a response to the host environment, for example oxygen 
radicals produced by neutrophils as an immune response101. A longitudinal study of CF 
children has shown a median time of transition from non-mucoid to mucoid PA infection of 
10.9 years. The study also demonstrated acquisition of the mucoid phenotype was associated 
with a greater decline in lung function 102. However, that study examined chronic changes in 
spirometry. No study to date has addressed the difference in outcomes of exacerbations 
comparing mucoid and non-mucoid PA. 
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In this study the first sample was at collected at a time of exacerbation rather than during a 
stable clinical state and it could be that the balance of non-mucoid versus mucoid PA is very 
different   at   the   time   of   an   exacerbation.   If   Sauer’s   biofilm   stages103 are to be considered, 
exacerbation may be occurring at Stage 5, the dispersal stage where there are more likely to 
be motile, non-mucoid PA released from the biofilm. In the study, those subjects isolating 
both mucoid and non-mucoid strains were included with the mucoid-only group for analysis. 
It could be argued that they represent a separate group and should have been analysed 
accordingly, but small numbers would have made the interpretation of findings difficult. 
Quantitative Microbiology 
Whether there is a change in PA bacterial density during antibiotic treatment is a contentious 
issue. A previous study has suggested that bacterial numbers do not increase in the immediate 
prodrome of infection104. During antibiotic treatment, studies have shown conflicting data 
with some showing a significant decrease in bacterial numbers29;52;105and others no 
significant change in bacterial numbers30;106. In this study overall bacterial numbers did not 
change significantly between the beginning and end of therapy. Those in the treatment failure 
group (who have been identified as having a greater decline in lung function from the pre-
exacerbation stable value) had a log10 greater median PA bacterial density at the start of 
antibiotic therapy, but this was not a statistically significant finding. Equally no significant 
changes were seen between the treatment outcome groups at any of the time points. As 
previously discussed however, the patients in both groups improved clinically and so it may 
be more informative to look at absolute changes in lung function and their relationship with 
bacterial density. 
There was no correlation between day 1 spirometry measures and PA bacterial density. 
However when the relationship between change in spirometry and change in PA bacterial 
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density was correlated, there was a moderate negative correlation seen which did not quite 
reach statistical significance. It would appear therefore that there may be some relationship 
between bacterial killing and improvement in lung function. This is in disagreement with a 
previous study which showed no relationship between lung function and bacterial density 
changes107 during IV antibiotics. To determine whether these current study findings are true 
would require an adequately powered study, examining this question specifically. 
Clearance of PA bacteria 
All the subjects included in the study had chronic PA infection which had been defined as at 
least 2 positive cultures in the preceding 6 months. It was therefore a surprising finding to see 
20% of patients failing to isolate PA in their sputum cultures by the end of treatment. It is 
unlikely this is true eradication as the limit of detection for our PA culture was 1 x 103 cfu/ml. 
It may also be an effect of antibiotics in the sputum samples inhibiting growth on the 
selective media plate, or sputum volumes decreasing. It was not limited to only those patients 
isolating non-mucoid strains of PA and it had no relationship with clinical outcomes. A 
further examination of this finding will be discussed with the results of the 16S rRNA gene 
sequencing method of bacterial identification in Chapter 5. 
Antibiotic Resistance and Treatment Response 
The presence of antibiotic resistance had no effect on treatment response in terms of 
spirometry improvement and changes in inflammatory markers. However, the PA bacterial 
density was higher in the patients with resistant organisms at both the beginning and end of 
treatment. No significant differences were seen in the change in bacterial density during 
treatment when comparing fully sensitive and resistant isolates, although this echoes the 
previous result of no significant changes in bacteria during an exacerbation. Previous studies 
examining PA antibiotic resistance have examined multiple-antibiotic-resistant PA(MARPA), 
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which is defined as PA resistant to all antibiotics in at least 2 of the following classes; 
quinolones, beta-lactams and aminoglycosides108. Studies of subjects with these strains of PA 
have shown an association with more severe lung disease and a more rapid rate of lung 
function decline109;110. In the current study, data was only collected on resistance to the 
antibiotic used to treat the exacerbation rather than multiple resistances. The data is therefore 
not comparable. Equally the study reported by Foweraker et al.111 should be borne in mind 
when interpreting this data. These authors have shown that antibiotic sensitivity testing is 
highly variable and not necessarily reproducible. Those organisms with some degree of 
antibiotic resistance appear to persist at higher numbers in the CF airway regardless of 
treatment.  
Liverpool Epidemic Strain 
Epidemic strains of PA such as the Liverpool Epidemic Strain (LES) have been shown to be 
more virulent with increased transmissibility98;99. It would therefore have affected the validity 
of the clinical data if large numbers of the cohort isolated such strains. The study revealed 
only 2 subjects with LES isolates; both isolated PA with resistance to the treatment antibiotic 
used and both subjects were in the treatment failure group. The LES isolate subjects are too 
low in number to make any meaningful comment on the effect of treatment of the 
exacerbation. A potential weakness of the study would be not testing for other epidemic 
strains. However, while other epidemic strains exist in the CF community, strain typing in the 
RBH patient cohort has not identified it as a significant issue. 
Co-existent Bacteria and other Organisms 
The routine clinical culture of sputum samples in CF care involves the use of selective media 
to isolate only what are thought to be potentially pathogenic bacteria. In this study therefore 
the isolation of other bacteria was very selective and perhaps does not give a true view of all 
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the bacteria that could be isolated from the sputum samples. However the microbiome will be 
examined in more detail for its diversity in a subsequent chapter. Clearly Staphylococcus 
aureus (SA) is a commonly isolated organism in CF, especially in younger individuals. In 
this study, co-isolation of SA study did not appear to have any effect on clinical measures. 
Previous studies have shown an effect of co-infection with SA and PA. Rosenbluth et al. 
identified co-infection as a significant risk factor for rapidly declining lung function112. A 
much smaller study in children also showed an increased mortality rate in subjects with PA 
and SA infection compared with SA or PA infection alone113. The numbers of co-infected 
subjects were very small (7/81) and the 10 yr survival estimate of 57% in the co-infected 
group compared with 92-100% in other groups seems unfeasible low. The results of this 
study should therefore be interpreted with caution. 
The chronic isolation of Candida albicans has previously been shown to be associated with a 
greater rate of decline in FEV1 and more frequent hospital-treated exacerbations114, although 
whether this is a causal relationship is not clear. Its presence in patients with severe deficits in 
FEV1 may represent the extra antibiotic burden in these patients. In the current study, 55% of 
patients isolated Candida during antibiotic treatment. This is perhaps not the same clinical 
situation as those patients chronically isolating Candida, and also possibly represents oro-
pharyngeal candidiasis contaminating sputum samples. However there did appear to be an 
association with Candida isolation and a greater decline in PA bacterial density (although this 
did not reach statistical significance). No other clinical marker appeared to be affected by 
Candida isolation, but it may be that it represents a surrogate marker for a decline in 
pathogenic organisms, allowing other organisms to predominate. 
In summary, the presence of PA mucoid morphotypes does not appear to have a significant 
effect on exacerbation severity or treatment response. PA bacterial density does not change 
significantly during treatment although a trend towards a relationship between lung function 
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change and the change in PA bacterial density was seen. The co-isolation of SA in sputum 
culture had no effect on treatment outcomes or exacerbation severity. The emergence of 
Candida albicans during treatment was associated with a greater decline in PA bacterial 
density but did not have an effect on treatment outcomes. 
If PA bacterial numbers do not change significantly but patients clinically improve, is a 
change occurring in the expression of virulence factors of PA that is being switched on at the 
time of exacerbation and switched off during treatment? Or does the overall diversity of the 
bacteria present have an effect on treatment outcomes. PA hypermutators allow the rapid 
acquisition of virulence in PA populations. The following chapters will examine the role of 
hypermutator strains of PA and their role in infective exacerbations, the role of bacterial 
diversity as determined by bacterial identification through gene sequencing and finally an 
examination of QS molecule production in PA, to determine what, if any, this system has on 
exacerbation severity and treatment response.  
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CHAPTER 4 
HYPERMUTATOR STRAINS OF PSEUDOMONAS AERUGINOSA – THEIR ROLE 
IN CF EXACERBATIONS 
 
4.1 Introduction 
Hypermutator phenotypes of Pseudomonas aeruginosa have been noted to be present in 
significant numbers in CF sputum samples. The relative abundance of hypermutator 
phenotypes has been shown to increase with duration of chronic infection115 and its presence 
has been shown to be associated with poorer lung function116.  Their presence has been 
shown to be associated with increased antibiotic resistance in vitro115 and in a mouse 
model117. No clinical study has shown the effect of its presence on the severity of an 
exacerbation or the response to antibiotic treatment. 
Aims of the Hypermutator study 
1. To determine if the presence of hypermutator strains of PA is associated with a more 
severe clinical state. 
2. To determine if the presence of hypermutator strains of PA is associated with a poorer 
response to antibiotic therapy. 
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4.2 Methods 
Sputum samples for this hypermutator assay were collected at the beginning and end of the 
IV antibiotic treatment course. 
Sputum was homogenised as per the microbiology assay described in the previous chapter 
and plated onto chocolate agar and Pseudomonas plates and incubated at 37°C in CO2 for 24-
48 hours 
P.aeruginosa was identified by morphological appearances and/or by API reaction kit. 
Isolates of each morphotype of PA were sub-cultured along with 2 control organisms (PA01 
and PA01 mut S, a control hypermutator strain of PA) onto half blood agar and re-incubated 
at 37°C in CO2. After 24 hours 3-5 bacterial colonies of each isolate were suspended in 15ml 
of Muller Hinton Broth and incubated overnight at 37°C in a rocking incubator at 140rpm. 
After incubation, broth samples were examined for opacity, a heavy swirl suggestive of >108 
cfu/ml. Samples with lesser opacity were centrifuged at 4000 rpm for 10 minutes and 5 ml of 
supernatant removed. The remaining 10ml was vortexed and the supernatant added back until 
the desired opacity was reached. 
2ml of each isolate broth was removed and pooled. 
Serial tenfold dilutions with PBS were then made of the pooled and controlled samples to 
give final concentrations of >103 cfu/ml of pooled and mutS control samples, and >102 cfu/ml 
of PA01 control samples. 
Rifampicin-incorporated plates and MHA plates were then inoculated in triplicate using a 
spiral plater. 50ul and 200ul of each of the diluted pooled broth and control sample broths 
were plated onto rifampicin-incorporated plates and 50 μl of each sample were inoculated 
onto the MHA plates. 
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Plates were then incubated at 37°C, with colony counts performed at 24 and 48 hours. Colony 
counts were calculated after allowing for volume and dilution of samples. 
Mutation frequency was calculated as the mean growth on rifampicin incorporated plates 
divided by the mean growth on MHA plates.  
An isolate was considered to contain a hypermutator strain if the mutation frequency was 
more than 20 times greater than that of the PA01 control organism118. For analysis, only the 
presence or absence of a hypermutator strain in each sputum sample was considered. 
Statistical analysis was performed as described in Chapter 2 methods.  
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4.3 Results 
Data from 24 patients were available for analysis. Twelve subjects (50%) of patients had PA 
hypermutator strains isolated from sputum prior to commencing antibiotic therapy. 
There was a trend to those subjects isolating hypermutator strains being older than those who 
didn’t  isolate  them  but  this  did  not  reach  statistical  significance  (hypermutator  strain  present,  
41years (30,46); hypermutator strain absent 27 years (23,20), p=0.05) as documented in 
Table 4.1 
The presence of hypermutator strains was not associated with a significant difference in 
FEV1 % predicted at the start of the exacerbations. The median FEV1 %OBL was higher in 
those with hypermutator strains present but these failed to reach statistical significance. The 
CRP median values were not significantly different between the groups. Using a Fishers 
exact test there was a trend to more hypermutator strains in the treatment success group 
(11/17) versus the treatment failure group (1/6) (p=0.07). 
 
 
 
 
 
 
Table 4.1 A comparison of clinical measures on day 1 of antibiotic treatment in groups defined 
by the presence or absence of hypermutator strains of PA.  
 Hypermutator 
strain absent 
Hypermutator 
strain present 
p-value 
Day 1 Values 
Age 27 
(23,30) 
41 
(30,46) 
0.05 
FEV1 % pred 38 
(26,47) 
41 
(25,48) 
0.69 
FEV1 as % of 
baseline 
73 
(59, 89) 
88 
(77, 94) 
0.07 
CRP 23 
(9,38) 
9 
(3, 24) 
0.14 
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Pseudomonas Hypermutator Strains during Antibiotic Treatment 
16 patients had matched data for hypermutator samples at the beginning and end of treatment. 
Of these, three subjects isolated hypermutator strains only at the end of treatment. No patient 
who isolated hypermutator strains at the start of treatment failed to do so at the end of 
treatment. 
In those patients who isolated hypermutator strains at day 1, the median percentage change in 
FEV1 during treatment was 13% (-1, 31), compared with 27% (15, 49), p=0.07, in those 
without hypermutator strains as shown in Figure 4.1 
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Figure 4.1 Individual changes in FEV1 %predicted between the start and end of treatment. 
Those patients with a hypermutator strain (red) had a trend towards a smaller 
improvement in FEV1 % predicted as than those without a hypermutator strain 
(blue), 13% vs. 27% (p=0.07). 
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Effect of Hypermutator Status on Changes in Bacterial Density 
There was no association between the presence of hypermutator strains and PA bacterial 
density at the beginning or end of therapy with no significant differences between the median 
values. However, the change in PA density between groups was significantly different with a 
median value of -2.4 x 108 in those without hypermutator strains compared with 1.1 x 108 for 
those with hypermutator strains(p=0.02), Table 4.2 and F 
igure 4.2. 
There was no relationship between antibiotic resistance at day 1 of treatment and the presence 
of hypermutators, Fisher exact test p=1.0. 
 
 
 
 
 
Table 4.2 A comparison of PA bacterial density at the beginning and end of antibiotic therapy 
and the median change in bacterial density in groups defined by the presence or 
absence of hypermutator strains of PA. 
 
 Hypermutator strain 
absent 
Hypermutator 
strain present 
p-value 
 
Day 1 PA cfu/ml 3.3x108 
(2.2x107, 1.2x109) 
3.6x107 
(6.0x106,6.3x108) 
0.21 
End of Rx PA 
cfu/ml 
8.2x106 
(4.2x106, 9.4x108) 
1.5x108 
(9.9x106,7.7x108) 
0.21 
Change in PA 
cfu/ml 
-2.4x108 
(-6.1x108, -1.2x107) 
1.1x108 
(-3.9x107, 8.7x108) 
0.02 
108 
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Figure 4.2 A box and whisker plot comparing the change in PA bacterial density during 
antibiotic therapy between groups defined by the presence or absence of hypermutator 
strains of PA. The boxes represent median values and interquartile ranges and the 
whiskers represent maximum and minimum values. The change in PA bacterial 
density is significantly higher in the hypermutator negative group p=0.02 
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4.4 Discussion 
The hypothesis of this study was that hypermutator strains of PA were not significantly more 
pathogenic but appeared when the PA population was under stress, in this case antibiotic 
therapy, as a mechanism to survive through a process of rapid beneficial mutation. Has this 
hypothesis been proved? 
Fifty percent of subjects had hypermutator strains present at the commencement of therapy, a 
frequency consistent with previous studies116;119. The median age of subjects isolating 
hypermutator strains was not significantly older. This would be in keeping with previous 
findings of hypermutation being associated with duration of chronic infection with PA, 
although data in this study was not collected regarding time of first PA infection115 and age of 
subject may not be an appropriate substitute measure.  The presence of hypermutators was 
associated with a trend to a smaller decline in FEV1 from baseline which did not reach 
statistical significance (Table 4.1). There was also a trend to more hypermutator strains in the 
treatment success group, although this is likely representative of the lesser decline in FEV1 as 
a percentage of baseline at day 1. The median percentage change in FEV1 during treatment 
was higher in those without hypermutator strains but again this is likely to represent a bigger 
drop in lung function prior to commencing therapy rather than an effect of the hypermutator 
strains on treatment response. From these results it would appear that hypermutator strains 
are associated with less severe exacerbations. Previous studies have shown that hypermutator 
strains are less virulent120;121 in vitro. The current study data may be consistent with the 
findings of these studies. 
Of the 16 patients who had matched data for the beginning and end of therapy, only 3 
acquired new hypermutator strains and no patients lost hypermutator strains during treatment. 
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This number is too small to determine the effect, if any, of new hypermutator isolation during 
treatment.  
PA bacterial density at the beginning and end of therapy was not significantly affected by the 
presence of hypermutator strains but an interesting observation was a significantly greater 
decline in PA density during treatment in the absence of hypermutator strains. This may 
suggest that hypermutator strains of PA are better able to withstand bacterial killing by 
antibiotics. Antibiotic resistance did not appear to be significantly more common in subjects 
with hypermutator strains and no increased antibiotic resistance was seen during treatment in 
any subjects. Waine et al have previously demonstrated this similar lack of new antibiotic 
resistance in the presence of hypermutator strains116. The method of analysis does limit the 
analysis of resistance however. This study is only examining the presence or absence of 
hypermutator strains. The hypermutator strains themselves were not tested for antibiotic 
sensitivities directly and it is possible that the resistance profiles are for non-hypermutator 
strains of PA cultured from the same sample. 
This study does have other limitations. Firstly the numbers are small and even smaller for 
matched data from the beginning and end of treatment. However the percentage of isolates is 
similar to previous studies so is likely to be representative of the CF population. Age may be 
a major confounding factor. The clinical tracking study identified an older population in the 
treatment success group and in this study there was a trend towards an older median age in 
those who isolated hypermutator strains. It is possible that hypermutator strains are seen more 
commonly in older patients because, by extrapolation, they have experienced a longer period 
of chronic PA infection and our findings merely represent older patients with less severe 
exacerbations. A larger scale study without such a skew in age may answer this more clearly. 
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As mentioned previously the method of the assay and analysis depending only on presence or 
absence of hypermutator strains limits the study. It is possible that a subject with 80 % of PA 
in their sputum being hypermutator strains would have different clinical responses to 
treatment than someone with only 8% of PA being hypermutators. 
In summary, hypermutator strains are more prevalent in older patients but may be associated 
with less severe exacerbations. This would be in keeping with previous work suggesting they 
are less virulent organisms and act to sustain PA populations by allowing mutations that 
ensure survival of the bacteria in the CF host, but perhaps at the cost of virulence89. 
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CHAPTER 5 
THE CF INFECTIVE EXACERBATION – A MICROBIOME ANALYSIS USING 16S 
rRNA GENE SEQUENCING 
5.1 Introduction 
The introduction of high throughput gene sequencing has allowed the detection of large 
numbers of genetic sequences in clinical samples. This technology has been used in CF 
research to examine the bacterial ecology of the chronic lung infection that is common to all 
CF patients. Previous work has examined patients who are both stable122;123 and 
exacerbating29;30. The previous exacerbation data has been limited to changes in bacterial 
diversity alone and has not examined the associated clinical responses. Using 16S rRNA gene 
sequencing this study will examine in a much greater detail the bacterial diversity of the CF 
lung during treatment of an exacerbation and by comparing these changes with clinical data 
will examine whether relationships exist between clinical measures and bacterial diversity. 
Aims of the microbiome analysis 
To determine if: 
1. The bacterial diversity of samples changes during antibiotic therapy. 
2. Treatment outcome is related to differences in the effect of treatment on the 
microbiome. 
3. Changes in PA bacterial density is associated with changes in overall bacterial 
diversity. 
4. If antibiotic choice has an effect on bacterial diversity. 
5. If bacterial diversity at the end of antibiotic treatment is associated with time to next 
exacerbation. 
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5.2 Methods 
Extraction of DNA from Sputum Samples 
16S rRNA DNA was extracted from sputum samples using the FastDNA SPIN kit for soil 
(MP  Biomedicals,   Ohio,  USA),   following   the  manufacturer’s   instructions,   substituting   soil  
for  750  μl  of   sputum  and  using  a  Precellys  24  homogeniser  at  6800rpm   for  2  x  30  secs to 
homogenise the samples. DNA was eluted in 100 μl of ultrapure water. 
Measuring Extracted DNA Quantity and Purity 
The extracted DNA was tested for quality and quantity using a microvolume 
spectrophotometer (Nanodrop ND-1000  Spectrophotometer).  2μl  of  eluted DNA was placed 
in the spectrophotometer and samples were deemed suitable if the DNA content was greater 
than  30ng/μl  and  the  purity  of  the  DNA  (as  measured  by  ratio  of  absorbance  at  wavelengths  
of 260nm and 280nm) was greater than 1.8. 
Eluted DNA was then stored in a -20°C freezer for later analysis. 
16S rRNA Gene PCR 
DNA PCR, gene sequencing and preparation of the raw sequencing data were performed by 
members of the Molecular Genetics Group, National Heart and Lung Institute, Imperial 
College. PCR methods were based on a previously published protocol124. 
The V3-V5 hypervariable regions of the 16S rRNA gene were amplified using primer 357F 
with adaptor B from 454 Life Sciences:  
5’   CTATCCCCTGTGTGCCTTGGCAGTCTCAGCCTACGGGAGGCAGCAG   3’,   and  
primer 926R which included the 454 Life Sciences adaptor A and a 12 base-pair error-
correcting Golay barcode125 (denoted  with  ‘N’),  which  allows  samples  to  be  multiplexed  in  a  
single run:  
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5’CCATCTCATCCCTGCGTGTCTCCGACTCAGNNNNNNNNNNNNCCGTCAATTCM
TTTRAGT  3’.   
Primers were ordered from Eurofins MWG Operon and HPSF (high purity salt-free) purified. 
PCRs were carried out in quadruplicate to decrease the possibility of random mispriming 
affecting the population of amplicons produced. No-template PCR controls were also 
included to exclude contamination. 
PCR  was  performed  in  a  96  well  plate,  with  each  well  containing  a  25μl  solution. 
Each 25µl reaction contained 1µL each of forward and reverse primers (10µM), 1µl of 
template  (extracted)  DNA,  0.5  μl  of  dNTP  mix  (10mM  each),  2.5  μl  of  FastStart  10x  Buffer,  
0.25µl of 5U/µl FastStart HiFi Polymerase (Roche), 1µl of 20g/mL BSA (Sigma), and 6.5µl 
of   5M   Betaine   (Sigma),   with   the   remainder   of   the   25μl   being   Molecular Biology Grade 
Water.  
PCR reactions were assembled within a PCR hood in which all surfaces and equipment were 
decontaminated  using  ‘DNAase  free’  solution  (Ambion)  and  had  been  UV-irradiated for 20 
minutes.  
Thermal cycling was performed using a PTC-225 (MJ Research) thermal cycler. It consisted 
of initial denaturation at 94°C for 2 minutes followed by 30 cycles of denaturation at 94°C 
for 20 seconds, annealing at 50°C for 30 seconds, and extension at 72°C for 5 minutes, 
ending on a final hold at 4°C.  
Amplicon Pooling, Quantification and Pyrosequencing 
The   quadruplicate   amplicons   were   pooled   together   (total   volume   100μl)   and   then   purified  
twice (AMPure XP kit, Agencourt) following the recommendations in the Roche amplicon 
sequencing protocol and using a ratio of 0.7 volumes of AMPure beads to 1 volume of PCR 
product. The DNA content of the cleaned pool was quantified using the Quant iT PicoGreen 
dsDNA assay (Invitrogen) following  the  manufacturer’s  instructions  and  then  diluted  in  Tris-
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EDTA to obtain a final pool containing 105/μL molecules. 30µl of this pool was added to the 
emulsion PCR reaction to attain a ratio of 0.3 molecules per bead. Sequencing of 16S rRNA 
amplicons was carried out on a Roche 454 FLX Titanium pyrosequencing platform by the 
Biochemistry   Department’s   Sequencing   Facility   at   the   University   of   Cambridge and 
processed using the shotgun processing pipeline.  Raw data was returned as an SFF file to the 
Molecular Genetics and Genomics Group, NHLI, Imperial College, London. 
Preparation of Gene Sequencing Raw Data 
Reads were extracted per sample from the sequencing file by matching barcode sequences.  
The flowgrams for each sample were clustered, with poor quality reads being removed by 
AmpliconNoise126 running on Imperial College   London’s   Bioinformatics   Support   Service  
compute cluster.  In addition chimeric sequences created during PCR were detected using 
Perseus126 and also removed.  This curated set of reads, now separated by sample was used in 
all further analyses. 
Curated reads were clustered into OTUs (operational taxonomic units) at 97% identity using 
UCLUST in the QIIME pipeline127.  The most abundant read in each OTU was selected as a 
representative sequence and this was compared to the SilvaNR version 111 database using a 
retrained RDP Classifier.  OTUs are identified by the lowest taxonomic level of ID that was 
possible for the reference sequence and a unique OTU number, e.g. 
Pseudomonas_aeruginosa_321. 
The numbers of reads per sample ranged from between 0 and 3502.  Rarefaction (random re-
sampling of reads per sample to obtain a representative set) was conducted in QIIME to 529 
reads, retaining 94 samples of the original 111 sequenced and 209 OTUs.  Procrustes analysis 
in QIIME was used to compare rarefaction at the next possible level (709 reads), but the 
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datasets were not significantly different, so 529, which retained an additional stable post 
treatment sample, was deemed acceptable.   
Statistical Methodology 
Three measures of diversity were utilised in this study. 
Species richness is the number of bacterial species per sample, a simple measure of diversity 
that does not take into account the abundance of each bacterial species in a sample. 
The Shannon Diversity Index is calculated by using the relative abundance (x) of each OTU 
in a sample. For each OTU the Shannon diversity index is determined first by using the 
equation: 
−1 ∗ (
𝑥
ln(𝑥)
) 
Each OTU value in a sample is then summed together to give the Shannon diversity index for 
that sample. The Shannon diversity index was used as the measure of diversity (as opposed to 
other measures of diversity such as the Simpson index) as the logarithmic transformation 
performed reduces the weight of the abundant species versus the rarer species in the 
calculation, giving a more accurate representation of changes in a bacterial population which 
contains a dominant organism such as Pseudomonas aeruginosa.  
The evenness of a sample represents how similar the relative abundance of each bacterium is 
in a sample. The   Pielou’s   evenness   index   (J’)   of   a   sample   with   S number of species, is 
determined  from  the  Shannon  diversity  index  (H’)  using  the  equation: 
Jᇱ =
Hᇱ
H′max
 
where 
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  Hᇱmax = ln𝑆 
Each of these diversity indices give important information to understand community 
structure, with richness and evenness being more simple to understand measures and the 
Shannon diversity index allowing a calculation of diversity that includes both richness and 
evenness. 
Continuous variables were compared using Mann-Whitney testing for non-paired data, and 
Wilcoxon Matched pairs test for paired data. Categorical variables were examined user 
Fisher’s   exact   test.   Correlations   were   performed   using   Spearman’s   rank   correlation   co-
efficient.  
All data is expressed as median values with the interquartile range. All statistical analysis was 
performed using Graphpad Prism (GraphPad Software Inc). 
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5.3 Results 
OTU Data 
The  number  of  OTUs  ranged  from  1  to  41  per  sample.  The  commonest  20  OTU’s  are  listed  
below with their associated OTU identifier (Table 5.1). Some names appear more than once 
as identification of the OTU is not resolved to the species level. 27 samples were available 
for analysis of day 1 data. Of these, OTU 321 Pseudomonas aeruginosa, was the dominant 
OTU identified in 21 samples with 6 having other bacteria identified as the dominant OTU (2 
subjects had Achromobacter, 2 Staphylococcus aureus, 1 Streptococcus sp. and 1 
Haemophilus influenzae) One patient had no detectable OTU 321 Pseudomonas aeruginosa; 
this subject did, however, have a positive microbiology culture for PA (Subject 20, Figure 
5.1). Figure 5.1 demonstrates graphically the varying relative abundance of bacteria on day 1 
of treatment between subjects. For day 1 samples, the median relative abundance of the OTU 
321 Pseudomonas aeruginosa was 80 % (IQR, 55-90). There was no significant correlation 
between relative abundance of this OTU on day 1 and FEV1, FEV1 %predicted or FEV1 as a 
percentage of baseline.  
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Rank OTU % Rank OTU % 
1 321_s_Pseudomonas_aeruginosa 57.3 11 11_g_Actinomyces 1.0 
2 190_g_Streptococcus 8.9 12 74_g_Prevotella 1.0 
3 36_g_Staphylococcus 8.2 13 284_g_Porphyromonas 0.7 
4 218_g_Streptococcus 5.3 14 162_s_Prevotella_scopos 0.5 
5 132_s_Achromobacter_xylosoxidans 3.7 15 221_g_Rothia 0.5 
6 121_g_Streptococcus 2.2 16 291_g_Gemella 0.4 
7 166_g_Granulicatella 1.5 17 109_g_Neisseria 0.4 
8 194_g_Haemophilus 1.5 18 294_g_Derxia 0.3 
9 192_g_Lactobacillus 1.1 19 214_g_Stenotrophomonas 0.3 
10 293_g_Veillonella 1.1 20 154_s_Uncultured_oribacterium 0.2 
 
Table 5.1 Relative  Abundance  of  the  top  20  OTU’s  for  all  samples. OTUs are identified by 
number, followed by whether it was identified to a genus (g) or species (s) and then 
the identified bacterial species or genus.
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Subject Number 
321_s__Pseudomonas_aeruginosa 36_g__Staphylococcus 190_g__Streptococcus 132_s__Achromobacter_xylosoxidans 
218_g__Streptococcus 194_g__Haemophilus 121_g__Streptococcus 11_g__Actinomyces 
293_g__Veillonella 109_g__Neisseria 166_g__Granulicatella 162_s__Prevotella_scopos 
284_g__Porphyromonas 291_g__Gemella 74_g__Prevotella 154_s__Uncultured_oribacterium_sp 
221_g__Rothia 253_g__Fusobacterium 54_g__Haemophilus 214_g__Stenotrophomonas 
Other OTU's 
Figure 5.1 Relative  Abundance  of  OTU’s  on  day  1  of  treatment  for  each  subject  colour  coded  by  sequence  identity.  The  top  20  are  
shown  with  lower  frequency  OTU’s  collated  as  ‘Other  OTU’s’ 
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Principal Co-ordinate Analysis of OTU data 
Principle co-ordinate analysis (PCoA) was performed on the rarefied OTU data using the 
weighted UniFrac128 distance to determine if there was any clustering of samples based on 
clinical variables. A number of clinical variables were examined. These included age, FEV1 
% predicted, patient ID, day of treatment, and beta-lactam antibiotic used. While the study 
was aimed at hypothesis generation, these were the variables that were expected to show a 
clustering effect. However, significant clustering was only seen with patient ID, R2 = 0.69 p = 
<0.001. Analysis of clustering was performed using adonis in R. Figure 5.2 shows a 
selected number of subjects with each colour representing a different subject, highlighting the 
clustering by patient ID. 
 
Figure 5.2  Principal co-ordinate analysis of weighted Unifrac distances of 4 patients 
(each assigned a separate colour). Each point is noted with patient ID and day 
of treatment. This plot identifies that most clustering is due to patient ID with a 
lesser effect of treatment causing increased variance. 
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No clustering was seen between the structure of the bacterial community and day of 
treatment, suggesting that antibiotic therapy had no significant effect on bacterial 
communities as a whole. Using a bi-plot and overlaying bacteria it could be seen that the 
position of samples tended to correspond with the position of PA with Streptococci and 
Staphylococci associated with those samples separated from PA in PC1 (figure 5.3) 
 
Figure 5.3 Bi-plot of PCoA of variance in weighted Unifrac distances overlaid with taxa data. 
The size of the sphere representing a taxon is proportional to the mean relative 
abundance of the taxon across all samples. 
 
Comparisons of 16S rRNA Gene Sequencing Data with Microbiology Culture Results 
An examination of the rarefied OTU data identified one subject who did not have identifiable 
16s rRNA gene sequences attributable to PA. In the microbiology culture result, the subject 
was noted to have 1x103 cfu/ml of non-mucoid PA, which is the lowest limit of detection of 
bacteria in the assay. Examination of the raw OTU data however, showed that gene sequence 
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reads attributable to PA were detected in the sample but at a low level and hence discarded 
during the process of rarefaction.  
During antibiotic treatment, five subjects appeared to clear PA from bacterial cultures.  An 
examination of the non-rarefied data confirmed at least one read of sequence attributable to 
PA was seen in all samples except for one of the subjects, in a sample taken on the last day of 
antibiotic treatment. 
Is There a Relationship Between Diversity Indices and Lung Function Measures at the 
Start of Antibiotic Therapy? 
To determine a possible relationship, bacterial diversity indices were correlated with 
spirometry values obtained prior to commencing antibiotic therapy. There was no correlation 
between species richness and any measure of spirometry. There was a significant correlation 
between FEV1 and  Pielou’s  evenness   index  but   this  was  not   seen   for  FEV1 % predicted or 
FEV1 as a % of baseline. No significant correlations were seen between the Shannon 
diversity index and lung function measure.  While no significant correlations were seen 
between age and bacterial diversity on day 1 of treatment, there was a trend towards a 
negative  correlation  between  age  and  both  Pielou’s  evenness  index  and  the  Shannon  diversity  
index, i.e. evenness and diversity were decreased in older patients, as shown in Table 5.2.  
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 R p 
Species Richness 
FEV1 0.23 0.29 
FEV1 % predicted 0.15 0.48 
FEV1 % of baseline -0.16 0.46 
Age -0.19 0.38 
Pielou’s  Evenness  Index 
FEV1 0.51 0.01 
FEV1 % predicted 0.37 0.08 
FEV1 % of baseline -0.14 0.54 
Age -0.38 0.06 
Shannon Diversity Index 
FEV1 0.38 0.08 
FEV1 % predicted 0.24 0.27 
FEV1 % of baseline -0.21 0.33 
Age -0.39 0.06 
 
Table 5.2 Correlations between bacterial diversity indices and spirometry values on day 1 of 
treatment. p values  were  determined  using  Spearman’s  rank  correlation  co-efficient.  
 
Diversity Indices during Antibiotic Therapy 
No  measure   of   diversity   (species   richness,   Pielou’s   evenness   index,   or   Shannon   diversity  
index) showed significant changes from the day 1 value at any of the subsequent follow-up 
samples as shown in Table 5.3 and figures 5.4-5.6.  
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 n Median 
(IQR) 
p value 
(c.f day 1 
value) 
Species Richness 
Day1 28 15 (8,23)  
Day 7 21 12 (8,23) 0.64 
End of Rx 21 10 (6,18) 0.25 
Stable post 10 15 (9,24) 0.72 
Pielou’s  Evenness  Index 
Day1 28 0.30 (0.14,0.53)  
Day 7 21 0.42 (0.30,0.58) 0.12 
End of Rx 21 0.36 (0.25,0.46 0.83 
Stable post 10 0.32 (0.25,0.54) 0.76 
Shannon Diversity Index 
Day1 28 0.77 (0.27,1.6)  
Day 7 21 0.99 (0.65,1.7) 0.38 
End of Rx 21 0.75 (0.55,1.4) 0.86 
Stable post 10 0.89 (0.53,1.6) 0.85 
 
Table 5.3 Diversity indices during antibiotic therapy and a comparison with day 1 of treatment 
values. 
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Figure 5.4  Species richness at each measured time point of the exacerbation. No significant 
differences are seen between time points. Line represents median, box represents 
interquartile range and whiskers are the minimum and maximum values. 
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Figure 5.5  Pielou’s   evenness index at each measured time point of the exacerbation. No 
significant differences are seen between time points. Line represents median, box 
represents interquartile range and whiskers are the minimum and maximum values. 
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Figure 5.6  Shannon diversity index at each measured time point of the exacerbation. No 
significant differences are seen between time points. Line represents median, box 
represents interquartile range and whiskers are the minimum and maximum values. 
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Is Bacterial Diversity Significantly Different Between Treatment Outcome Groups? 
The data was then examined by comparing groups of subjects by treatment outcomes, success 
versus failure. There were no significant differences between the treatment outcome groups 
for any of the diversity indices at any time point in the study as detailed in table 5.4 and 
illustrated in figures 5.7 – 5.9. 
 
Diversity Index Day of 
Rx 
Treatment 
Success 
Treatment  
Failure 
p 
 
Species Richness 1 14 (7,26) 14 (8,19) 1.0 
7 19 (11,28) 10 (6,19) 0.12 
End Rx 10 (7,18) 12 (6,17) 0.96 
Stable 10 (7,25) 10 (13,24) 0.52 
 
Pielou’s  Evenness  Index 1 0.28 
(0.13,0.50) 
0.20 
(0.12,0.57) 
1.0 
7 0.43 
(0.33,0.62) 
0.36 
(0.15,0.59) 
0.27 
End Rx 0.32 
(0.25,0.56) 
0.47 
(0.24,0.66) 
0.24 
Stable 0.26 
(0.21,0.53) 
0.71, 
(0.32,0.71) 
0.38 
 
Shannon Diversity Index 1 0.67 
(0.26,1.3) 
0.56 
(0.25,1.8) 
0.80 
7 1.3 
(0.84,1.9) 
0.78 
(0.21,1.8) 
0.27 
End Rx 0.75 
(0.55,1.1) 
1.1 
(0.53,1.8) 
0.36 
Stable 0.84 
(0.41,1.6) 
0.32 
(0.32,0.71) 
0.12 
 
Table 5.4  Diversity indices at each measured time point comparing treatment outcome groups. No 
significant differences are seen between the groups. P value is calculated using Mann-
Whitney u-test. 
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Figure 5.7  A comparison of species richness in treatment outcome groups at each measured time 
point of an exacerbation treatment. No significant differences were seen at any time 
point between treatment success (blue) and treatment failure (red). Data is presented 
as median values with interquartile ranges. 
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Figure 5.8  A  comparison  of  Pielou’s  evenness  indices  in  treatment  outcome  groups  at  each  
measured time point of an exacerbation treatment. No significant differences were 
seen at any time point between treatment success (blue) and treatment failure (red). 
Data is presented as median values with interquartile ranges. 
 
130 
 
Day 1 Day 7 End of Rx Stable
0.0
0.5
1.0
1.5
2.0
Treatment Success
Treatment Failure
Sh
an
no
n 
Di
ve
rs
ity
 In
de
x
 
 
Figure 5.9 A comparison of Shannon diversity indices in treatment outcome groups at each 
measured time point of an exacerbation treatment. No significant differences were 
seen at any time point between treatment success (blue) and treatment failure (red). 
Data is presented as median values with interquartile ranges. 
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Is There a Relationship Between the Change in Lung Function and the Change in 
Bacterial Diversity? 
Comparing the change in bacterial diversity indices between the beginning and end of 
treatment with changes in spirometry values over the same period revealed no significant 
correlations (Table 5.5) 
 R p 
∆Species Richness 
Change in FEV1 (L) 0.05 0.85 
% change in FEV1 0.05 0.84 
∆Pielou’s  Evenness  Index 
Change in FEV1(L) -0.21 0.40 
% change in FEV1 0.02 0.93 
∆Shannon Diversity Index 
Change in FEV1(L) -0.11 0.64 
% change in FEV1 0.01 0.98 
 
Table 5.5 Correlations between the change in bacterial diversity indices and the change in 
spirometry  over  the  treatment  course.  p  values  are  determined  using  Spearman’s  rank  
correlation co-efficient. 
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Is There a Relationship Between Changes in PA Bacterial Density and Diversity 
Indices? 
Examining paired data, there was no significant correlation between the change in species 
richness and the change in PA bacterial density. However a significant negative correlation 
was   seen  with   both  Pielou’s   evenness index (R= -0.53, p=0.04) and the Shannon diversity 
index (R=-0.54, p=0.03). (Table 5.6 and figures 5.10 and 5.11) 
 R p 
∆ in PA bacterial density vs. 
∆Species Richness -0.40 0.13 
∆Pielou’s  Evenness  Index -0.53 0.04 
∆Shannon Diversity Index -0.54 0.03 
 
Table 5.6 Correlations between the change in PA bacterial density and the change in 
bacterial diversity indices. 
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Figure 5.10  The correlation between change in PA bacterial density (cfu/ml) over the treatment 
course and the  change  in  the  Pielou’s  evenness  index.  r  =  -0.53, p = 0.04, correlations 
determined  using  Spearman’s  rank  correlation  co-efficient. 
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Figure 5.11  The correlation between change in PA bacterial density (cfu/ml) over the treatment 
course and the change in the Shannon diversity index. r = -0.54, p = 0.03, correlations 
determined  using  Spearman’s  rank  correlation  co-efficient. 
 
 
 
Does Antibiotic Choice Affect Bacterial Diversity? 
Bacterial diversity indices were compared at each time point for patients receiving 
meropenem and ceftazidime. As detailed in table 5.7, species richness was significantly 
greater  in  the  ceftazidime  group  at  day  7  and  the  end  of  treatment.  Pielou’s  evenness  values  
did not differ significantly at any time-point. When examining the Shannon diversity index 
there was a trend to a lower value in the meropenem group but this did not reach statistical 
significance (0.60 in the meropenem cohort versus 1.3 in the ceftazidime cohort, p = 0.06). 
The data is graphically represented in Figures 5.12-5.14. 
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Diversity Index Day of 
Rx 
Meropenem Ceftazidime p 
 
Species Richness 1 14 (8,19) 
n=11 
15 (6,24) 
n=12 
1.0 
7 11 (6,14) 
n=10 
19 (17,23) 
n=7 
0.04 
End Rx 7 (6,10) 
n=8 
18 (12,19) 
n=9 
0.05 
Stable 15 (9,26) 
n=6 
19 (9,25) 
n=3 
0.9 
 
Pielou’s  Evenness  Index 1 0.31 
(0.15,0.55) 
n=11 
0.25 
(0.11,0.50) 
n=12 
0.48 
7 0.38 
(0.27,0.44) 
n=10 
0.44 
(0.32,0.63) 
n=7 
0.31 
End Rx 0.29 
(0.18,0.40) 
n=8 
0.43 
(0.26,0.59) 
n=9 
0.17 
Stable 0.42 
(0.20,0.60) 
n=6 
0.26 
(0.26,0.32) 
n=3 
0.71 
 
Shannon Diversity Index 1 0.85 
(0.28,1.7) 
n=11 
0.56 
(0.25,1.2) 
n=12 
0.44 
7 0.84 
(0.54,1.1) 
n=10 
1.3  
(0.97,1.8) 
n=7 
0.11 
End Rx 0.60 
(0.31,0.74) 
n=8 
1.3 (0.67,1.6) 
n=9 
0.06 
Stable 1.2 
 (0.4,1.9) 
n=6 
0.26 
(0.26,0.32) 
n=3 
0.02 
 
Table 5.7  Bacterial diversity indices in cohorts divided by beta-lactam antibiotic received 
during treatment. p-values between the meropenem and ceftazidime groups were 
determined using Mann-Whitney tests. 
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Figure 5.12 (a)Species richness during antibiotic therapy comparing those subjects receiving 
meropenem (red) with those receiving ceftazidime (blue). Species richness was 
significantly lower at day7 and end of treatment in the meropenem cohort. Data is 
presented as median values with interquartile ranges. 
(b) Species richness during antibiotic therapy comparing those subjects receiving 
meropenem (red) with those receiving ceftazidime (blue). Species richness was 
significantly lower at day7 and end of treatment in the meropenem cohort. Data is 
presented as individual subjects. 
(a) 
(b) 
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Figure 5.13 Pielou’s  evenness  index  during  antibiotic  therapy  comparing  those  subjects  receiving  
meropenem (red) with those receiving ceftazidime (blue).No significant differences 
were seen between cohorts. Data is presented as median values with interquartile 
ranges. 
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Figure 5.14 Shannon diversity index during antibiotic therapy comparing those subjects receiving 
meropenem (red) with those receiving ceftazidime (blue). Shannon diversity index 
trended to a lower value at the end of treatment in the meropenem cohort. Data is 
presented as median values with interquartile ranges. 
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Does The Presence of PA Hypermutators Affect Bacterial Diversity? 
Bacterial diversity indices were compared between groups divided on the basis of isolation of 
PA hypermutator strains. No significant differences were seen for any of the calculated 
diversity indices at either the beginning of the study or at the end of the treatment, when 
comparing groups using a Mann-Whitney test as detailed in Table 5.8. Samples for 
hypermutator strain isolation were not taken on day 7 of treatment or at the stable visit post-
treatment. 
 
Diversity Index Day of Rx Hypermutator 
 absent  
Hypermutator 
 present  
P  
 
Species Richness 1 11 (7,16) 
 n=11 
22 (7,31)  
n=10 
0.16 
End of Rx 13 (7,19)  
n=6 
11 (6,20)  
n =10 
0.91 
 
Pielou’s  Evenness   1 0.20 (0.10,0.57)  
n=11 
0.37 (0.13,0.54)  
n=10 
0.92 
End of Rx 0.32 (0.24,0.48)  
n=6 
0.31 (0.19,0.48) 
 n =10 
1.0 
 
Shannon Diversity 1 0.41 (0.25,1.50) 
 n=11 
1.20 (0.24, 1.90) 
 n=10 
0.31 
End of Rx 0.83 (0.49,1.4)  
n=6 
0.72 (0.43,1.50) 
n =10 
0.95 
 
Table 5.8 Bacterial diversity indices in the presence and absence of PA hypermutator strains. 
No significant differences were seen between groups at either time-point measured. p-
values were determined using Mann-Whitney test. 
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Does Bacterial Diversity at the End of an Exacerbation Predict Time to Next 
Exacerbation? 
Bacterial diversity indices at the end of antibiotic treatment were correlated with time to next 
exacerbation values to determine if a relationship existed. No significant correlations were 
seen with any of the indices calculated as detailed in Table 5.9. 
 R p 
TTNE vs. diversity index at end of Rx vs. 
Species Richness 0.09 0.71 
Pielou’s  Evenness  Index -0.14 0.56 
Shannon Diversity Index -0.14 0.54 
 
Table 5.9 Correlations between bacterial diversity indices at the end of antibiotic therapy and 
time to next exacerbation values. No significant correlations were found. Correlations 
were  performed  using  Spearman’s  rank  correlation  co-efficient. 
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5.4 Discussion 
 
This aim of this study was to determine whether bacterial communities in the CF lung 
changed significantly during antibiotic treatment of an infective exacerbation and if so, did 
this have an effect on treatment outcome. Previous studies have shown that antibiotic therapy 
for exacerbations does not significantly affect bacterial diversity29-31;129. Some of these 
studies have utilised T-RFLP29;30, a technique which has a much lower sensitivity for 
detecting individual species than 16S rRNA gene sequencing. Two studies have utilised 16s 
rRNA sequencing to examine exacerbations. Fodor et al.129 examined samples taken from 23 
subjects during an exacerbation and demonstrated only a small decrease in species richness 
during antibiotic treatment. Zhao et al31 noted a greater change during treatment but recovery 
of the bacterial community after treatment. 
The data presented in this study would suggest that bacterial diversity is not significantly 
affected during treatment. Cluster analysis of the sequencing data revealed that samples 
clustered by subject ID more than any other variable; this suggests that each subject harbours 
a unique bacterial ecosystem. Equally, when examining co-plotting with bacteria, it was clear 
that PA was the dominant bacteria with most subjects clustering around this organism. The 
clustering around PA bacteria is perhaps to be expected given that the major inclusion 
criterion for the study was the presence of chronic PA infection. The results discussed here 
may therefore only relate to this patient group, although this is the majority of patients in the 
CF clinic. 
Bacterial identification from 16S rRNA sequence data is based on known sequences from 
bacteria being entered into a database. The quality of the data is therefore very dependent on 
the quality of the information in the database. A possible example of mis-identification can 
be seen in the top 20 OTUs (Table 5.1). At number 18 is an OTU identified as Derxia sp. 
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This is a genus of organism found in tropical soils130 and lakewater131 and not noted to be a 
human pathogen. It does however have a close phylogenetic relationship with Alcaligenes 
sp132 which are more commonly seen in the CF lung. Contamination of the samples should 
also be considered although the methods have stringent processes to detect contamination. 
All sputum samples were handled using sterile equipment and all PCR reactions were 
performed  within  a  PCR  hood  which  had  been  decontaminated  with   ‘DNAse  free’  solution  
and UV-irradiation. A no-template control was also added to the PCR reaction to maximise 
detection of contaminated materials.  
 
When  examining  measures  of  bacterial  diversity,  namely  species  richness,  Pielou’s  evenness 
and the Shannon diversity index, it would appear that when all patients are analysed together 
there is no significant change in bacterial diversity during antibiotic treatment. Subgroup 
analysis allows further information to be gleaned from the data. One aim of this study was to 
determine if treatment outcome was related to changes in bacterial diversity. In the previous 
clinical tracking study it was demonstrated that the treatment failure group were more unwell 
at the start of treatment with a greater drop in FEV1 from baseline. In this current study there 
were no significant differences in diversity measures between the treatment outcome groups 
at day 1 or any subsequent time-points. This may well be related to two factors. Firstly when 
spirometry measures were correlated with bacterial diversity measures, no relationship was 
seen with FEV1 as a percentage of baseline. However there was a trend towards a relationship 
between   Pielou’s   evenness   and   the   Shannon   Diversity   index   with   FEV1 and, to a lesser 
degree, FEV1 % predicted. This suggests that diversity is related more to the chronic baseline 
lung function measure of patients rather than the severity of the exacerbation (as determined 
by FEV1 as a percentage of baseline). The negative correlation seen between age of the 
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patient and bacterial diversity on day 1 would further strengthen this theory. A previous study 
has also noted this association of decreasing bacterial diversity with age133. 
An examination of changes in PA bacterial density did suggest that there was a significant 
negative  correlation  between  both  Pielou’s  evenness  index  and  the  Shannon  diversity  index.  
This result is perhaps to be expected for a measure of evenness; as antibiotics kill the 
dominant organism present in the sputum so the bacterial environment becomes more even. 
The negative correlation with the Shannon diversity index suggests that as PA bacterial 
numbers decrease other bacterial species become more prominent, making the bacterial 
microbiome more diverse. The data therefore may suggest that the antibiotics are killing more 
PA bacteria than other bacteria present.  
An analysis of the effect of antibiotic choice on changes in bacterial diversity provides further 
information. The majority of patients received either meropenem or ceftazidime as the beta-
lactam antibiotic choice. Ceftazidime is a cephalosporin antibiotic with anti-pseudomonal 
activity. It has good activity against Gram positive bacteria and Pseudomonas aeruginosa but 
lesser effects on anaerobic bacteria134. Meropenem however is active against Gram positive 
and Gram negative bacteria as well as anaerobic bacteria135. In this study there was a trend to 
lesser diversity at the end of treatment in those subjects receiving meropenem. The 
differences in bacterial diversity had resolved by the stable follow-up observation. It could be 
speculated that repeated courses of meropenem could decrease bacterial diversity at a greater 
rate than ceftazidime a finding that requires further longitudinal studies. 
This study is limited by its design of recruiting patients at the time of exacerbation. A more 
detailed study would involve patients being recruited and providing clinical data and sputum 
samples when they are stable. This would allow detection of any changes in the microbiome 
in the lead up to an exacerbation. 
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In   summary,   this   microbiota   analysis   in   CF   patients   has   confirmed   that   each   patient’s  
microbiome is unique. Antibiotic treatment has been demonstrated to have no significant 
effect on the bacterial diversity within this microbiome. An association was seen between 
changes in bacterial numbers of PA and diversity indices suggesting PA is the major 
pathogen affected by antibiotic therapy. Subjects treated with meropenem had lower diversity 
measures at the end of therapy than those receiving ceftazidime. It remains to be seen in a 
longitudinal study whether repeated courses of meropenem decreases bacterial diversity more 
rapidly over time than ceftazidime. Low bacterial diversity is associated with lower lung 
function31;129. The causal relationship between them however remains unclear. A longitudinal 
study with a large number of patients would be required to elucidate this relationship 
allowing analysis of patients with similar levels of diversity, stratified by the severity of lung 
function deficit. 
If bacterial diversity is not changing significantly during exacerbations and antibiotic therapy 
perhaps a change is occurring in the expression of virulence factors within PA populations to 
trigger exacerbations?  Quorum sensing systems, which can activate bacterial virulence 
factors, will be examined in the following chapter to determine if it plays a role in the 
pathogenesis of exacerbations.  
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CHAPTER 6 
QUORUM SENSING BY PSEUDOMONAS AERUGINOSA  
 IN CF EXACERBATIONS 
 
6.1 Introduction 
A number of bacteria secrete quorum-sensing molecules as a form of communication 
between organisms. PA is probably one of the most studied of the bacterial communication 
systems. There are a number of quorum-sensing molecules produced by PA, falling into 2 
main groups, the N-acyl-homoserine lactone group (which includes N-butanoyl-homoserine 
lactone (C4-AHL) and N-(3-oxo-dodecanoyl)-L-homoserine lactone (3-oxo-C12-AHL)) and 
the 4-hydroxy-2-alkylquinolones (HAQs) group (including 2-heptyl-3,4-dihydroxyquinolone 
(PQS), its biosynthetic precursor, 4-hydroxy-2-heptylquinolone (HHQ), and 2-heptyl-4-
hydroxyquinolone N-oxide (HQNO)).  
As previously discussed QS systems are involved in the activation of bacterial virulence 
factors including the production of rhamnolipids136 and alkaline protease137. No previous 
study has shown whether QS signalling is affected by antibiotic treatment and whether that 
has an effect on clinical response. By utilising techniques noted in previous studies138, these 
QS molecules can be measured directly from sputum samples allowing an in-depth 
investigation of bacterial signalling during exacerbation therapy.  
This study examined sputum levels of C4-AHL, 3-oxo-C12-AHL, HHQ, HQNO and PQS 
during treatment of an infective exacerbation of CF and at a stable level post treatment. These 
molecules were extracted from sputum samples and quantified using a process of liquid 
chromatography-tandem mass spectrometry (LC-MS/MS). 
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Aims of the study 
1. To determine whether a relationship exists between QS molecule 
concentration and markers of severity of an exacerbation 
2. To determine if QS molecule concentrations at the start of an exacerbation can 
predict treatment outcome responses. 
3.  To determine if mucoidy is associated with decreased QS molecule 
concentration 
4. To determine if hypermutator strains are associated with lower decreased QS 
molecule concentration 
5. To determine if QS levels change during antibiotic therapy and if this is 
related to changes in PA bacterial density. 
 
6.2 Methods 
The quorum sensing molecule assays were kindly performed by Nigel Halliday, School of 
Molecular Medicine, University of Nottingham from sputum samples collected during the 
clinical tracking study as described in Chapter 2. 
Sample Preparation 
Extracts of sputum samples for LC-MS/MS analysis were prepared by solvent extraction. Up 
to 1.0 ml of 50% (v/v) sputum suspension was spiked with 10 µl of an internal standard mix 
(1.0 µM solution of deuterated PQS (PQS-d4) in MeOH), and extracted in triplicate with 0.5 
ml volumes of 0.01% (v/v) AcOH in EtOAc. After the addition of acidified solvent the 
samples were vortexed for approximately 1 min. The two immiscible layers were encouraged 
to separate fully by centrifugation (3 min at 13000 rpm) with the analytes of interest 
partitioning into the organic phase. The combined organic extracts were dried under vacuum. 
145 
 
Dried extracted samples were re-solved in 50 µl of 0.1% (v/v) formic acid in MeOH prior to 
LC-MS/MS analysis. 
Preparation of Calibration and Quality Control (QC) Standards 
In the absence of blank sputum samples to spike with analytes and produce matrix matched 
calibration and QC samples, 1.0 ml aliquots of 0.9% (w/v) NaCl were used, spiking with 50 
µl of methanolic analyte mix at 0, 5, 25, 50, 100, 200, 400, and 1000 nM. QC samples were 
prepared at 75 and 800 nM.  
All calibration and QC samples were prepared in triplicate, extracted and prepared ready for 
LC-MS/MS analysis as described above. 
LC-MS/MS Analysis 
LC-MS/MS analysis was conducted on a 4000 QTRAP hybrid triple-quadrupole linear ion 
trap mass spectrometer in tandem with a Shimadzu series 10AD VP LC system as previous 
published139. 20 µl of the prepared sputum samples were injected into the LC instrument for 
analysis. The chromatographic separation was achieved using a Phenomonex Gemini C18 
reversed phase column (3.0 µm, 100 x 3.0 mm) with a constant mobile phase flow rate of 450 
µl/min. Mobile phases consisted of aqueous 0.1% (v/v) formic acid (A) and 0.1% (v/v) 
formic acid in MeOH (B). The binary gradient began initially at 10% B and ran isocratically 
for the first 1 min before increasing linearly to 50% B over 1.5 min. After a further linear 
increase to 99% B over 4 min, the gradient was maintained at this composition for 2 min. The 
gradient was then returned to 10% B over 0.2 min and allowed to re-equilibrate for 2.3 min. 
The MS, operating in the positive electrospray (+ES) mode, was set up for multiple reaction 
monitoring (MRM) to constantly screen the eluent from the LC column for all the analytes of 
interest. 
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Sample Quantification 
For each analyte, ratios of LC-MS/MS peak areas to internal standard (d4-PQS) peak areas 
were calculated and used to construct calibration lines of peak area ratio against analyte 
concentration (see Appendix 3). Results from the QC samples were used to assess precision 
and accuracy at both the high end and low end of the calibration lines. Sample concentrations 
for each analyte (calculated from the slope of the calibration line) were then adjusted to 
reflect the differing volumes of sputa that each sample was prepared from, to give a final 
calculated sputum concentration 
Statistical Methodology 
Continuous variables were compared using Mann-Whitney testing for non-paired data, and 
Wilcoxon Matched pairs test for paired data. Categorical variables were examined using 
Fisher’s   exact   test.   Correlations   were   performed   using   Spearman’s   rank correlation co-
efficient.  
All data is expressed as median values with the interquartile range. All statistical analysis was 
performed using Graphpad Prism (GraphPad Software Inc). 
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6.3 Results 
Day 1 QS Analyte Concentrations 
28 subjects provided samples for the day 1 analysis. The samples for the subject excluded 
from the clinical study for not culturing PA was analysed and contained no measured QS 
analytes. 
Four subjects had no detectable QS analytes at day 1. Of these, three had no detectable QS 
analytes for any time-point measured and one only had measurable QS analytes at the stable 
follow-up visit.  
For each analyte, it was determined what proportion of subjects had no detectable level of the 
analyte at any time point. There were no significant differences in age of those subjects who 
had detectable QS analytes when compared with those who had no detectable analytes as 
detailed in Table 6.1. Table 6.2 and figure 6.1 represent the median concentrations of each 
analyte on day 1.  
 No detectable 
QS analyte 
Detectable QS 
analyte 
 
n Age 
(years) 
n Age 
(years) 
P value 
 
C4-AHL 16 30 
(25,42) 
12 32 
(23,45) 
0.98 
3-oxo-C12-AHL 14 30 
(20,47) 
14 30 
(25,40) 
0.87 
HHQ 12 30 
(21,46) 
16 30 
(24,42) 
0.98 
HQNO 3 30 
(18,42) 
25 31 
(25,44) 
0.64 
PQS 14 35 
(24,46) 
14 29 
(23,42) 
0.40 
 
Table 6.1 Detection of QS analytes in samples at all time points and median ages 
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 Median(IQR) 
Day 1 QS analyte concentration (nM) 
C4-AHL 6 (0,96) 
3-oxo-C12-AHL 13 (1.2,89) 
HHQ 0 (0,9.1) 
HQNO 6.6 (0,83) 
PQS 0 (0,54) 
 
Table 6.2 Median Day 1 concentrations (nM) of the QS analytes 
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Figure 6.1  Median concentrations of QS analytes on day 1 of the study. Data is presented as box 
and whisker plots with the boxes representing median values and interquartile ranges 
and whickers representing maximum and minimum values. 
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Is Age a Factor in QS Analyte Concentrations? 
Correlations were performed between age and QS analyte concentrations at the beginning of 
an exacerbation. A significant negative correlation was seen for HQNO, with correlations for 
the other analytes not meeting significance but with a trend towards a negative correlation as 
detailed in table 6.3. 
 R p 
Age vs. Day 1 QS analyte concentration 
C4-AHL -0.35 0.09 
3-oxo-C12-AHL -0.37 0.08 
HHQ -0.39 0.06 
HQNO -0.44 0.03 
PQS -0.41 0.05 
 
Table 6.3 Correlations between subject age and QS analyte concentrations on day 1 of the 
clinical study. Correlations   were   performed   using   Spearman’s   rank   correlation   co-
efficient. 
 
Is There a Relationship Between Day 1 Lung Function and QS Analyte Concentration? 
Correlations were performed between spirometry measures and QS analyte concentrations on 
day 1 of the study. No significant correlations were seen between any of the QS analytes and 
FEV1. There was a significant correlation between C4-AHL and FEV1 % predicted, but this 
was not seen for the other analytes. When examining the correlation between FEV1 as a 
percent of baseline there appeared to be a trend to a negative correlation, but this only 
reached statistical significance for HQNO as detailed in Table 6.4 
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Is There a Relationship Between Inflammatory Markers and QS Analyte 
Concentration? 
Correlations were performed comparing inflammatory markers (C-reactive protein (CRP), 
total white cell count and neutrophil count) with QS analyte concentrations on day 1 of 
treatment. No significant correlations were seen. However when correlating both HQNO and 
QS with total white cell count and neutrophil count there did appear to be a weak correlation 
but this failed to reach statistical significance as detailed in table 6.5. 
 
 R p 
FEV1 vs. day 1 QS analyte concentration 
C4-AHL 0.33 0.12 
3-oxo-C12-AHL 0.14 0.52 
HHQ 0.13 0.55 
HQNO 0.13 0.55 
PQS 0 0.98 
FEV1% pred  vs. day 1 QS analyte 
concentration 
  
C4-AHL 0.43 0.04 
3-oxo-C12-AHL 0.08 0.71 
HHQ 0.13 0.56 
HQNO 0.12 0.57 
PQS 0.05 0.82 
FEV1%OBL  vs. day 1 QS analyte 
concentration 
  
C4-AHL -0.35 0.09 
3-oxo-C12-AHL -0.37 0.08 
HHQ -0.39 0.07 
HQNO -0.43 0.04 
PQS -0.39 0.06 
 
Table 6.4  Correlations between QS analyte concentrations and spirometry measures on day 1 of 
the clinical study. Correlations were performed  using  Spearman’s  rank  correlation  co-
efficient. 
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 R p 
CRP  vs. day 1 QS analyte concentration 
C4-AHL -0.07 0.73 
3-oxo-C12-AHL -0.02 0.91 
HHQ -0.05 
 
0.80 
HQNO 0.05 0.83 
PQS 0.06 0.80 
Total white cell count  vs. day 1 QS 
analyte concentration 
  
C4-AHL 0.13 0.55 
3-oxo-C12-AHL 0.11 0.62 
HHQ 0.29 0.16 
HQNO 0.37 0.07 
PQS 0.40 0.06 
Neutrophil count  vs. day 1 QS analyte 
concentration 
  
C4-AHL 0.12 0.19 
3-oxo-C12-AHL 0.19 0.37 
HHQ 0.31 0.14 
HQNO 0.37 0.08 
PQS 0.39 0.06 
 
Table 6.5  Correlations between QS analytes and inflammatory markers on day 1 of treatment. 
Correlations were performed  using  Spearman’s  rank  correlation  co-efficient. 
 
Do QS Analyte Concentrations at Day 1 Predict Treatment Outcome? 
Median QS analytes concentrations on day 1 of the study were compared between groups 
cohorted by treatment outcome (success or failure as defined in the earlier clinical tracking 
study). No significant differences were seen between groups for any of the QS analytes as 
detailed in table 6.6. The same analysis was performed for the end of treatment values of QS 
analyte concentration. This again revealed no significant differences between treatment 
outcome groups for any of the analytes measured. 
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QS analyte Rx failure Rx success p 
Day 1                            n=7                 n=19 
C4-AHL 0 (0,6.3) 0 (0,86) 0.28 
3-oxo-C12-AHL 0(0,460) 6.6 (0,68) 0.76 
HHQ 5.1 (0,42) 79 (0,151) 0.57 
HQNO 17 (1.3,450) 9.7 (0.0,48) 0.43 
PQS 0 (0,33) 28 (0,150) 0.30 
End of Rx                      n=5                 n=15 
C4-AHL 0 0 (0,23) 0.17 
3-oxo-C12-AHL 2 (0,130) 0 (0,2.8) 0.20 
HHQ 0 0(0,17) 0.96 
HQNO 5.1 (0,44) 0.70 (0,1.9) 0.27 
PQS 0 (0,4.5) 0 (0,18) 0.75 
 
Table 6.6 QS analyte concentrations at the beginning and end of treatment comparing treatment 
outcome groups. Values are presented as medians with interquartile ranges. 
Do Mucoid Morphotypes of PA have Different Levels of QS Molecule Production? 
The concentrations of QS analytes were measure on day 1 of treatment and grouped by 
whether the sputum sample had a positive culture of mucoid PA or not. Comparisons of these 
groups revealed the levels of HHQ and HQNO were significantly higher in sputum samples 
with mucoid PA present. This relationship was not seen for C4-AHL or 3-oxo-C12-AHL. 
There was a trend towards higher concentrations in the mucoid group for PQS but this failed 
to reach statistical significance as detailed in table 6.7 and figure 6.2. 
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QS analyte Non-mucoid Mucoid p 
Day 1                               n=5                 n=19 
C4-AHL 0 (0,24) 0 (0,11) 0.94 
3-oxo-C12-AHL 0 (0,410) 15 (0,92) 0.26 
HHQ 0 (0,2.3) 27 (2.9,120) 0.01 
HQNO 1.1 (0.1,7.4) 24 (5.7,190) 0.02 
PQS 0 (0,3.3) 15 (0,79) 0.09 
 
Table 6.7 Median QS analyte concentrations in sputum samples grouped by the presence or 
absence of mucoid PA. Data is expressed as median values with interquartile ranges. 
 
Do Hypermutator Strains of PA Produce Greater Concentrations of QS Molecules? 
Median concentrations of each QS analyte were determined for samples from day 1 of 
treatment for those samples where hypermutator strains were isolated and compared with 
those where the hypermutator strains were absent. No significant difference was seen 
between groups for any of the QS analytes measured, although a trend to higher 
concentrations of HHQ and HQNO in the hypermutator negative group was seen but this 
failed to reach statistical significance as detailed in table 6.8 and figure 6.3.  Fisher’s   exact  
tests comparing the number of subjects with hypermutator strains and the number of subjects 
without any significant QS analyte concentrations throughout treatment showed no statistical 
significant differences for any analyte. 
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QS analyte Hypermutator 
–ve 
Hypermutator 
+ve 
p 
Day 1                                n=11                 n=10 
C4-AHL 0 (0,63) 0 (0,8.2) 0.72 
3-oxo-C12-AHL 6.6 (0,200) 59 (0,130) 0.69 
HHQ 88 (0,150) 3.8 (0,16) 0.08 
HQNO 59 (1.4,450) 10 (0.6,30) 0.09 
PQS 44 (0,150) 2.1 (0,19) 0.17 
 
Table 6.8 Comparing QS analyte concentrations by the presence or absence of PA hypermutator 
strains. Data is expressed as median values with interquartile ranges. 
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Figure 6.2 Median QS analyte concentrations in sputum samples grouped by the presence or 
absence of mucoid PA. Data is expressed as box and whisker plots with the box 
representing median values and interquartile ranges and the whiskers representing 
minimum and maximum values. Significant differences are seen for the HHQ and 
HQNO analytes as noted. 
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Figure 6.3 Median QS analyte concentrations in sputum samples grouped by the presence or 
absence of hypermutator strains of PA. Data is expressed as box and whisker plots 
with the box representing median values and interquartile ranges and the whiskers 
representing minimum and maximum values. No significant differences are seen. 
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Do QS Analyte Levels Change During Antibiotic Therapy? 
Each analyte was analysed separately. Any subject who had no measurable QS analyte 
throughout the study period was not included in the analysis of that analyte. This did not 
affect p-values as a paired sample t-test was performed. No significant difference was seen 
for levels of C4-AHL for subsequent time-points when compared with day 1 values. For all 
the other analytes there was a significant drop in QS analyte concentrations for each 
treatment time point as detailed in table 6.9 and figure 6.4. The stable post treatment values 
however were not significantly different to the day 1 values.  
 n Median 
(IQR) 
p value 
(compared 
with day 1 
value) 
C4-AHL 
Day1 13 7.4 (0,53)  
Day 7 10 0 (0,0) 0.16 
End of Rx 10 0 (0,13) 0.20 
Stable post 6 0 (0,4.5) 0.25 
3-oxo-C12-AHL 
Day1 15 68 (9,233)  
Day 7 12 0 (0,30) 0.002 
End of Rx 13 3.9 (0,59) 0.02 
Stable post 5 7.2 (0,260) 0.37 
HHQ 
Day1 20 42 (5.6,137)  
Day 7 17 0 (0,32) 0.02 
End of Rx 18 0 (0,1.2) 0.0001 
Stable post 12 32 (7.6,75) 0.15 
HQNO 
Day1 28 8.7 (0.35,57)  
Day 7 24 0.3 (0,32) 0.03 
End of Rx 24 0.9 (0,3.4) 0.0003 
Stable post 13 2.3 (0.3,48) 0.13 
PQS 
Day1 16 33 (4,150)  
Day 7 14 6 (0,32) 0.02 
End of Rx 14 0 (0,22) 0.001 
Stable post 9 17 (0,107) 0.38 
 
Table 6.9  QS analyte concentrations at each time point of the study. Data is presented as 
median values with interquartile range. 
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Figure 6.4  QS analyte concentrations during antibiotic therapy. Data is presented as a box and 
whisker plot with the box representing the median and interquartile ranges and the 
whiskers representing the minimum and maximum values. Significant p-values are 
documented. 
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Is QS Analyte Concentration Related to PA Bacterial Density? 
Correlation was performed for QS analyte concentrations versus PA bacterial density on day 
1 of the study. No significant correlations were seen for any of the measured analytes. 
Correlations were then performed between the changes in QS analyte concentration over the 
treatment course and the change in PA bacterial density. Again no significant relationship 
was found for any of the measured QS analytes as detailed in table 6.10 
 R p 
Day 1 PA density vs. QS analyte concentration 
C4-AHL 0.25 0.23 
3-oxo-C12-AHL 0.31 0.13 
HHQ 0.16 0.45 
HQNO 0.17 0.42 
PQS 0.22 0.29 
∆PA density vs. ∆QS analyte concentration 
C4-AHL -0.22 0.36 
3-oxo-C12-AHL 0.16 0.51 
HHQ 0.26 0.29 
HQNO 0.05 0.83 
PQS 0.07 0.78 
 
Table 6.10 Correlations between PA bacterial density and QS analyte concentration on day 1 of 
treatment and between the change in PA density and the change in QS analyte 
concentration over the course of antibiotic therapy.  
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6.4 Discussion 
This study has determined that there may be a relationship between the sputum concentration 
of some QS molecules at the time of an exacerbation and the severity of the exacerbation as 
determined by percentage drop in spirometry. It has also determined that some QS molecule 
concentrations drop during antibiotic treatment which is not correlated with a change in 
bacterial numbers suggesting the inhibition of QS production by antibiotic therapy. 
Is Age a Factor in QS Analyte Concentrations? 
A previous study has suggested that PA quorum sensing systems are lost in late infection140. 
In this study we did not examine time from first isolation of PA. However if age is used as a 
surrogate marker for this measure it has been shown that there were no significant differences 
in the median ages between those subjects who did produce QS molecules and those who did 
not. However, the median concentrations of the QS analytes on day 1 of treatment appeared 
to trend towards a negative correlation with age of the subjects. This only reached statistical 
significance for HQNO. This could represent a gradual decline in the number of bacteria 
within a chronic PA CF lung infection having a functioning QS system in keeping with the 
previous study. Previously it has been shown that mutations in the QS regulatory genes lasR 
and rhlR have been associated with a decrease in QS molecule production. In this current 
study, sputum was analysed directly without isolation of PA bacteria. To determine the 
mechanism of declining QS analyte concentration with age would require isolation of all 
distinct PA strains in a sample followed by sequencing of the QS regulatory genes to 
determine the incidence of mutation. 
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Is There a Relationship Between QS Analyte Concentrations and Lung Function 
Changes? 
 This is the first study to examine QS analyte levels in an acute exacerbation with directly 
obtained clinical sputum samples. It has been shown that QS analyte levels of HQNO and 
PQS are related to the severity of infection as determined by the negative correlations 
between these concentrations and FEV1 as a percentage of the baseline. The results also 
demonstrate that QS analyte concentrations are not related to the other spirometry markers of 
FEV1 and FEV1 % predicted. It therefore would appear that QS molecule levels are related to 
the severity of the exacerbation for the individual subject rather than the absolute level of 
lung function. This is a very interesting observation and raises the possibility that the QS 
molecules themselves could be contributing to the severity of the exacerbation.  
QS molecules have previously been shown to have a direct on CF airway epithelial cells. 
Mayer et al141, have shown that 3-oxo-C12-AHL could stimulate CF epithelial cells to secrete 
IL-6 (IL-6 being a pro-inflammatory cytokine). The same QS molecule has been shown to 
induce other inflammatory mediators in human lung fibroblasts (although not a CF model) 
including IL-8, PGE-2 and cyclo-oxygenase 2 (Cox-2)142;143. In the current study there were 
no significant correlations with serum inflammatory markers and QS analyte concentration 
although there was a trend to a positive correlation between both HQNO and PQS with total 
white cell count and neutrophil count on day 1 of treatment. However these are systemic 
inflammatory markers, a study of pulmonary inflammatory markers in sputum may show a 
more significant relationship. 
Bacterial density has been shown to not alter significantly during the exacerbation and in this 
study no correlation was seen between PA bacterial density and QS analyte concentration for 
any of the molecules analysed.  This suggests that at the time of exacerbation either the 
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relative abundance of QS-proficient PA organisms increase, or those QS-proficient PA 
organisms up-regulate their QS molecule production. Logically, the former is more likely. QS 
systems have presumably evolved with each bacteria secreting a similar quantity of QS 
molecules. If some bacteria increased their QS production, this would give a false 
representation of the number of bacteria present and trigger changes in virulence factors 
without the necessary numbers of bacteria to be effective.  
To examine this further would require quantitative PCR of the lasR and rhlR genes, 
comparing stable sputum samples with those collected at exacerbation to determine the 
relative frequency of mutations in these QS regulating genes at each time point. 
Mucoidy and Quorum Sensing 
The relationship between PA mucoidy and QS analyte levels was also examine in this study. 
Previous studies have shown that mucoid PA produce greater quantities of C4-AHL than 
non-mucoid strains140. In the current study, on day 1 of treatment there were no significant 
differences in C4-AHL or 3-oxo-C12-AHL median concentrations in sputum samples 
containing mucoid or non-mucoid samples. However, significantly higher concentrations of 
HHQ, HQNO and PQS were seen in sputum samples containing mucoid PA as compared 
with those only isolating non-mucoid PA.  In the previous study, QS analytes were measured 
from PA cultures rather than clinical sputum samples, and the 4-hydroxy-2-alkylquinolones 
(HAQs) signalling systems were not measured. No previous work has identified this 
relationship between mucoidy and the HAQ signalling system. PQS has previously been 
shown to upregulate a number of virulence factors in PA including the production of 
rhamnolipids144, iron chelation145 and the formation of biofilm146 in wild-type organisms. 
This finding of a relationship with mucoidy should be further examined with isolated 
bacterial cultures to confirm this relationship. 
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Hypermutator Strains of PA and Quorum Sensing 
Hypermutator strains of PA have the ability to undergo rapid mutation to maintain their 
presence in chronic infections. As they undergo rapid mutation it could be postulated that 
they are more likely to develop mutations of the genes coding for the QS signalling systems 
and as such have decreased expression of QS molecules. A previous study140 has 
demonstrated increased mutation of QS regulatory genes in hypermutator strains of PA, 
although did not determine associated QS molecule concentrations. In this study, QS analyte 
concentrations in those samples containing hypermutator strains were not significantly 
different to those that did not. However there was a trend to lower levels of HHQ and HQNO 
in hypermutator-containing samples, although this did not reach statistical significance. It 
could be considered that hypermutator strains might eliminate all QS production and the data 
skewed by multiple zero values, but there was no significant difference in the number of 
subjects with absent QS production between groups cohorted by presence or absence of 
hypermutator strains. A significant limitation of this study was the hypermutator assay itself. 
The analysis of hypermutators was based only on their presence or absence in a sputum 
sample. Therefore in those sputum samples with hypermutators present, there would likely to 
have been significant numbers of non-hypermutator strains present. To determine whether 
hypermutator strains are having an effect on HHQ and HQNO production would require an 
assay based on known hypermutator strains grown in vitro.  
Antibiotic Effect on Quorum Sensing 
This study also examined the effect of antibiotic treatment on QS molecule levels. With the 
exception of C4-AHL, all QS analytes significantly decreased in concentrations during 
antibiotic treatment. The stable samples taken post-treatment were not significantly different 
to the day 1 levels taken prior to starting antibiotic therapy. It was also demonstrated that 
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changes in QS analyte concentrations were not related to the change in PA bacterial density. 
This suggests that the mechanism for a decrease in QS analyte concentration is either a 
selective killing of QS-proficient  PA  bacteria  or  an  action  of  the  antibiotic  therapy  to  “switch  
off”   the   QS   signalling   system.   It   would   be   difficult   to   postulate   why   antibiotics   would  
selectively kill QS-proficient bacteria, especially as quorum sensing is involved with 
upregulation of virulence factors to evade antimicrobial killing. Certainly it has been shown 
that a number of antibiotics can inhibit QS signalling. Skindersoe et al147 have previously 
demonstrated azithromycin, ceftazidime and ciprofloxacin could all inhibit QS signalling at 
sub-lethal  dosing  i.e.  could  inhibit  quorum  sensing  without  killing  bacteria.  Such  “switching  
off”   of   QS   signalling   by   antibiotic   may   explain   why   the   QS   analyte   levels   had increased 
again by the stable post-treatment measure. It has been previously shown that inhibiting 
quorum sensing in PA can increase biofilm eradication by antibiotics, make the biofilm more 
susceptible to neutrophil phagocytosis in murine models72 and eradicate biofilms in PA 
cultures148. It is therefore possible that the effect of antibiotics in CF exacerbations is two-
fold; it has an effect of inhibiting QS-molecule signalling which then increases the effect of 
its anti-microbial killing ability by weakening the biofilm and down-regulating virulence 
factors in the PA bacteria present. A limitation of this study was the widespread prophylactic 
use of azithromycin in the subject group, which was continued through the treatment. 
Twenty-three subjects were receiving azithromycin at the time of study. This may have 
affected QS molecule levels in some patients. 
Effect of Antibiotic Therapy on QS regulation 
The QS signalling system is both multi-system and hierarchical. As previously mentioned the 
AHL systems are regulated by the las and rhl genes; these systems are linked to the AQ 
system regulated through the pqs genes. They act in a hierarchical fashion with the gene 
products of the las system positively regulating the rhl system (the las system produces 3-
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oxo-C12-AHL and the rhl system produces C4-AHL)149. The gene products of the las system 
also positively regulate the pqs system whereas the gene product of the rhl system are 
negative regulators of the pqs system (which produce HHQ, HQNO and PQS). There is also a 
feedback mechanism whereby pqs gene product inhibits the rhl system. To fully understand 
what effect antibiotic therapy has on this regulatory system and where it acts would require 
multiple assays of infection models with knock-out gene variants of PA bacteria. However 
the global decline in QS levels would suggest that antibiotic therapy is having an effect at the 
higher levels of the hierarchical system, possibly the las system. A further investigation of las 
mutants in a clinical infection model would be a priority for investigation. 
 
The study described in Chapter 6 is the first study to measure quorum-sensing molecules 
produced by PA directly from sputum samples collected during an exacerbation. There 
appeared to be a relationship between the severity of an exacerbation, as determined by the 
FEV1 on day 1 as a percentage of the stable baseline value, with levels of QS molecules 
(Table 6.4). Median concentrations of most QS molecules dropped significantly during 
treatment but had increased to pre-treatment levels by the stable follow-up time-point. The 
lack of association with changes in PA bacterial numbers suggested that the drop in 
concentrations represented an active process of inhibition of QS-molecule production. It has 
previously been demonstrated that QS production can be inhibited by sub-lethal 
concentrations of antibiotics147 and other compounds including garlic150. QS molecules have 
also been shown to be pro-inflammatory. It is possible therefore that this QS inhibition effect 
of antibiotics may be involved in the recovery from exacerbation, both by reducing the 
inflammatory stimulus within the lung and by allowing more effective killing of bacteria as 
described in the previous chapter. 
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CHAPTER 7 
DISCUSSION AND PLANS FOR FUTURE STUDY 
 
The thesis has provided an in-depth analysis of a number of aspects of the infective 
pulmonary exacerbation in cystic fibrosis. This work has shown agreement with previously 
published work in CF and has also provided new insights, particularly with respect to 
hypermutator strains of PA and quorum-sensing systems during antibiotic treatment of an 
infection. 
The clinical tracking study was performed as a means of data collection for subsequent 
microbiological investigations but provides corroboration of previous observational and 
registry data analysis studies. Of the 27 subjects analysed in the clinical study, 8 failed to 
return to within 90 % of baseline lung function. Clearly the concern of failing to return to 
baseline is the cumulative effect of such exacerbations leading to inexorable decline in lung 
function with the associated significant morbidity and ultimately mortality. Analysis of the 
factors that lead to this failure revealed similar results of a far larger US Registry data 
analysis91; those patients who failed to return to baseline had a bigger drop in lung function at 
the time of exacerbation and a longer time from stable measure to exacerbation. As discussed 
in Chapter 2, this may have significant implications for the treatment of CF patients. If this 
longer time between stable measures and exacerbation were to actually represent patients 
waiting longer to start treatment after the onset of symptoms of an exacerbation, it would 
suggest that patients should start treatment promptly at the onset of symptoms. Clearly this 
would require both significant patient education and hospital bed management changes. The 
data as it stands however is not conclusive on the matter. It would require a more in-depth 
study requiring a cohort of patients to record daily symptoms, perhaps in a similar manner to 
the East London COPD cohort that has been extensively investigated151. This would allow a 
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far more accurate estimation of the timing of onset of exacerbation symptoms and, if 
combined with home spirometry measures, would provide a wealth of data on the evolution 
of an exacerbation.  
A further noted observation in the clinical tracking study was that, in those patients who 
returned to baseline lung function during treatment, the majority of lung function 
improvement was seen within the first 7 days of treatment. This had also been noted in a 
previous retrospective review of data collected by the US CF Twin and Sibling Study. The 
authors of this study noted lung function improvement plateaued after 7-10 days of treatment. 
The appropriate duration of antibiotic therapy for CF exacerbations is a topical subject. 
Previous Cochrane reviews152 have highlighted the dearth of good-quality randomised studies 
investigating the problem.  The lack of further improvement after 7 days of treatment raises a 
number of issues. For those patients who have returned to baseline lung function at day 7, 
should antibiotics be stopped and the patient discharged? The answer to this depends on 
whether lung function is the only significant variable to consider regarding treatment 
response. The clinical tracking study showed that inflammatory markers are often in the 
normal range and did not correlate with severity of an exacerbation. Symptom questionnaires 
are not validated for exacerbations. In the quantitative microbiology study presented in 
Chapter 3, there were no significant changes in PA density at any treatment time-point 
compared with the start of treatment and in this study no new antibiotic resistance emerged 
during the antibiotic treatments. The apparent inhibition of quorum sensing during antibiotic 
therapy noted in Chapter 6 is noted at day 7 (although this is the first time-point measured 
after commencing treatment). It is possible that the time to next exacerbation (TTNE) could 
be decreased by stopping antibiotics early. A previous study examining the factors present at 
the end of treatment that led to a shorter TTNE, demonstrated that lower FEV1 and older age 
was associated with shorter exacerbation-free times153. The same group also showed that 
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extending antibiotics beyond 14 days had no effect on improvement in clinical variables other 
than symptom score154. It may be too simplistic to suggest that all patients receive an 
antibiotic course of x number of days, and a study requiring patients to be randomised to 
duration and then further stratified on lung function may require unfeasibly large numbers of 
subjects to adequately power the study. Perhaps it would be more useful to look at threshold 
targets of treatment, for example stopping antibiotics when FEV1 reaches 90% of baseline. 
This  however  raises  the  point  of  what  to  do  with  patients  who  don’t  return  to  baseline  within  
7-10 days, as was the case in the treatment failure group. As previously mentioned, extending 
antibiotic course has been shown to have no effect on lung function markers154. A study to 
determine if a change of antibiotics after 7 days has added benefit may be very informative 
and relatively simple to design. 
Bacterial identification in routine clinical practice is based upon culture of sputum samples. 
In this thesis, both routine culture results were analysed as well as bacteria identified through 
16S rRNA sequencing. The routine cultures are performed on selective media plates to grow 
those bacteria that are thought to be pathogenic and to inhibit the growth of those thought to 
be commensal. This provides information such as bacterial numbers and can lead on to 
antibiotic sensitivity testing, but gives less information on bacterial diversity. 16s rRNA gene 
sequencing can provide a wealth of information regarding what bacteria are present but is less 
helpful in determining what organisms are pathogenic. It also only identifies the species of 
bacteria and cannot provide information regarding virulence factor expression such as 
mucoidy.  
The major inclusion criteria for the study included chronic infection with PA. This was 
cultured from all patients, except one who cultured only Achromobacter xylosidans and was 
excluded from the data analysis. Using the 16s rRNA gene sequencing however it was shown 
that in 6 of the 27 subjects analysed, PA was not the dominant organism (based on the 
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number of gene sequences attributable to each bacterium). The dominant organisms in the 
other patients were all common respiratory pathogens but treatment was not directed at these 
bacteria. However the notion of a dominant organism based on gene sequence copy numbers 
is rather artificial and cannot be directly extrapolated to bacterial numbers in the CF lung and 
equally the most prolific organism is not necessarily the most pathogenic to the CF patient. 
In the microbiology study, PA bacterial numbers at the start of an exacerbation were not 
associated with any clinical measures of severity of the exacerbation although there was a 
trend towards a correlation between a decline in bacterial numbers and improvement in lung 
function (Table 3.4). This suggests PA bacterial killing may play some role in lung function 
recovery during antibiotic treatment. The change in PA bacterial density was also 
demonstrated   to   be   correlated   with   the   change   in   bacterial   diversity,   namely   Pielou’s  
evenness and the Shannon diversity index. This suggests that PA bacteria are decreasing in 
numbers making the bacterial population more even, and the relative abundance of other 
bacteria increases to make the population more diverse. 
Decreasing bacterial numbers were also shown to be associated with the emergence of 
Candida albicans in sputum cultures (Table 3.6). In this study, the emergence of Candida did 
not have an effect on clinical outcomes. Previous studies have suggested chronic Candida 
albicans is associated with increased exacerbation frequency and long term FEV1 decline114 
but the emergence during treatment has not previously been examined. While oro-pharyngeal 
contamination could lead to its emergence in sputum samples during treatment, the 
association with PA bacterial numbers does suggest the organism is within the lung, and is 
likely a mirror of what we see in the microbiome data; of a decrease in PA bacterial numbers 
allowing other organisms to increase in relative abundance. 
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PA hypermutator strains have been documented for a number of years in CF sputum. The 
study documented in Chapter 4 is the first clinical study to examine the effect of their 
presence during exacerbation treatment. The presence of hypermutator strain of PA was 
associated with less severe exacerbations although the numbers in the study were small, 
limiting the interpretation of the results. As a pilot study however it does suggest the need for 
larger scale studies. The presence of hypermutators had no effect on bacterial diversity. 
Bacterial diversity was shown to decrease with age and hypermutator strains were seen more 
frequently with increasing age. It could therefore be suggested that an association may have 
been predicted. A larger study would allow multiple regression analyses to remove age as a 
confounding factor and may give more information regarding a possible association. 
In recent years, with the introduction of multiplex gene sequencing, a number of investigators 
have examined the CF airway microbiome both in chronic stable states and at the time of 
exacerbation. The overwhelming message from these studies has been that  each  CF  patient’s  
lungs harbour a unique community of bacteria which may becomes less diverse over time 
with increasing age and progressive lung disease31;133. Studies examining bacterial diversity 
during exacerbations have shown resilience of the community with minimal changes at the 
time of treatment29-31. The study described in Chapter 5 would agree with these studies. The 
original hypothesis being examined was that increased bacterial diversity was associated with 
a better outcome in exacerbations but no evidence has been shown to confirm this theory. The 
observation of decreased bacterial diversity during treatment in those receiving meropenem 
when compared with those receiving ceftazidime is perhaps worth exploring in a further 
study. This would require a longitudinal study over many years to determine if repeated 
courses of meropenem lead to a more rapid decline in bacterial diversity. The clinical 
relevance of such a decline in bacterial diversity remains unclear. 
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The study described in Chapter 6 is the first study to measure quorum-sensing molecules 
produced by PA directly from sputum samples collected during an exacerbation. The study 
demonstrates an active inhibition of QS molecule production during antibiotic treatment. This 
is not the first study to show antibiotics have this effect on bacteria but it is the first to show it 
occurring during the treatment of an exacerbation.  It raises a number of questions regarding 
both the pathogenesis of an infective exacerbation and the response to treatment. The 
apparent relationship between QS molecule concentration and FEV1 as a percentage of 
baseline on day 1 of treatment, but not absolute FEV1 or FEV1 % predicted suggests that QS 
molecule concentration may be directly related to the severity of an exacerbation. This may 
suggest a greater density of QS-proficient PA bacteria is present at the time of exacerbation, 
and their selective growth may be the trigger for an exacerbation. Clearly this would not be 
the scenario for all exacerbations, especially considering some subjects produced none of the 
QS molecules analysed or only a proportion of them.  
The appearances of the active inhibition of QS molecule production during antibiotic therapy 
suggests another role for antibiotics beyond that of bacterial killing. This study furthers the 
argument for the clinical trials of non- antibiotic QS inhibitors, which may offer alternative 
therapies to treat or prevent exacerbations. 
 
A better understanding of pulmonary infections in CF is a key component to continuing the 
advances in CF survival figures that have been seen over the previous decades. The collection 
of studies presented in this thesis has added to the knowledge of the pathogenesis and 
treatment of infective exacerbations of CF but equally has identified areas for further study. 
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PLANS FOR FUTURE STUDY 
1. The Development of a CF Patient Cohort 
The East London COPD cohort has provided a large quantity of high-quality research into 
that condition. The development of a CF patient cohort including daily symptom diaries and 
regular home spirometry, combined with data already collected at clinics and annual reviews 
would provide a wealth of information. A multi-centre approach could recruit a larger 
number of patients and provide significant data in a relatively short time period. The data 
collected would give a more detailed view of the pathogenesis of an exacerbation as well as 
potentially allowing earlier treatment. 
2. Antibiotic Duration Study 
As discussed above, the logistics and number of patients required to adequately power a 
study to determine the optimum duration of antibiotics may be unfeasible and not particularly 
clinically relevant. Two alternative studies could be considered. One would involve stopping 
antibiotics when patients reach a threshold of FEV1 recovery (for example, 90%). Clearly this 
would   exclude   some   patients  who   don’t   have   a   significant   decline   in   FEV1 at the time of 
exacerbation and a protocol would need to include a maximum duration of antibiotic therapy 
(and  what   to  do  with  those  subjects  who  don’t  reach  the  threshold).  Another  possible  study  
would involve randomising patients to either a 14 day course of one antibiotic combination or 
a 14 day course involving a switch in antibiotics after 7 days. This would determine if further 
lung function improvement is possible after 7-10 days of treatment. 
3. Larger scale Hypermutator assay 
The data presented in this thesis suggested that hypermutator strains were associated with less 
severe exacerbations. The small number of subjects in the study limited the validity of this 
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finding and a larger scale study is indicated. The hypermutator assay as described is rather 
labour-intensive with multiple cultures of PA required. An assay based on gene sequencing of 
mutations associated with hypermutation may be possible although a number of mutations 
can lead to the development of a hypermutator phenotype which may limit its use. 
4. Long term microbiome study 
The study presented in Chapter 5 adds to the evidence that the CF lung microbiome changes 
slowly over time. Previous studies have shown that the biggest driver of change in the 
microbiome is antibiotic courses. The study shows that meropenem is associated with a 
greater decline in diversity during antibiotic treatment. A retrospective study of the 
relationship between bacterial diversity and the number of days of meropenem versus 
ceftazidime could be completed rapidly (and could be done with the samples collected in this 
study). However, a prospective study with regular sputum samples would provide more detail 
of the shifts in bacterial populations. 
5. Quorum-sensing Inhibitors 
The study presented in Chapter 6 suggests a role of antibiotics in quorum-sensing inhibition. 
A number of non-antibiotic compounds have been shown to have similar inhibitory properties 
and may provide alternative therapeutic options. Some compounds such as garlic have 
already been studied but further work is indicated to determine the clinical effect of such 
inhibitors. 
  
 
 
 
174 
 
Reference List 
 
 (1)  Andersen DH. Cystic fibrosis of the pancreas and its relation to celiac disease  
a clinical and pathologic study. Am J Dis Child. 56(2), 344-993. 1-1-1938.  
 
 (2)  Andersen DH. Celiac syndrome V. Genetics of cystic fibrosis of the pancreas with 
consideration of the etiology. Am J Dis Child. 72, 62-80. 1-1-1946.  
 
 (3)  Kessler WR, Andersen DH. Heat prostration in fibrocystic disease of the pancreas and other 
conditions. Pediatrics 1951; 8(5):648-656. 
 (4)  Di Sant'agnese PA, Darling RC, Perera GA, Shea E. Abnormal electrolyte composition of 
sweat in cystic fibrosis of the pancreas; clinical significance and relationship to the disease. 
Pediatrics 1953; 12(5):549-563. 
 (5)  Quinton PM. Chloride impermeability in cystic fibrosis. Nature 1983; 301(5899):421-422. 
 (6)  Tsui LC, Buchwald M, Barker D, Braman JC, Knowlton R, Schumm JW et al. Cystic 
fibrosis locus defined by a genetically linked polymorphic DNA marker. Science 1985; 
230(4729):1054-1057. 
 (7)  Rommens JM, Iannuzzi MC, Kerem B, Drumm ML, Melmer G, Dean M et al. 
Identification of the cystic fibrosis gene: chromosome walking and jumping. Science 1989; 
245(4922):1059-1065. 
 (8)  Kerem B, Rommens JM, Buchanan JA, Markiewicz D, Cox TK, Chakravarti A et al. 
Identification of the cystic fibrosis gene: genetic analysis. Science 1989; 245(4922):1073-
1080. 
 (9)  Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, Grzelczak Z et al. Identification 
of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 
1989; 245(4922):1066-1073. 
 (10)  Sheppard DN, Welsh MJ. Structure and function of the CFTR chloride channel. Physiol Rev 
1999; 79(1 Suppl):S23-S45. 
 (11)  Estivill X, Bancells C, Ramos C. Geographic distribution and regional origin of 272 cystic 
fibrosis mutations in European populations. The Biomed CF Mutation Analysis 
Consortium. Hum Mutat 1997; 10(2):135-154. 
 (12)  Rowntree RK, Harris A. The phenotypic consequences of CFTR mutations. Ann Hum 
Genet 2003; 67(Pt 5):471-485. 
 (13)  Simmonds NJ, Cullinan P, Hodson ME. Growing old with cystic fibrosis - the 
characteristics of long-term survivors of cystic fibrosis. Respir Med 2009; 103(4):629-635. 
 (14)  Boucher RC. An overview of the pathogenesis of cystic fibrosis lung disease. Adv Drug 
Deliv Rev 2002; 54(11):1359-1371. 
 (15)  Matsui H, Grubb BR, Tarran R, Randell SH, Gatzy JT, Davis CW et al. Evidence for 
periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of 
cystic fibrosis airways disease. Cell 1998; 95(7):1005-1015. 
175 
 
 (16)  Tarran R, Button B, Picher M, Paradiso AM, Ribeiro CM, Lazarowski ER et al. Normal and 
cystic fibrosis airway surface liquid homeostasis. The effects of phasic shear stress and viral 
infections. J Biol Chem 2005; 280(42):35751-35759. 
 (17)  Scanlin TF, Glick MC. Terminal glycosylation in cystic fibrosis. Biochim Biophys Acta 
1999; 1455(2-3):241-253. 
 (18)  Kim D, Steward MC. The role of CFTR in bicarbonate secretion by pancreatic duct and 
airway epithelia. J Med Invest 2009; 56 Suppl:336-342. 
 (19)  Perez A, Issler AC, Cotton CU, Kelley TJ, Verkman AS, Davis PB. CFTR inhibition 
mimics the cystic fibrosis inflammatory profile. Am J Physiol Lung Cell Mol Physiol 2007; 
292(2):L383-L395. 
 (20)  Cystic Fibrosis Patient UK Registry Report.  2008.  
 
 (21)  Stone A, Quittell L, Zhou J, Alba L, Bhat M, DeCelie-Germana J et al. Staphylococcus 
aureus nasal colonization among pediatric cystic fibrosis patients and their household 
contacts. Pediatr Infect Dis J 2009; 28(10):895-899. 
 (22)  Mearns MB, Hunt GH, Rushworth R. Bacterial flora of respiratory tract in patients with 
cystic fibrosis, 1950-71. Arch Dis Child 1972; 47(256):902-907. 
 (23)  Millar FA, Simmonds NJ, Hodson ME. Trends in pathogens colonising the respiratory tract 
of adult patients with cystic fibrosis, 1985-2005. J Cyst Fibros 2009; 8(6):386-391. 
 (24)  Worlitzsch D, Rintelen C, Bohm K, Wollschlager B, Merkel N, Borneff-Lipp M et al. 
Antibiotic-resistant obligate anaerobes during exacerbations of cystic fibrosis patients. Clin 
Microbiol Infect 2009; 15(5):454-460. 
 (25)  Tunney MM, Field TR, Moriarty TF, Patrick S, Doering G, Muhlebach MS et al. Detection 
of anaerobic bacteria in high numbers in sputum from patients with cystic fibrosis. Am J 
Respir Crit Care Med 2008; 177(9):995-1001. 
 (26)  Jones AM. Anaerobic bacteria in cystic fibrosis: pathogens or harmless commensals? 
Thorax 2011; 66(7):558-559. 
 (27)  Rogers GB, Carroll MP, Serisier DJ, Hockey PM, Jones G, Bruce KD. characterization of 
bacterial community diversity in cystic fibrosis lung infections by use of 16s ribosomal 
DNA terminal restriction fragment length polymorphism profiling. J Clin Microbiol 2004; 
42(11):5176-5183. 
 (28)  Cox MJ, Allgaier M, Taylor B, Baek MS, Huang YJ, Daly RA et al. Airway microbiota and 
pathogen abundance in age-stratified cystic fibrosis patients. PLoS One 2010; 5(6):e11044. 
 (29)  Tunney MM, Klem ER, Fodor AA, Gilpin DF, Moriarty TF, McGrath SJ et al. Use of 
culture and molecular analysis to determine the effect of antibiotic treatment on microbial 
community diversity and abundance during exacerbation in patients with cystic fibrosis. 
Thorax 2011; 66(7):579-584. 
 (30)  Daniels TW, Rogers GB, Stressmann FA, van der Gast CJ, Bruce KD, Jones GR et al. 
Impact of antibiotic treatment for pulmonary exacerbations on bacterial diversity in cystic 
fibrosis. J Cyst Fibros 2013; 12(1):22-28. 
176 
 
 (31)  Zhao J, Schloss PD, Kalikin LM, Carmody LA, Foster BK, Petrosino JF et al. Decade-long 
bacterial community dynamics in cystic fibrosis airways. Proc Natl Acad Sci U S A 2012; 
109(15):5809-5814. 
 (32)  Dakin C, Henry RL, Field P, Morton J. Defining an exacerbation of pulmonary disease in 
cystic fibrosis. Pediatr Pulmonol 2001; 31(6):436-442. 
 (33)  Ramsey BW, Boat TF. Outcome measures for clinical trials in cystic fibrosis. Summary of a 
Cystic Fibrosis Foundation consensus conference. J Pediatr 1994; 124(2):177-192. 
 (34)  Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML, Ramsey BW et al. Effect 
of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on 
pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J 
Med 1994; 331(10):637-642. 
 (35)  Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J et al. 
Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic 
Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 1999; 340(1):23-30. 
 (36)  Rosenfeld M, Emerson J, Williams-Warren J, Pepe M, Smith A, Montgomery AB et al. 
Defining a pulmonary exacerbation in cystic fibrosis. J Pediatr 2001; 139(3):359-365. 
 (37)  Pitt TL, Sparrow M, Warner M, Stefanidou M. Survey of resistance of Pseudomonas 
aeruginosa from UK patients with cystic fibrosis to six commonly prescribed antimicrobial 
agents. Thorax 2003; 58(9):794-796. 
 (38)  Doring G, Conway SP, Heijerman HG, Hodson ME, Hoiby N, Smyth A et al. Antibiotic 
therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur 
Respir J 2000; 16(4):749-767. 
 (39)  McLaughlin FJ, Matthews WJ, Jr., Strieder DJ, Sullivan B, Taneja A, Murphy P et al. 
Clinical and bacteriological responses to three antibiotic regimens for acute exacerbations 
of cystic fibrosis: ticarcillin-tobramycin, azlocillin-tobramycin, and azlocillin-placebo. J 
Infect Dis 1983; 147(3):559-567. 
 (40)  Smith AL, Doershuk C, Goldmann D, Gore E, Hilman B, Marks M et al. Comparison of a 
beta-lactam alone versus beta-lactam and an aminoglycoside for pulmonary exacerbation in 
cystic fibrosis. J Pediatr 1999; 134(4):413-421. 
 (41)  Bosso JA, Black PG. Controlled trial of aztreonam vs. tobramycin and azlocillin for acute 
pulmonary exacerbations of cystic fibrosis. Pediatr Infect Dis J 1988; 7(3):171-176. 
 (42)  Jackson MA, Kusmiesz H, Shelton S, Prestidge C, Kramer RI, Nelson JD. Comparison of 
piperacillin vs. ticarcillin plus tobramycin in the treatment of acute pulmonary 
exacerbations of cystic fibrosis. Pediatr Infect Dis 1986; 5(4):440-443. 
 (43)  Padoan R, Cambisano W, Costantini D, Crossignani RM, Danza ML, Trezzi G et al. 
Ceftazidime monotherapy vs. combined therapy in Pseudomonas pulmonary infections in 
cystic fibrosis. Pediatr Infect Dis J 1987; 6(7):648-653. 
 (44)  McCarty JM, Tilden SJ, Black P, Craft JC, Blumer J, Waring W et al. Comparison of 
piperacillin alone versus piperacillin plus tobramycin for treatment of respiratory infections 
in children with cystic fibrosis. Pediatr Pulmonol 1988; 4(4):201-204. 
177 
 
 (45)  Gold R, Overmeyer A, Knie B, Fleming PC, Levison H. Controlled trial of ceftazidime vs. 
ticarcillin and tobramycin in the treatment of acute respiratory exacerbations in patients 
with cystic fibrosis. Pediatr Infect Dis 1985; 4(2):172-177. 
 (46)  Parry MF, Neu HC. A comparative study of ticarcillin plus tobramycin versus carbenicillin 
plus gentamicin for the treatment of serious infections due to gram-negative bacilli. Am J 
Med 1978; 64(6):961-966. 
 (47)  Flume PA, Mogayzel PJ, Jr., Robinson KA, Goss CH, Rosenblatt RL, Kuhn RJ et al. Cystic 
fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit 
Care Med 2009; 180(9):802-808. 
 (48)  Elborn JS, Hodson M, Bertram C. Implementation of European standards of care for cystic 
fibrosis--control and treatment of infection. J Cyst Fibros 2009; 8(3):211-217. 
 (49)  Aaron SD, Ramotar K, Ferris W, Vandemheen K, Saginur R, Tullis E et al. Adult cystic 
fibrosis exacerbations and new strains of Pseudomonas aeruginosa. Am J Respir Crit Care 
Med 2004; 169(7):811-815. 
 (50)  Burns JL, Gibson RL, McNamara S, Yim D, Emerson J, Rosenfeld M et al. Longitudinal 
assessment of Pseudomonas aeruginosa in young children with cystic fibrosis. J Infect Dis 
2001; 183(3):444-452. 
 (51)  Foweraker JE, Laughton CR, Brown DF, Bilton D. Phenotypic variability of Pseudomonas 
aeruginosa in sputa from patients with acute infective exacerbation of cystic fibrosis and its 
impact on the validity of antimicrobial susceptibility testing. J Antimicrob Chemother 2005; 
55(6):921-927. 
 (52)  Ordonez CL, Henig NR, Mayer-Hamblett N, Accurso FJ, Burns JL, Chmiel JF et al. 
Inflammatory and microbiologic markers in induced sputum after intravenous antibiotics in 
cystic fibrosis. Am J Respir Crit Care Med 2003; 168(12):1471-1475. 
 (53)  Stressmann FA, Rogers GB, Marsh P, Lilley AK, Daniels TW, Carroll MP et al. Does 
bacterial density in cystic fibrosis sputum increase prior to pulmonary exacerbation? J Cyst 
Fibros 2011. 
 (54)  Gold R, Overmeyer A, Knie B, Fleming PC, Levison H. Controlled trial of ceftazidime vs. 
ticarcillin and tobramycin in the treatment of acute respiratory exacerbations in patients 
with cystic fibrosis. Pediatr Infect Dis 1985; 4(2):172-177. 
 (55)  Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J et al. 
Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic 
Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 1999; 340(1):23-30. 
 (56)  Abman SH, Ogle JW, Butler-Simon N, Rumack CM, Accurso FJ. Role of respiratory 
syncytial virus in early hospitalizations for respiratory distress of young infants with cystic 
fibrosis. J Pediatr 1988; 113(5):826-830. 
 (57)  Collinson J, Nicholson KG, Cancio E, Ashman J, Ireland DC, Hammersley V et al. Effects 
of upper respiratory tract infections in patients with cystic fibrosis. Thorax 1996; 
51(11):1115-1122. 
 (58)  Chattoraj SS, Ganesan S, Jones AM, Helm JM, Comstock AT, Bright-Thomas R et al. 
Rhinovirus infection liberates planktonic bacteria from biofilm and increases chemokine 
responses in cystic fibrosis airway epithelial cells. Thorax 2011; 66(4):333-339. 
178 
 
 (59)  Sauer K, Camper AK, Ehrlich GD, Costerton JW, Davies DG. Pseudomonas aeruginosa 
displays multiple phenotypes during development as a biofilm. J Bacteriol 2002; 
184(4):1140-1154. 
 (60)  Bucior I, Pielage JF, Engel JN. Pseudomonas aeruginosa pili and flagella mediate distinct 
binding and signaling events at the apical and basolateral surface of airway epithelium. 
PLoS Pathog 2012; 8(4):e1002616. 
 (61)  Luthi E, Baur H, Gamper M, Brunner F, Villeval D, Mercenier A et al. The arc operon for 
anaerobic arginine catabolism in Pseudomonas aeruginosa contains an additional gene, 
arcD, encoding a membrane protein. Gene 1990; 87(1):37-43. 
 (62)  Worlitzsch D, Tarran R, Ulrich M, Schwab U, Cekici A, Meyer KC et al. Effects of reduced 
mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J 
Clin Invest 2002; 109(3):317-325. 
 (63)  Boucher JC, Yu H, Mudd MH, Deretic V. Mucoid Pseudomonas aeruginosa in cystic 
fibrosis: characterization of muc mutations in clinical isolates and analysis of clearance in a 
mouse model of respiratory infection. Infect Immun 1997; 65(9):3838-3846. 
 (64)  Song Z, Wu H, Ciofu O, Kong KF, Hoiby N, Rygaard J et al. Pseudomonas aeruginosa 
alginate is refractory to Th1 immune response and impedes host immune clearance in a 
mouse model of acute lung infection. J Med Microbiol 2003; 52(Pt 9):731-740. 
 (65)  Pier GB, Coleman F, Grout M, Franklin M, Ohman DE. Role of alginate O acetylation in 
resistance of mucoid Pseudomonas aeruginosa to opsonic phagocytosis. Infect Immun 2001; 
69(3):1895-1901. 
 (66)  Bjarnsholt T, Jensen PO, Fiandaca MJ, Pedersen J, Hansen CR, Andersen CB et al. 
Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis patients. Pediatr 
Pulmonol 2009; 44(6):547-558. 
 (67)  Jensen PO, Bjarnsholt T, Phipps R, Rasmussen TB, Calum H, Christoffersen L et al. Rapid 
necrotic killing of polymorphonuclear leukocytes is caused by quorum-sensing-controlled 
production of rhamnolipid by Pseudomonas aeruginosa. Microbiology 2007; 153(Pt 
5):1329-1338. 
 (68)  Schuster M, Greenberg EP. A network of networks: quorum-sensing gene regulation in 
Pseudomonas aeruginosa. Int J Med Microbiol 2006; 296(2-3):73-81. 
 (69)  Rampioni G, Pustelny C, Fletcher MP, Wright VJ, Bruce M, Rumbaugh KP et al. 
Transcriptomic analysis reveals a global alkyl-quinolone-independent regulatory role for 
PqsE in facilitating the environmental adaptation of Pseudomonas aeruginosa to plant and 
animal hosts. Environ Microbiol 2010. 
 (70)  Davies DG, Parsek MR, Pearson JP, Iglewski BH, Costerton JW, Greenberg EP. The 
involvement of cell-to-cell signals in the development of a bacterial biofilm. Science 1998; 
280(5361):295-298. 
 (71)  Singh PK, Schaefer AL, Parsek MR, Moninger TO, Welsh MJ, Greenberg EP. Quorum-
sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms. 
Nature 2000; 407(6805):762-764. 
179 
 
 (72)  Hentzer M, Wu H, Andersen JB, Riedel K, Rasmussen TB, Bagge N et al. Attenuation of 
Pseudomonas aeruginosa virulence by quorum sensing inhibitors. EMBO J 2003; 
22(15):3803-3815. 
 (73)  Bjarnsholt T, Jensen PO, Burmolle M, Hentzer M, Haagensen JA, Hougen HP et al. 
Pseudomonas aeruginosa tolerance to tobramycin, hydrogen peroxide and 
polymorphonuclear leukocytes is quorum-sensing dependent. Microbiology 2005; 151(Pt 
2):373-383. 
 (74)  Smith RS, Fedyk ER, Springer TA, Mukaida N, Iglewski BH, Phipps RP. IL-8 production 
in human lung fibroblasts and epithelial cells activated by the Pseudomonas autoinducer N-
3-oxododecanoyl homoserine lactone is transcriptionally regulated by NF-kappa B and 
activator protein-2. J Immunol 2001; 167(1):366-374. 
 (75)  Smith RS, Kelly R, Iglewski BH, Phipps RP. The Pseudomonas autoinducer N-(3-
oxododecanoyl) homoserine lactone induces cyclooxygenase-2 and prostaglandin E2 
production in human lung fibroblasts: implications for inflammation. J Immunol 2002; 
169(5):2636-2642. 
 (76)  Bjarnsholt T, Jensen PO, Jakobsen TH, Phipps R, Nielsen AK, Rybtke MT et al. Quorum 
sensing and virulence of Pseudomonas aeruginosa during lung infection of cystic fibrosis 
patients. PLoS One 2010; 5(4):e10115. 
 (77)  Kohler T, Guanella R, Carlet J, van DC. Quorum sensing-dependent virulence during 
Pseudomonas aeruginosa colonisation and pneumonia in mechanically ventilated patients. 
Thorax 2010; 65(8):703-710. 
 (78)  Armbruster CE, Hong W, Pang B, Weimer KE, Juneau RA, Turner J et al. Indirect 
Pathogenicity of Haemophilus influenzae and Moraxella catarrhalis in Polymicrobial Otitis 
Media Occurs via Interspecies Quorum Signaling. MBio 2010; 1(3). 
 (79)  Saiman L, Marshall BC, Mayer-Hamblett N, Burns JL, Quittner AL, Cibene DA et al. 
Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas 
aeruginosa: a randomized controlled trial. JAMA 2003; 290(13):1749-1756. 
 (80)  Bala A, Kumar R, Harjai K. Inhibition of quorum sensing in Pseudomonas aeruginosa by 
azithromycin and its effectiveness in urinary tract infections. J Med Microbiol 2011; 60(Pt 
3):300-306. 
 (81)  Kohler T, Perron GG, Buckling A, van DC. Quorum sensing inhibition selects for virulence 
and cooperation in Pseudomonas aeruginosa. PLoS Pathog 2010; 6(5):e1000883. 
 (82)  Hoffmann N, Lee B, Hentzer M, Rasmussen TB, Song Z, Johansen HK et al. Azithromycin 
blocks quorum sensing and alginate polymer formation and increases the sensitivity to 
serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates 
chronic P. aeruginosa lung infection in Cftr(-/-) mice. Antimicrob Agents Chemother 2007; 
51(10):3677-3687. 
 (83)  Leigh E.G. Jt. Natural Selection and Mutability. The American Naturalist 1970; 
104(937):301-305. 
 (84)  Smith EE, Buckley DG, Wu Z, Saenphimmachak C, Hoffman LR, D'Argenio DA et al. 
Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients. 
Proc Natl Acad Sci U S A 2006; 103(22):8487-8492. 
180 
 
 (85)  Sniegowski PD, Gerrish PJ, Lenski RE. Evolution of high mutation rates in experimental 
populations of E. coli. Nature 1997; 387(6634):703-705. 
 (86)  Oliver A, Canton R, Campo P, Baquero F, Blazquez J. High frequency of hypermutable 
Pseudomonas aeruginosa in cystic fibrosis lung infection. Science 2000; 288(5469):1251-
1254. 
 (87)  Mandsberg LF, Ciofu O, Kirkby N, Christiansen LE, Poulsen HE, Hoiby N. Antibiotic 
resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to 
inactivation of the DNA oxidative repair system. Antimicrob Agents Chemother 2009; 
53(6):2483-2491. 
 (88)  Waine DJ, Honeybourne D, Smith EG, Whitehouse JL, Dowson CG. Association between 
hypermutator phenotype, clinical variables, mucoid phenotype, and antimicrobial resistance 
in Pseudomonas aeruginosa. J Clin Microbiol 2008; 46(10):3491-3493. 
 (89)  Montanari S, Oliver A, Salerno P, Mena A, Bertoni G, Tummler B et al. Biological cost of 
hypermutation in Pseudomonas aeruginosa strains from patients with cystic fibrosis. 
Microbiology 2007; 153(Pt 5):1445-1454. 
 (90)  Hoiby N, Flensborg EW, Beck B, Friis B, Jacobsen SV, Jacobsen L. Pseudomonas 
aeruginosa infection in cystic fibrosis. Diagnostic and prognostic significance of 
Pseudomonas aeruginosa precipitins determined by means of crossed 
immunoelectrophoresis. Scand J Respir Dis 1977; 58(2):65-79. 
 (91)  Sanders DB, Bittner RC, Rosenfeld M, Hoffman LR, Redding GJ, Goss CH. Failure to 
recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation. Am J 
Respir Crit Care Med 2010; 182(5):627-632. 
 (92)  Sanders DB, Bittner RC, Rosenfeld M, Hoffman LR, Redding GJ, Goss CH. Failure to 
recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation. Am J 
Respir Crit Care Med 2010; 182(5):627-632. 
 (93)  Latzin P, Fehling M, Bauernfeind A, Reinhardt D, Kappler M, Griese M. Efficacy and 
safety of intravenous meropenem and tobramycin versus ceftazidime and tobramycin in 
cystic fibrosis. J Cyst Fibros 2008; 7(2):142-146. 
 (94)  Blumer JL, Saiman L, Konstan MW, Melnick D. The efficacy and safety of meropenem and 
tobramycin vs ceftazidime and tobramycin in the treatment of acute pulmonary 
exacerbations in patients with cystic fibrosis. Chest 2005; 128(4):2336-2346. 
 (95)  Collaco JM, Green DM, Cutting GR, Naughton KM, Mogayzel PJ, Jr. Location and 
duration of treatment of cystic fibrosis respiratory exacerbations do not affect outcomes. Am 
J Respir Crit Care Med 2010; 182(9):1137-1143. 
 (96)  Holmes B, Willcox WR, Lapage SP. Identification of Enterobacteriaceae by the API 20E 
system. J Clin Pathol 1978; 31(1):22-30. 
 (97)  Andrews JM. BSAC standardized disc susceptibility testing method (version 6). J 
Antimicrob Chemother 2007; 60(1):20-41. 
 (98)  Salunkhe P, Smart CH, Morgan JA, Panagea S, Walshaw MJ, Hart CA et al. A cystic 
fibrosis epidemic strain of Pseudomonas aeruginosa displays enhanced virulence and 
antimicrobial resistance. J Bacteriol 2005; 187(14):4908-4920. 
181 
 
 (99)  McCallum SJ, Corkill J, Gallagher M, Ledson MJ, Hart CA, Walshaw MJ. Superinfection 
with a transmissible strain of Pseudomonas aeruginosa in adults with cystic fibrosis 
chronically colonised by P aeruginosa. Lancet 2001; 358(9281):558-560. 
 (100)  Smart CH, Walshaw MJ, Hart CA, Winstanley C. Use of suppression subtractive 
hybridization to examine the accessory genome of the Liverpool cystic fibrosis epidemic 
strain of Pseudomonas aeruginosa. J Med Microbiol 2006; 55(Pt 6):677-688. 
 (101)  Kong KF, Jayawardena SR, Indulkar SD, Del PA, Koh CL, Hoiby N et al. Pseudomonas 
aeruginosa AmpR is a global transcriptional factor that regulates expression of AmpC and 
PoxB beta-lactamases, proteases, quorum sensing, and other virulence factors. Antimicrob 
Agents Chemother 2005; 49(11):4567-4575. 
 (102)  Li Z, Kosorok MR, Farrell PM, Laxova A, West SE, Green CG et al. Longitudinal 
development of mucoid Pseudomonas aeruginosa infection and lung disease progression in 
children with cystic fibrosis. JAMA 2005; 293(5):581-588. 
 (103)  Sauer K, Camper AK, Ehrlich GD, Costerton JW, Davies DG. Pseudomonas aeruginosa 
displays multiple phenotypes during development as a biofilm. J Bacteriol 2002; 
184(4):1140-1154. 
 (104)  Stressmann FA, Rogers GB, Marsh P, Lilley AK, Daniels TW, Carroll MP et al. Does 
bacterial density in cystic fibrosis sputum increase prior to pulmonary exacerbation? J Cyst 
Fibros 2011; 10(5):357-365. 
 (105)  Regelmann WE, Elliott GR, Warwick WJ, Clawson CC. Reduction of sputum 
Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis 
more than do bronchodilators and chest physiotherapy alone. Am Rev Respir Dis 1990; 
141(4 Pt 1):914-921. 
 (106)  Gold R, Jin E, Levison H, Isles A, Fleming PC. Ceftazidime alone and in combination in 
patients with cystic fibrosis: lack of efficacy in treatment of severe respiratory infections 
caused by Pseudomonas cepacia. J Antimicrob Chemother 1983; 12 Suppl A:331-336. 
 (107)  McLaughlin FJ, Matthews WJ, Jr., Strieder DJ, Sullivan B, Taneja A, Murphy P et al. 
Clinical and bacteriological responses to three antibiotic regimens for acute exacerbations 
of cystic fibrosis: ticarcillin-tobramycin, azlocillin-tobramycin, and azlocillin-placebo. J 
Infect Dis 1983; 147(3):559-567. 
 (108)  Saiman L, Mehar F, Niu WW, Neu HC, Shaw KJ, Miller G et al. Antibiotic susceptibility 
of multiply resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis, 
including candidates for transplantation. Clin Infect Dis 1996; 23(3):532-537. 
 (109)  Lechtzin N, John M, Irizarry R, Merlo C, Diette GB, Boyle MP. Outcomes of adults with 
cystic fibrosis infected with antibiotic-resistant Pseudomonas aeruginosa. Respiration 2006; 
73(1):27-33. 
 (110)  Ren CL, Konstan MW, Yegin A, Rasouliyan L, Trzaskoma B, Morgan WJ et al. Multiple 
antibiotic-resistant Pseudomonas aeruginosa and lung function decline in patients with 
cystic fibrosis. J Cyst Fibros 2012; 11(4):293-299. 
 (111)  Foweraker JE, Laughton CR, Brown DF, Bilton D. Phenotypic variability of Pseudomonas 
aeruginosa in sputa from patients with acute infective exacerbation of cystic fibrosis and its 
impact on the validity of antimicrobial susceptibility testing. J Antimicrob Chemother 2005; 
55(6):921-927. 
182 
 
 (112)  Rosenbluth DB, Wilson K, Ferkol T, Schuster DP. Lung function decline in cystic fibrosis 
patients and timing for lung transplantation referral. Chest 2004; 126(2):412-419. 
 (113)  Hudson VL, Wielinski CL, Regelmann WE. Prognostic implications of initial 
oropharyngeal bacterial flora in patients with cystic fibrosis diagnosed before the age of two 
years. J Pediatr 1993; 122(6):854-860. 
 (114)  Chotirmall SH, O'Donoghue E, Bennett K, Gunaratnam C, O'Neill SJ, McElvaney NG. 
Sputum Candida albicans presages FEV(1) decline and hospital-treated exacerbations in 
cystic fibrosis. Chest 2010; 138(5):1186-1195. 
 (115)  Ciofu O, Riis B, Pressler T, Poulsen HE, Hoiby N. Occurrence of hypermutable 
Pseudomonas aeruginosa in cystic fibrosis patients is associated with the oxidative stress 
caused by chronic lung inflammation. Antimicrob Agents Chemother 2005; 49(6):2276-
2282. 
 (116)  Waine DJ, Honeybourne D, Smith EG, Whitehouse JL, Dowson CG. Association between 
hypermutator phenotype, clinical variables, mucoid phenotype, and antimicrobial resistance 
in Pseudomonas aeruginosa. J Clin Microbiol 2008; 46(10):3491-3493. 
 (117)  Macia MD, Borrell N, Segura M, Gomez C, Perez JL, Oliver A. Efficacy and potential for 
resistance selection of antipseudomonal treatments in a mouse model of lung infection by 
hypermutable Pseudomonas aeruginosa. Antimicrob Agents Chemother 2006; 50(3):975-
983. 
 (118)  Oliver A, Canton R, Campo P, Baquero F, Blazquez J. High frequency of hypermutable 
Pseudomonas aeruginosa in cystic fibrosis lung infection. Science 2000; 288(5469):1251-
1254. 
 (119)  Macia MD, Blanquer D, Togores B, Sauleda J, Perez JL, Oliver A. Hypermutation is a key 
factor in development of multiple-antimicrobial resistance in Pseudomonas aeruginosa 
strains causing chronic lung infections. Antimicrob Agents Chemother 2005; 49(8):3382-
3386. 
 (120)  Hogardt M, Hoboth C, Schmoldt S, Henke C, Bader L, Heesemann J. Stage-specific 
adaptation of hypermutable Pseudomonas aeruginosa isolates during chronic pulmonary 
infection in patients with cystic fibrosis. J Infect Dis 2007; 195(1):70-80. 
 (121)  Mena A, Macia MD, Borrell N, Moya B, de FT, Perez JL et al. Inactivation of the mismatch 
repair system in Pseudomonas aeruginosa attenuates virulence but favors persistence of 
oropharyngeal colonization in cystic fibrosis mice. J Bacteriol 2007; 189(9):3665-3668. 
 (122)  Rogers GB, Hart CA, Mason JR, Hughes M, Walshaw MJ, Bruce KD. Bacterial diversity in 
cases of lung infection in cystic fibrosis patients: 16S ribosomal DNA (rDNA) length 
heterogeneity PCR and 16S rDNA terminal restriction fragment length polymorphism 
profiling. J Clin Microbiol 2003; 41(8):3548-3558. 
 (123)  Rogers GB, Carroll MP, Serisier DJ, Hockey PM, Jones G, Bruce KD. characterization of 
bacterial community diversity in cystic fibrosis lung infections by use of 16s ribosomal 
DNA terminal restriction fragment length polymorphism profiling. J Clin Microbiol 2004; 
42(11):5176-5183. 
 (124)  Sim K, Cox MJ, Wopereis H, Martin R, Knol J, Li MS et al. Improved detection of 
bifidobacteria with optimised 16S rRNA-gene based pyrosequencing. PLoS One 2012; 
7(3):e32543. 
183 
 
 (125)  Fierer N, Hamady M, Lauber CL, Knight R. The influence of sex, handedness, and washing 
on the diversity of hand surface bacteria. Proc Natl Acad Sci U S A 2008; 105(46):17994-
17999. 
 (126)  Quince C, Lanzen A, Davenport RJ, Turnbaugh PJ. Removing noise from pyrosequenced 
amplicons. BMC Bioinformatics 2011; 12:38. 
 (127)  Caporaso JG, Kuczynski J, Stombaugh J, Bittinger K, Bushman FD, Costello EK et al. 
QIIME allows analysis of high-throughput community sequencing data. Nat Methods 2010; 
7(5):335-336. 
 (128)  Lozupone C, Knight R. UniFrac: a new phylogenetic method for comparing microbial 
communities. Appl Environ Microbiol 2005; 71(12):8228-8235. 
 (129)  Fodor AA, Klem ER, Gilpin DF, Elborn JS, Boucher RC, Tunney MM et al. The adult 
cystic fibrosis airway microbiota is stable over time and infection type, and highly resilient 
to antibiotic treatment of exacerbations. PLoS One 2012; 7(9):e45001. 
 (130)  Jensen HL. A new nitrogen fixing bacterium: Derxia gummosa 
 nov. gen. nov. spec.  Arch.Mikrobiol 36, 182-195. 1960.  
 
 (131)  Chen WM, Huang WC, Sheu SY. Derxia lacustris sp. nov., a nitrogen-fixing bacterium 
isolated from a freshwater lake. Int J Syst Evol Microbiol 2013; 63(Pt 3):965-970. 
 (132)  Xie CH, Yokota A. Phylogenetic analyses of the nitrogen-fixing genus Derxia. J Gen Appl 
Microbiol 2004; 50(3):129-135. 
 (133)  Cox MJ, Allgaier M, Taylor B, Baek MS, Huang YJ, Daly RA et al. Airway microbiota and 
pathogen abundance in age-stratified cystic fibrosis patients. PLoS One 2010; 5(6):e11044. 
 (134)  Wise R, Andrews JM, Bedford KA. Comparison of in vitro activity of GR 20263, a novel 
cephalosporin derivative, with activities of other beta-lactam compounds. Antimicrob 
Agents Chemother 1980; 17(5):884-889. 
 (135)  Edwards JR, Turner PJ, Wannop C, Withnell ES, Grindey AJ, Nairn K. In vitro 
antibacterial activity of SM-7338, a carbapenem antibiotic with stability to 
dehydropeptidase I. Antimicrob Agents Chemother 1989; 33(2):215-222. 
 (136)  Ochsner UA, Fiechter A, Reiser J. Isolation, characterization, and expression in Escherichia 
coli of the Pseudomonas aeruginosa rhlAB genes encoding a rhamnosyltransferase involved 
in rhamnolipid biosurfactant synthesis. J Biol Chem 1994; 269(31):19787-19795. 
 (137)  Latifi A, Winson MK, Foglino M, Bycroft BW, Stewart GS, Lazdunski A et al. Multiple 
homologues of LuxR and LuxI control expression of virulence determinants and secondary 
metabolites through quorum sensing in Pseudomonas aeruginosa PAO1. Mol Microbiol 
1995; 17(2):333-343. 
 (138)  Middleton B, Rodgers HC, Camara M, Knox AJ, Williams P, Hardman A. Direct detection 
of N-acylhomoserine lactones in cystic fibrosis sputum. FEMS Microbiol Lett 2002; 
207(1):1-7. 
 (139)  Ortori CA, Dubern JF, Chhabra SR, Camara M, Hardie K, Williams P et al. Simultaneous 
quantitative profiling of N-acyl-L-homoserine lactone and 2-alkyl-4(1H)-quinolone families 
of quorum-sensing signaling molecules using LC-MS/MS. Anal Bioanal Chem 2011; 
399(2):839-850. 
184 
 
 (140)  Bjarnsholt T, Jensen PO, Jakobsen TH, Phipps R, Nielsen AK, Rybtke MT et al. Quorum 
sensing and virulence of Pseudomonas aeruginosa during lung infection of cystic fibrosis 
patients. PLoS One 2010; 5(4):e10115. 
 (141)  Mayer ML, Sheridan JA, Blohmke CJ, Turvey SE, Hancock RE. The Pseudomonas 
aeruginosa autoinducer 3O-C12 homoserine lactone provokes hyperinflammatory responses 
from cystic fibrosis airway epithelial cells. PLoS One 2011; 6(1):e16246. 
 (142)  Smith RS, Kelly R, Iglewski BH, Phipps RP. The Pseudomonas autoinducer N-(3-
oxododecanoyl) homoserine lactone induces cyclooxygenase-2 and prostaglandin E2 
production in human lung fibroblasts: implications for inflammation. J Immunol 2002; 
169(5):2636-2642. 
 (143)  Smith RS, Fedyk ER, Springer TA, Mukaida N, Iglewski BH, Phipps RP. IL-8 production 
in human lung fibroblasts and epithelial cells activated by the Pseudomonas autoinducer N-
3-oxododecanoyl homoserine lactone is transcriptionally regulated by NF-kappa B and 
activator protein-2. J Immunol 2001; 167(1):366-374. 
 (144)  Alhede M, Bjarnsholt T, Jensen PO, Phipps RK, Moser C, Christophersen L et al. 
Pseudomonas aeruginosa recognizes and responds aggressively to the presence of 
polymorphonuclear leukocytes. Microbiology 2009; 155(Pt 11):3500-3508. 
 (145)  Bredenbruch F, Geffers R, Nimtz M, Buer J, Haussler S. The Pseudomonas aeruginosa 
quinolone signal (PQS) has an iron-chelating activity. Environ Microbiol 2006; 8(8):1318-
1329. 
 (146)  Diggle SP, Winzer K, Chhabra SR, Worrall KE, Camara M, Williams P. The Pseudomonas 
aeruginosa quinolone signal molecule overcomes the cell density-dependency of the 
quorum sensing hierarchy, regulates rhl-dependent genes at the onset of stationary phase 
and can be produced in the absence of LasR. Mol Microbiol 2003; 50(1):29-43. 
 (147)  Skindersoe ME, Alhede M, Phipps R, Yang L, Jensen PO, Rasmussen TB et al. Effects of 
antibiotics on quorum sensing in Pseudomonas aeruginosa. Antimicrob Agents Chemother 
2008; 52(10):3648-3663. 
 (148)  Kiran S, Sharma P, Harjai K, Capalash N. Enzymatic quorum quenching increases 
antibiotic susceptibility of multidrug resistant Pseudomonas aeruginosa. Iran J Microbiol 
2011; 3(1):1-12. 
 (149)  Dubern JF, Diggle SP. Quorum sensing by 2-alkyl-4-quinolones in Pseudomonas 
aeruginosa and other bacterial species. Mol Biosyst 2008; 4(9):882-888. 
 (150)  Smyth AR, Cifelli PM, Ortori CA, Righetti K, Lewis S, Erskine P et al. Garlic as an 
inhibitor of Pseudomonas aeruginosa quorum sensing in cystic fibrosis--a pilot randomized 
controlled trial. Pediatr Pulmonol 2010; 45(4):356-362. 
 (151)  Seemungal TA, Donaldson GC, Bhowmik A, Jeffries DJ, Wedzicha JA. Time course and 
recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J 
Respir Crit Care Med 2000; 161(5):1608-1613. 
 (152)  Plummer A, Wildman M. Duration of intravenous antibiotic therapy in people with cystic 
fibrosis. Cochrane Database Syst Rev 2011;(1):CD006682. 
 (153)  Sequeiros IM, Jarad N. Factors associated with a shorter time until the next pulmonary 
exacerbation in adult patients with cystic fibrosis. Chron Respir Dis 2012; 9(1):9-16. 
185 
 
 (154)  Sequeiros IM, Jarad NA. Extending the course of intravenous antibiotics in adult patients 
with cystic fibrosis with acute pulmonary exacerbations. Chron Respir Dis 2012; 9(4):213-
220. 
 
 
 
  
186 
 
APPENDIX 
 
1. Cystic Fibrosis Questionnaire – Revised (CFQ-R) UK Adolescent and Adult version 
2. Brompton CF Questionnaire 
3. Quorum Sensing Study - Calibration lines of peak area ratio against analyte 
concentration. 
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3. Quorum Sensing Study - Calibration lines of peak area ratio against analyte concentration 
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